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Metabolomics has emerged as one of the latest of the "-omics" disciplines that can detect 
metabolite biomarkers in biological samples. The diverse characteristics of metabolites 
make the analytical platform challenging in metabolomics. Two bioanalytical platforms 
were developed in this study to investigate metabolite abundance changes under different 
biological conditions. We first developed a bioanalytical platform that coupled linear trap 
quadruple - Fourier transform ion cyclotron mass spectrometer (LTQ-FTICR MS) with 
direct infusion chip-based nano-electrospray ionization (DI-nESI) and applied it to study 
polychlorinated biphenyls (PCB) effects on non-alcoholic fatty liver disease (NAFLD). 
We also employed this platform in conjunction with in vivo metabolite deuterium 
labeling to study whether chronic alcohol exposure disturbs lipid homeostasis by 
analyzing triacylglycerol regulation alteration in adipose tissue and liver tissue. We 
further developed a comprehensive two-dimensional gas chromatography time-of-flight 
mass spectrometry (GC×GC-TOF MS) platform for metabolomic profiling and applied it 
to study the effects of arsenic exposure in a mouse model of diet-induced fatty liver 
disease, as well as the effects of Lactobacillus rhamnosus GG on alcoholic fatty liver 
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disease (AFLD) in mice. The results of our metabolomics analyses agreed with the results 
of histological studies and provided molecular level information for further understanding 
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Metabolomics is the study of biochemical process involving small-molecule metabolites 
in a biological system. It aims to simultaneously measure and interpret the complex 
time-related concentration, activity, and flux of all metabolites present in metabolome. In 
contrast to classical biochemical approaches that often focus on a single metabolite, 
metabolomics reveals biochemical activities of a broad range of small molecules such as 
lipids, amino acids, sterols, organic acids, carbohydrates, and vitamins and as such 
provides a comprehensive overview of the impact of the pathophysiological processes or 
pharmacological interventions of interest on metabolism and metabolic dynamics[1]. 
Even though one still does not know how many types of metabolites are present in the 
metabolome, the human metabolome database (HMDB) has collected 41,808 metabolite 
entries[2]. Metabolites have a wide range of molecular weights and a large variation in 
concentration. Metabolites can be polar or nonpolar, as well as organic or inorganic 
molecules. Also the metabolome is much more dynamic than proteome and genome, 
which makes the metabolome more time sensitive. The large number of metabolites and 
diverse characteristics of metabolites make the chemical separation the most challenging 
technical step in metabolomics. 
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With the extreme complexity of metabolome, metabolomics becomes an interdisciplinary 
field of science, which combines biology, chemistry, mathematics, computer science, 
statistics with biomedical sciences. Metabolomics studies can be divided into three 
analytical approaches: untargeted metabolomics, targeted metabolomics, and stable 
isotope assisted metabolomics. 
 
1.1.1. Untargeted Metabolomics 
Untargeted metabolomics intends the comprehensive analysis of all measurable 
metabolites in a sample, such as tissues (e.g., liver, heart, lung, muscle, kidney), biofluids 
(e.g., blood, serum ,plasma, urine, bile and saliva), cell lines, feces or volatile organic 
compounds (e.g., those found in breath). This approach is mainly used to investigate the 
regulation alteration of all detectable metabolites in metabolome. A suite of 
bioinformatics tools are then employed to deconvolute the instrumental data, perform 
metabolite identification, quantification, network association analysis and pathway 
analysis[3-5]. Untargeted metabolomics is mainly used for metabolite biomarker 
discovery, disease diagnosis, indication of the disease mechanisms, and monitoring 
responses to therapy, etc.  
1.1.2. Targeted Metabolomics  
Targeted metabolomics measures predefined groups of chemically characterized and 
biochemically annotated metabolites. It is often used to determine relative abundance and 
concentrations of a limited number of known metabolites. By analyzing the known 
metabolites, predefined metabolite-specific signals are measured in biological samples, 
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using selected reaction monitoring (SRM) by tandem mass spectrometry (MS/MS)[6], or 
selected ion recording (SIR) by gas chromatography mass spectrometry (GC-MS)[7].  
1.1.3. Stable Isotope Assisted Metabolomics (SIAM) 
All metabolites are associated with each other in the metabolome to form a large network 
of molecular reactions. The outputs from one enzymatic biochemical reaction are inputs 
to another. If multiple pathways result in the same product metabolite, the measured 
abundance of this metabolite by untargeted metabolic profiling or targeted metabolomics 
will be the summed abundance of this metabolite in all metabolic pathways. Therefore, 
the abundance measurement alone is frequently insufficient to determine whether and 
where a dysregulation took place, and the importance of the individual roles may be 
misinterpreted or lost.  




N) to support studies of biochemical 
mechanisms[8-10]. For example, when a primary substrate such as 
13
C-glucose is added 
to a biological system, the relative abundances of formation of particular isotopologues 
(metabolites that differ only in isotopic composition) of metabolic intermediates from 
13
C-labeled precursors in living cells provide information on the routes taken by the 
initial 
13
C-atoms. The unique isotopologue patterns of metabolic products reflecting the 
biosynthetic history of the metabolite under study, i.e., SIAM follows the fate of each 
atom and its incorporation into a multitude of metabolites produced from the labeled 
tracer and therefore helps identify and quantify stable isotope labeled molecules and leads 
to exact biochemical pathway assignment.  
While SIAM is able to differentiate the biochemical source of a metabolite, the coverage 
of metabolites by SIAM is limited to the precursor molecule(s). The metabolites that do 
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not inherent labeled atoms, i.e., heavy atoms, from the precursor molecules will not be 
studied. Another disadvantage of SIAM is that it requires much improved bioinformatics 
tools to decipher the biochemical information from the experimental data. For example, 
analysis of unlabeled samples have to be performed to limit the search space of 
metabolite identification; two dimensional nuclear magnetic resonance (NMR) data have 
to be used to determine the positions of labeled atoms in a metabolite. The low sensitivity 
of NMR induces a significant number of isotopologues without chemical structure 
information.  
1.2. Analytical Platforms for Metabolomics 
Owing to the significant complexity of the metabolome, there is nosingle instrument that 
can analyze all metabolites simultaneously. Several types of instruments have been 
utilized to analyze metabolites, including nuclear magnetic magnetic resonance 
spectroscopy(NMR)[11-17], gas chromatography mass spectrometry GC-MS[18-25] and 
liquid chromatography mass spectrometry (LC-MS)[26-29]. Each type of instrumental 
analysis affords limited coverage of the metabolites and therefore, only provides a partial 
metabolite profile of each sample. The development of comprehensive analytical 
platforms by integrating the modern instrumental analytical approaches has unraveled the 
ideal outcomes in metabolomics, and is beneficial to increase the coverage of metabolites 
that cannot be achieved by a single analytical platform[30]. 
1.2.1. Nuclear Magnetic Resonance (NMR) Spectroscopy 
Nuclear magnetic resonance spectroscopy is a technique that exploits magnetic properties 
of certain atomic nuclei. It determines the physical and chemical properties of atoms in 
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each molecule. Suitable samples range from small compounds analyzed with one 
dimensional proton or 
13
C NMR spectroscopy to large proteins or nucleic acids using 
even four dimensional techniques. NMR spectra are unique and often highly predictable 
for small molecules. Different functional groups are distinguishable and even identical 
functional groups with differing neighboring substituents still give distinguishable signals. 
As one of the most common spectroscopic techniques, NMR can uniquely identify and 
simultaneously quantify a wide range of organic compounds.  
NMR-based metabolomics is able to provide a ‘holistic view’ of the metabolites under 
certain conditions, and thus is well-suited and advantageous for metabolomic 
studies[11-17]. Compared
 
with other techniques, NMR-based metabolomics is able to 
measure intact biomaterials nondestructively and provides rich molecular structural 
information as well as quantitative information of each detected metabolite. NMR also 
has good reproducibility with simple sample preparation. However, the sensitivity of 
NMR is relatively poor compared with MS methods, resulting in metabolites with low 
abundance not detectable. In case of metabolite biomarker discovery, concentrations of 
potential biomarkers may be below the detection limit of NMR and these metabolite 
biomarkers will be missed[30]. Therefore, NMR is inappropriate for the analysis of large 
number of low-abundance metabolites.  
1.2.2. Direct Infusion Mass Spectrometry (DI-MS) 
Mass spectrometer is a molecular detector as well as a separation device. It measures the 
mass-to-charge (m/z) ratio and abundance of gas-phase ions to help identify the type  
and the amount  of species present in a sample[31]. Mass spectrometry has become the 
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technique of choice in metabolomics because of its high sensitivity, high accuracy and 
wide range of covered metabolites[32].  
DI-MS directly analyzes metabolites on a high resolution, high accuracy mass 
spectrometer without any previous separation. A typical analytical platform involves 
coupling a chip-based nanoelectrospray ion source (nESI) with a Fourier transform ion 
cyclotron resonance mass spectrometer (FTICR-MS). DI-MS has been used for 
metabolomics fingerprinting, such as analysis of urine[33], plasma[34] and plant 
extract[35]. DI-MS has the advantages of high sensitivity and accuracy, large dynamic 
range, capable of identifying and quantifying metabolites from complex samples, no 
sample cross-contamination, unchanging sample matrix and high reproducibility[36-42]. 
The significant drawbacks of DI-MS include severe ion suppression and low ionization 
efficiencies owing to no pre-separation.  
1.2.3. Liquid Chromatography Mass Spectrometry (LC-MS) 
LC-MS is currently the most widely used analytical platform in metabolomics. It allows 
for the collection of both quantitative and structural information of each metabolite, and 
can achieve pg mL
-1 
sensitivity, Therefore, LC-MS offers a very versatile tool for 
metabolic study[43]. The LC-MS based metabolomics has been applied to study 
serum[44,45], liver[46], lung[47] and other diseases.  
The choice of LC column and mobile phase composition are the two important 
components for optimization of a LC-MS system. While most of the LC-MS analyses use 
reverse phase liquid chromatography (RP-LC) to separate metabolites before MS 
analysis[48], hydrophobic interaction liquid chromatography (HILIC) has emerged as 
another choice of separation platform for LC-MS based metabolomics[49]. HILIC is 
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similar to normal phase LC, in that the stationary phase is polar; however, in contrast to 
normal phase LC, the mobile phase in HILIC uses water miscible solvents, such as 
acetonitrile or methanol, and also contains a substantial amount of water.  
To improve the coverage of metabolites, two-dimensional liquid chromatography mass 
spectrometry (2D LC-MS) has been studied. Some applications combined a HILIC 
column with a reverse phase column to obtain maximum coverage of the metabolome[50]. 
Strong cation exchange (SCX) has also been combined with HILIC to get a better 
separation for water soluble compounds[51].   
Coupling LC separation with MS detection leads toimproved MS sensitivity and signal 
reproducibility by reducing sample complexity, thereby alleviating matrix interferences 
in the ionization process. Also good separation will result in better quality MS data due to 
reduced background noise, which will significantly benefits the downstream data analysis 
for metabolite identification and quantification[52-53].  
1.2.4. Gas Chromatography Mass Spectrometry (GC-MS) 
In GC-MS based metabolomics, metabolites are first separated on a GC column and then 
subjected to mass spectrometry. GC separates molecules based on their partition 
coefficients between the mobile phase and stationary phase. The stationary phase of GC 
column can be categorized as polar, semi-nonpolar and nonpolar. The mobile phase in 
GC is usually He or N2. A GC column is usually coupled to a quadropole or time-of-flight 
mass spectrometer equipped with a chemical ionization or electron ionization source. 
GC-MS has been considered as a traditional and standard approach for metabolomics 
studies because of its high separation ability, high sensitivity and easy analyte 
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identification[54]. It has been widely used for metabolite profiling[55] and biomarker 
discovery[56]. However, GC-MS based metabolomics requires that all metabolites must 
be first derivatized and the derivatized metabolites must be volatile and thermally stable. 
The added metabolite derivatization step introduces a certain level of variation to the 
GC-MS analysis. For example, incomplete derivatization not only increases the sample 
complexity by introducing multiple chromatographic peaks, but also makes accurate 
metabolite identification and quantification challenging or even impossible.  
1.3. Liver Disease 
The liver is the largest internal organ and largest gland in the human body. It plays an 
important role in many functions, from protein production and blood clotting to 
cholesterol, glucose and iron metabolism. Liver disease is a type of damage to liver, also 
called hepatic disease. Symptoms of liver diseases include weakness and fatigue, weight 
loss, nausea, vomiting, and a yellow discoloration of the skin.  
Fatty liver disease (FLD) occurs when fat makes up more than 5%-10% of the weight of 
liver. Even though FLD is reversible, it may lead to inflammatory disease such as 
steatohepatitis and eventually cirrhosis[57]. FLD can occur after drinking large amount of 
alcohol(acute), or after a period of heavy drinking(chronic). Centers for Disease Control 
and Prevention (CDC) defines heavy drinking as consuming 15 drinks or more per week 
for men 8 drinks for women. Europe is the heaviest drinking region in the world, in terms 
of the prevalence of excessive alcohol consumption, with over 20% of the European 
population aged above 15 reporting heavy drinking[58]. Usally of all chronic heavey 
drinkers, about 15-20% develop hepatitis or cirrhosis. Alcoholic liver disease (ALD) 
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includes any hepatic manifestation of alcohol overconsumption, including fatty liver 
disease, alcoholic hepatitis, and cirrhosis.  
Ludwig reported a number of patients who had a liver histology characterized by fat 
accumulation and the presence of hepatic inflammation, with most of the cases presenting 
fibrosis in the absence of a history of excessive alcohol intake. Therefore, he coined the 
term “non-alcoholic steatohepatitis”[59,60]. Non-alcoholic fatty liver disease(NAFLD) is 
now the most common cause of chronic liver disease in the U.S. NAFLD consists of two 
clinicopathological entities: simple steatosis and non-alcoholic steatohepatitis (NASH). 
Simple steatosis usually follows a benign non-progressive clinical course. NASH may 
progress to cirrhosis. These people usually have high cholesterol or triglycerides and 
diabetes or prediabetes. There are about 10-20% of NASH among all NAFLD. Potential 
causes of fatty liver disease include obesity, type 2 diabetes mellitus, dyslipidemia, 
metabolic syndrome, medications, malnutrition, autoimmune or inherited liver disease, 
rapid weight loss. NAFLD usually related to insulin resistance and the metabolic 
syndrome and may also respond to treatments originally developed for other insulin 
resistant states such as weight loss. So there could be a vicious cycle involving these 
diseases. 
Several efforts have been devoted to liver disease to discover metabolite biomarkers 
using different metabolomics approaches such as GC-MS[61-63] and HPLC-MS[64-67]. 
The molecular mechanisms of liver disease are still not fully understood.   
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1.4. Objectives of This Dissertation 
The objectives of this dissertation were to develop a suite of bioanalytical platforms and 
related bioinformatics tools for the study of metabolite regulation changes under different 
physiological conditions, and to further apply the developed bioanalytical platforms to 
discover metabolite biomarkers for various liver diseases. The remaining parts of this 
dissertation are organized as follows: Chapter two introduces a bioanalytical platform of 
direct infusion coupled with high resolution mass spectrometry (DI-MS) for global 
metabolic profiling and its application to study polychlorinated biphenyls (PCB) effects 
on non-alcoholic fatty liver disease (NAFLD). Chapter Three describes a time course 
study to investigate how chronic alcohol exposure disturbs lipid homeostasis using 
DI-MS based metabolomics, where in vivo metabolite deuterium labeling was employed 
to analyze triacylglycerol in adipose tissue and liver tissue. Chapter Four presents a 
comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry 
(GCxGC-TOF MS) system and its application to study the effects of arsenic exposure in 
a mouse model of diet-induced fatty liver disease. Chapter Five introduces the application 
of GCxGC-TOF MS platform to study the effects of Lactobacillus rhamnosus GG on 












METABOLOMIC ANALYSIS OF THE EFFECTS 
OF POLYCHLORINATED BIPHENYLS IN 
NON-ALCOHOLIC LIVER DISEASE 
2.1. Introduction 
The burden of liver disease has increased in the United States in parallel with the obesity 
epidemic. The most common liver problems, nonalcoholic fatty liver disease (NAFLD) 
or its more advanced form, non-alcoholic steatohepatitis (NASH), are thought to be due 
to overweight/obesity. Polychlorinated biphenyls (PCBs) are persistent environmental 
pollutants. Exposures to PCBs have been associated with NAFLD in epidemiologic 
studies[68]. Among PCB congeners, PCB 153 (Figure 1) is present at the highest 
levels[69]. Dr.Cave’s group has been demonstrated that chronic PCB 153 exposure 
worsened obesity/NAFLD in mice fed a high fat diet (HFD), but had no pathologic effect 
in mice fed control diet (CD)[70]. To better understand the biochemical mechanisms 
underlying these observations, a comprehensive investigation using high throughput 




Figure 1. PCB 153 Structure 
Metabolomics is the study of low molecular weight molecules (i.e., metabolites) found 
within cells and biological systems.  Due to the extremely diverse chemical 
characteristics of metabolites, several types of instruments have been utilized to analyze 
metabolites including nuclear magnetic resonance (NMR)[13,16], liquid chromatography 
mass spectrometry (LC-MS) and gas chromatography mass spectrometry (GC-MS)[22, 
28,71]. Each type of instrumental analysis affords limited coverage of the metabolites, 
and therefore only provides a partial metabolite profile of each sample. With the 
advantages of high sensitivity and accuracy, wide dynamic range, and the ability to 
identify metabolites from complex sample[39,62,72], high-resolution mass spectrometry, 
such as Fourier transform ion cyclotron resonance mass spectrometer (FTICR-MS), is an 
attractive option in metabolomics research[73,74]. 
The objective of this study was to determine if PCB 153 induces NAFLD in mice fed a 
control diet and/or alters the metabolite profile, and/or exacerbates NAFLD in mice fed a 
high fat diet. C57BL/6J mice were fed either a control diet (normal chow, CD) or 43% 
milk fat diet (high fat diet, HFD) for 12 weeks with or without PCB 153 co-exposure. At 
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the end of the feeding period, the mice were anesthetized and liver samples were 
collected. The metabolite extracts from mouse livers were analyzed using linear trap 
quadruple - Fourier transform ion cyclotron resonance mass spectrometer (LTQ-FTICR 
MS) via direct infusion chip-based nano-electrospray ionization (DI-nESI) – mass 
spectrometry.  
2.2. Experimental 
2.2.1. Animals and Diets 
The animal experiment were carried out at the School of Medicine, University of 
Louisville,  and the animal protocol was approved by the University of Louisville 
Institutional Animal Care and Use Committee. Male C57BL/6J mice (8 weeks old, n = 40; 
The Jackson Laboratory, Bar Harbor, Maine) were divided into 4 study groups (n = 10 
per group) based on diet and PCB 153 exposure in this 12-week study utilizing a 2×2 
design. The control diet (CD) was the Autoclavable Rodent Diet 5010 from LabDiet, 
Lebanon, IN; and it consisted of 12.7% kcal from fat, 58.5% carbohydrate, and 28.7% 
protein from both animal and vegetable sources. The high fat diet (HFD) was TD.88137 
from Harlan Laboratories, Madison, WI; and it consisted of 42.7% kcal from fat (milk 
fat), 42.0% carbohydrate (sucrose and corn starch), and 15.2% protein (casein). PCB 153 
(Ultra Scientific, North Kingstown, RI) was administered in corn oil (vehicle) by i.p. 
injection (vs. corn oil alone) at a dose of 50 mg/kg on weeks 4, 6, 8, and 10. Mice were 
housed in a temperature- and light-controlled room (12 h light; 12 h dark) with food and 
water ad libitum. The animals were euthanized (sodium pentobarbital, 40 mg/kg body 
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weight, i.p.) at the end of week 12. Thus, four different treatment groups were evaluated 
in this fashion: CD, CD+PCB 153, HFD, HFD+PCB 153. 
2.2.2. Liver Histological Studies 
Liver sections were frozen using optimal cutting temperature (OCT), a liquid embedding 
medium or fixed in 10% buffered formalin for 24 h and embedded in paraffin for 
histological examinations. Tissue sections were stained with either Oil Red O (frozen 
OCT), hematoxylin–eosin (H&E; formalin-fixed) or Sirius red stain (formalin-fixed) and 
examined under light microscopy at 200× magnification. Photomicrographs were 
captured using a Nikon Eclipse E600 Microscope. 
2.2.3. Metabolite Sample Preparation 
Metabolites were extracted based on Bligh & Dyer’s method to cover both the polar and 
non-polar metabolites[75]. Each sample of liver tissue was weighed and homogenized for 
2 min after adding water at a concentration of 100 mg liver tissue/mL water. The 
homogenized sample was then stored at –80 °C until use. To extract metabolites from the 
homogenized liver tissue, 100 μL of homogenized liver tissue, 300 μL of water, and 1.5 
mL of chloroform–methanol (v/v = 1:2) were mixed in a glass tube and vortexed for 1 
min, followed by adding 0.5 mL chloroform, vortexing 1 min, adding 0.5 mL water and 
vortexing for 1 min. The mixture was then separated by centrifuging at room temperature 
for 8 min at 1100 rpm. 400 μL of the organic phase (bottom) were aspirated into another 
glass tube and dried under nitrogen. Each of the dried samples was dissolved in 100 μL of 
chloroform–methanol (v/v = 1:1) and further diluted 25 times before analysis. The 
aqueous phase was dried in a SpeedVac at 4 
o
C to remove methanol, followed by freeze 
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drying to vaporize water. Each of the dried water phase samples was re-dissolved in 100 
μL methanol and then further diluted 5 times before analysis. 
2.2.4. Spike-in Samples 
About 180 mg of liver tissue from three mice was mixed with deionized water at a 
concentration of 100 mg/mL. The mixture was then homogenized for 2 min and stored at 
–80 
o
C until use. To extract metabolites from liver, a 200 μL of homogenized liver 
sample was mixed with 1.6 mL of methanol and vortexed for 1 min, followed by 
centrifugation at 4 
o
C for 10 min at 15,000 rpm. 1.4 mL of the top solution was aspirated 
into a plastic tube and dried by N2 flow. After dissolving the dried sample with 200 μL of 
methanol, a stock solution was prepared by diluting the sample 10 times. Thirty aliquots 
of the stock solution were then prepared with a volume of 50 μL per aliquot.  
A mixture of 15 acid standards was prepared at a concentration of 10 μg/mL per acid. 
The acids included L-proline, L-cystine, L-histidine, L-phenylalanine, L-tyrosine, L-lysine, 
L-glutamic acid, L-aspartic acid, L-leucine, nonadecanoic acid, hepadecanoic acid, 
heptanoic acid, nonanoic acid, pentadecanoic acid, and undecanoic acid. Twenty μL of 
the acid mixture was added to each of the first 10 aliquots of the stock solution, while 24 
and 100 μL of the acid mixture were added to each of the second 10 aliquots and the third 
10 aliquots, respectively. Methanol was then added to each of the 30 aliquots to make the 
total volume of each aliquot to 200 μL. This resulted in three sample groups with 
spiked-in acid standards. The acid concentration in each of the spike-in sample groups is 
1.0 μg/mL, 1.2 μg/mL, and 5.0 μg/mL, respectively. 
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2.2.5. FTICR-MS and LTQ-MS/MS Analysis 
The direct infusion experiments were performed on a hybrid mass spectrometer, linear 
trap quadruple - Fourier transform ion cyclotron mass spectrometer (LTQ-FTICR MS or 
LTQ-FT MS) (Thermo Electron Corporation, Bremen, Germany) equipped with a 
chip-based nano-electrospray ionization (nESI) ion source (Triversa NanoMate) (Advion 
Biosciences, Ithaca, NY, USA). The mass spectrometer was operated in positive ion 
mode. Each metabolite extract was analyzed for 5 minutes with an m/z range of 50–1,600. 
Mass spectra were recorded using FTICR in the profile mode and the resolving power 
(RP) was set at 200,000 @ m/z = 400. The maximum ion accumulation time was set at 
1,000 ms. The ion optics was tuned for the sodium adduct of tricaprylin ([C27H50O6+Na
+
]) 
at m/z = 493.25 using the linear ion trap (LIT). The two most important nESI parameters 
were as follows: the spray voltage = +1.8 kV and the nitrogen gas pressure = 0.5 psi. The 
MS/MS spectrum of each metabolite ion was acquired with the LTQ-MS. The parameters 
were set as follows: parent ion m/z isolation window = ±0.5, spectrum accumulation time 
= 1 min. The collision-induced dissociation (CID) voltage is a molecule dependent 
parameter and ranged from 16 to 40 mV. 
2.2.6. Data Analysis 
The FT-MS data were processed using the software package MetSign[76]. For metabolite 
peak quantification, the raw instrument data were first reduced into a peak list using 
second-order polynomial fitting (SPF) and Gaussian mixture model (GMM). Cross 
sample alignment was performed using a two-step alignment approach implemented in 
MetSign, the primary alignment and partial alignment. After peak alignment, a contrast 
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based method was employed for normalization[77]. Pairwise two-tail t-test was used to 
study the abundance change of each metabolite between two testing sample groups.  
For metabolite identification, each peak detected in the FTICR-MS data was first 
assigned to metabolite(s) recorded in the public databases (Kyoto Encyclopedia of Genes 
and Genomes (KEGG, http://www.genome.jp/kegg/), LIPID MAPS 
(http://www.lipidmaps.org/), and the Human Metabolome Database (HMDB, 
http://www.hmdb.ca/), by matching the experimentally measured metabolite ion m/z 
value and the profile of the isotopic peaks with the theoretical data of database 
metabolites. The thresholds for m/z variation and isotopic peak profile similarity 
measured by Pearson’s correlation coefficient were set as ≤ 5 ppm and ≥ 0.75, 
respectively. To narrow down the metabolite candidates of the initial assignment, the 
MS/MS spectra were acquired for metabolites detected with significant abundance 
changes between two testing sample groups. Each experimental MS/MS spectrum was 
compared to the in silico MS/MS spectra of all candidate metabolites generated by Mass 
Frontier 7.0 (Thermo Scientific, FL, US). The spectral similarity between the 
experimental MS/MS spectrum and the in silico MS/MS spectrum of metabolite of 
interest was evaluated using Pearson’s correlation coefficient. The metabolite candidate(s) 
with the best MS/MS spectral similarity was (were) considered as the metabolite giving 
rise to the experimental spectrum, while the other candidates were discarded. The 
authentic standards of the metabolites of interest were then analyzed on LTQ-MS/MS to 
further confirm the metabolite identification. 
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To evaluate the accuracy of both the analytical platform and the data analysis method, the 
true-positive rate (TPR), the positive predictive value (PPV), and their harmonic mean F1 
score were calculated as follows: 


















           (3) 
where TP (true-positive) is the number of spiked-in acids that were detected as molecules 
with significant peak area changes between groups of spike-in samples by the statistical 
analysis, FP (false-positive) is the number of molecules that were not spiked-in acids but 
detected as molecules with significant peak area changes, and FN (false-negative) is the 
number of spiked-in acids that were not detected as molecules with significant peak area 
changes. TPR is called recall, and PPV is called precision and their harmonic mean F1 
score can be used as an accuracy of the statistical significant test. 
2.3. Results and Discussion 
2.3.1. PCB 153 Worsened Steatosis in Mice Fed a High Fat Diet 
(HFD) 
Oil Red O staining is used in histological visualization of fat cells and neutral fat. Oil Red 
O is a dye used for staining of neutral triglycerides and lipids on frozen sections. 
Haematoxylin and eosin (H&E) staining protocol is used frequently in histology to 
examin thin section of tissue. Haematoxylin stains cell nuclei blue, while eosin stains 
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cytoplasm, connective tissue and other extracellular substances pink or red. Histological 
examination showed that mice fed a control diet did not develop significant steatosis with 
or without PCB 153 administration (Oil Red O and H&E stains-Figure 2. A&B). Mice 
fed HFD showed minimal steatosis, but PCB 153 co-exposure drastically augmented this 
effect. Thus, co-administration of PCB 153 to HFD–fed mice clearly worsened hepatic 
steatosis while PCB 153 had no effect in the control diet fed-mice. 
 
Figure 2.  PCB 153 worsened hepatic steatosis in mice fed a high fat diet. (A) The 
HFD+PCB 153 mice showed macrovesicular steatosis by H and E staining (B) Oil Red O 
staining of hepatic sections established the occurrence of micro-vesicular steatosis in the  
same group of mice. 
2.3.2. Evaluation of Metabolomics Analysis Platform 
The FTICR-MS data of the spiked-in experiment were processed using MetSign[75]. Of 
the 15 spiked-in acids, the metabolite peaks of 10 acids (L-proline, L-cystine, L-histidine, 
L-phenylalanine, L-tyrosine, L-lysine, L-glutamic acid, L-aspartic acid, L-leucine, and 
nonadecanoic acid) were recognized based on the match of m/z values and isotopic peak 
profile. On the basis of the design of the spike-in experiment, all of the 10 detected 








between the two sample groups, while all other metabolites are false-positives if they are 
detected as the metabolites with significant concentration change between two sample 
groups. Of the 10 detected acids, L-histidine, L-lysine, and nonadecanoic acid were 
already present in the liver metabolite extract before the addition of the acid standards. 
The true concentration ratios of these three acids between samples groups depend on the 
amount of these acid originally present in the liver. 
A pairwise two-tail t-test was performed to recognize the metabolite peaks with 
significant peak area changes between the two testing groups constructed from the three 
sample groups of the spike-in experiment. Figure 3 displays the relation between the 
p-value threshold of the t-test and the recall, the precision and F1, respectively. With the 
increase in the p-value threshold, the TPR increases and it reaches the highest value of 
0.80 at a p-value of 0.03. There is a relatively large deviation between the PPV values of 
these three pairs of testing groups. The best PPV value reaches a value of 0.63 when 
comparing testing groups 1.0 μg/mL vs. 1.2 μg/mL, while it is only 0.30 for 1.0 μg/mL vs. 
5.0 μg/mL and 1.2 μg/mL vs. 5.0 μg/mL at a p-value of 0.05. The F1 value ranges from 
0.43 to 0.70 at a p-value of 0.05. The high value of TPR and moderate value of F1 
indicate that the analytical platform and the data analysis method employed in this study 
are able to detect the metabolites with abundance changes from the biological samples. 
However, the analytical platform variations also introduce a certain level of false-positive 
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Figure 3. Relationship between the cutoff value of the p-value of t-test and the values of TPR, 
PPV, and F1 during the analysis of the spiked-in experiments. (A) TPR (B) PPV (C) F1 
2.3.3. Metabolite Identification 
The metabolite putative assignment was accomplished by MetSign[75] software using the 
FTICR-MS data. About 800 metabolite peaks were putatively assigned to at least one 
database metabolite with an m/z variation window of ≤ 5 ppm and a minimum value of 
0.75 as Pearson’s correlation coefficient between the theoretical isotopic peak profile and 
the experimental one. To the metabolite peaks detected with significant abundance 
changes between two testing sample groups, an experimental MS/MS spectrum was 
acquired for each of these peaks on LTQ-MS/MS. An in silico MS/MS spectrum was 
generated for each of the putative metabolite candidates assigned to the metabolite peaks 
with significant abundance changes. The in silico MS/MS spectra were then matched to 
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the experimental MS/MS spectrum of the metabolite ion. The metabolite candidate with 
the best MS/MS spectral match was considered as the metabolite present in the sample.  
Figure 4 depicts an example of MS/MS identification. The molecular ion m/z value of the 
peak measured by FTICR-MS is 156.07731, which was tentatively assigned to the 
metabolite L-histidine (a metabolite recorded in human metabolite database with database 
identification number HMDB00177) with an m/z value deviation of 0.06 ppm and the 
isotopic peak profile similarity of 0.9974. The in  silico MS/MS spectrum of this 
putatively assigned metabolite was obtained using Mass Frontier, and the in silico 
MS/MS spectrum (Figure 4A) is highly similar to the experimental spectrum (Figure 4B) 
with a Pearson’s correlation coefficient of 1.00. Figure 4 shows the MS/MS spectrum of 
authentic L-histidine standard. The Pearson’s correlation coefficient between the MS/MS 
spectrum of the authentic L-histidine and the experimental MS/MS spectrum acquired 
from the biological sample is 0.85. Such a high spectral similarity significantly increases 




        
 
Figure 4. An example of identifying metabolites using MS/MS information. The metabolite 
ion m/z value was measured using FTICR-MS as 156.0773. (A) is the experiment MS/MS 
spectrum of the metabolite ion. (B) is the matching result of the metabolite between the 
experiment MS/MS spectrum and the in silico MS/MS spectrum of the same metabolite ion 
generated by Mass Frontier 7.0. The matched fragment ions are highlighted in red and the 
unmatched fragment ions in black. (C) is the MS/MS spectrum of the L-histidine standard. 
2.3.4. Metabolite Quantification 
Four sample groups were generated in this study, including CD group (animals fed a 
control diet), CD+PCB 153 group (animals fed a control diet with exposure to PCB 153), 
HFD group (animals fed a high fat diet), and HFD+PCB 153 group (animals fed a high 
fat diet with exposure to PCB 153). To investigate the metabolite abundance change 
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between two sample groups, pairwise two-tail t-test was employed with a p-value 
threshold of ≤ 0.05. Four pairs of sample groups were compared in this study after 
normalization. Specifically, we compared the metabolite profile difference between CD 
group and CD+PCB 153 group, CD group and HFD group, CD+PCB 153 group and 
HFD+PCB 153 group, and HFD group and HFD+PCB 153 group.  
In order to have high metabolite coverage, two samples were collected from each mouse 
liver: water phase metabolite extract and organic phase metabolite extract. The statistical 
test was applied to the water phase samples and the organic phase samples, respectively. 
The test results were then merged for summary. A few metabolites were detected in both 
the organic phase samples and the water phase samples, but none of them was recognized 
as a molecule with significant abundance changes between two sample groups. For each 
of the comparisons, the peak distribution of each metabolite in the samples of the two 
testing sample groups was generated. Figure 5 depicts a sample peak intensity 
distribution of metabolites recognized with significant abundance changes between the 
HFD group and the HFD+PCB 153 group. It can be seen that the abundance of this 
metabolite (fucose 1-phosphate) is significantly decreased in the HFD+PCB 153 group 






Figure 5. The peak area distribution of metabolite fucose 1-phosphate in the HFD samples 
(red triangles) and in the HFD+PCB 153 samples (blue stars). The abundance test (pairwise 
two-tail t-test) shows that the regulation of this metabolite in the HFD+PCB 153 group is 
decreased with a fold change of 2.65 and a p-value of 4.84×10–4.  
To measure the metabolite abundance changes between two sample groups, the term 
fold-change was defined as the ratio of the large abundance value (peak area) of a 
metabolite in one group divided by the small abundance value of the same metabolite in 
the other group. The positive sign and negative sign indicate the abundance increase and 
decrease in the testing group, respectively. No metabolite was detected with significant 
abundance changes between the CD group and the CD+PCB 153 group. This indicates 
that PCB 153 alone has no significant effect on liver at the metabolite level. However, a 
total of 14 metabolites were detected with significant abundance changes between the 























































significant changes between the HFD and HFD+PCB 153 groups, erythronic acid 
(Figure.6) had the largest abundance changes with a 28.8-fold increase in the HFD+PCB 
153 group (p = 8.35×10
-5
). Erythronic acid is formed either by oxidation of D-N-acetyl 
glucosamine, an alternating unit of hyaluronic acid [78] or by degradation of ascorbic acid 
(Vitamin C) and glycated proteins[79]. Compared with the changes observed between the 
CD group and CD+PCB 153 group, the metabolite abundance changes between the HFD 
and HFD+PCB 153 groups demonstrated the presence of a diet-toxin interaction between 
PCB 153 and HFD. This interaction may affect some metabolic pathways, and therefore 
induce the abundance changes of these measured compounds. Thus, PCB 153 alone does 
not induce NAFLD but it worsens NAFLD caused by a HFD, which agrees with our 
histological examination (Figure 2). 
 
 





Table 1.  Metabolites detected with significant abundance changes between the HFD group 
and the HFD+PCB 153 group. 
 
For the CD+PCB 153 vs. HFD+PCB 153 groups, 50 FTICR-MS peaks were detected 
with significant abundance changes in water phase samples and 14 peaks in organic 
phase samples. Combining the water phase and the organic phase results, 24 metabolites 
were identified by in silico MS/MS spectral matching, although three of them (m/z = 
369.1178, 203.0535 and 365.1075) do not have unique identification (Table 2). The 
identified metabolites include glycerolipids, sterol lipids, phospholipids, sphingolipids 










156.07731 L -Histidine H
+ C00135,HMDB00177 -1.80  4.64E-02 
170.03332 Creatine K+ HMDB00064,C00300 -1.83  4.72E-02 
175.00113 Erythronic acid K+ HMDB00613 28.77  8.35E-05 
260.05434 D-Glucosamine6-phosphate H+ C00352 -2.19  4.14E-03 
262.07009 Fucose 1-phosphate NH4
+ HMDB01265 -2.65  4.84E-04 
376.05929 S-(Hydroxymethyl)glutathione K+ HMDB04662 -2.97  1.14E-02 
346.0469 Glutathione K+ HMDB00125,C00051 -5.91  2.04E-03 
459.25103 Stearoylglyceronephosphate Na+ C03805 -1.67  3.14E-02 
266.153 Isobutylphendienamide Na+ C10944 -2.57  1.71E-02 
309.16728 Fructoselysine H+ C16488 -2.94  5.96E-03 
347.1235 Fructoselysine K+ C16488 -2.08  1.70E-02 
283.03409 Uridine K+ HMDB00296,C00299 -1.80  4.99E-02 





Na+ LMST01100006 2.05  3.68E-03 
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, respectively. The same fold change (-2.43) between the two testing sample 
groups confirms the accuracy of our FTIRC-MS and data analysis platforms. Another 
case is the identification of FTICR-MS peaks with m/z = 156.0773 and 194.0335. The in 
silico MS/MS spectral matching identified these two peaks as being generated by the 




, respectively. The fold changes of 
these two FTICR-MS peaks between the two testing groups are -1.90 and -1.94, 
respectively. 
For the CD vs. HFD groups, 57 FTICR-MS peaks were detected having significant 
abundance different between the CD group and the HFD group in the water phase 
samples and 17 peaks in the organic phase samples. Combining the results of the water 
phase and the organic phase samples, 25 metabolites were further confirmed by MS/MS 
spectral matching. Of the 25 compounds, two do not have a unique identification (Table 
3). It should be noted that metabolite PC (o-22:1(13Z)/20:4(8Z,11Z,14Z,17Z)) has a 
4.44-fold increase in the HFD group, which agrees with a previous study[80]. 
Several important limitations in the study design could impact the generalizability of 
these results. First, differences existed between CD and HFD, not only in macronutrient 
content and source, but also in micronutrient composition. However, similar, but not 
identical, vitamin and mineral mixes were given with each diet. These potential 
confounders could impact metabolite differences observed between diet groups 
regardless of PCB administration. However, the primary study objective was to 
determine the effects of PCB administration within a given diet (e.g. HFD vs. HFD+PCB 
153, and CD vs. CD +PCB 153), and these analyses would be unaffected. Thus, the most  
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Table 2. Metabolites detected with significant abundance changes between the CD+PCB 153 
group and the HFD+PCB 153 group. 
 
  
m/z Metabolite Name 
Adduct 
ion Metabolite database IDs 
Fold 
change p_value 
156.0773 L-histidine H+ C00135,HMDB00177 -1.90  1.18E-02 
194.0335 L-histidine K+ C00135,HMDB00177 -1.95  2.77E-02 
227.0439 N-acetylglutamine K+ HMDB06029 -2.17  2.23E-02 
175.0011 Erythronic acid K+ HMDB00613 16.73  2.90E-04 
219.0274 2S,4S,5R,6-tetrahydroxy-hexanoic acid K+ LMFA01050392 -2.81  1.64E-03 
249.0383 Chorismate Na+ HMDB12199 -2.38  3.39E-03 
260.0543 D-glucosamine6-phosphate H+ C00352 -1.84  4.85E-02 
268.1054 Adenosine H+ HMDB00050 -1.64  2.76E-02 
286.2757 heptadecasphing-4-enine H+ LMSP01040002 3.29  5.64E-03 
347.1235 Fructoselysine K+ C16488 -2.43  3.62E-02 
309.1673 Fructoselysine H+ C16488 -2.43  4.25E-02 
346.0469 Glutathione K+ C00051,HMDB00125  -19.86  9.13E-03 
376.0593 S-(hydroxymethyl)glutathione K+ HMDB04662 -3.67  5.56E-04 
381.0813 Melibiose K+ HMDB00048 -3.79  8.55E-04 
402.0964 S-lactoylglutathione Na+ C03451,HMDB01066 -3.51  9.51E-04 
559.3035 Cucurbitacin P K+ LMST01010114,C08804 -1.87  1.87E-02 
867.6961 PC(o-22:1(13Z)/20:4(8Z,11Z,14Z,17Z)) NH4
+ HMDB13451 2.45  1.20E-03 














K+ LMGL03010071 5.86  1.44E-05 
369.1178 O-feruloylquinate Na+ C02572 -3.29 2.01E-02 
 
Aucubin Na+ C09771,LMPR0102070006 
  203.0535 D-glucose Na+ C00031 -2.22  5.73E-03 
 
2S,4S,5R,6-tetrahydroxy-hexanoic acid Na+ LMFA01050392 
  365.1075 Melibiose Na+ C05402,HMDB00048 -5.86  5.38E-05 
 




Table 3. Metabolites detected with significant abundance changes between the CD group and 
the HFD group. 
m/z Metabolite Name 
Adduct 
ion Metabolite database IDs 
Fold 
Change p_value 
175.0011 Erythronic acid K+ HMDB00613 -26.70 4.16E-02 
219.0274 2S,4S,5R,6-tetrahydroxy-hexanoic acid K+ LMFA01050392 -1.72 1.21E-02 
251.054 2-Hydroxy-3-carboxy-6-oxo-7-methylocta-2,4-dienoate Na+ C06581 -2.25 4.58E-03 
262.0701 Fucose 1-phosphate NH4
+ HMDB01265 1.93 5.55E-03 
286.2757 heptadecasphing-4-enine H+ LMSP01040002 3.92 1.74E-03 
355.0671 2-Caffeoylisocitrate H+ C02927 -1.92 4.54E-02 
364.1238 Lactosamine Na+ HMDB06591 1.77 9.17E-03 
365.0966 Streptidine6-phosphate Na+ C01121 -1.80 6.33E-03 
365.102 Hinokitiolglucoside K+ C15451 -3.93 3.16E-04 
380.0977 Lactosamine K+ HMDB06591 1.36 4.94E-02 
381.069 Streptidine6-phosphate K+ C01121 -2.36 1.41E-03 




H+ LMFA08020020 -4.94 3.06E-02 
399.0858 Elephantopin K+ LMPR0103090004,C09403 -2.55 5.92E-03 
459.251 Stearoylglyceronephosphate Na+ C03805 2.10 1.33E-03 
497.3475 25-Hydroxy-24-epi-brassinolide H+ C11050 2.05 4.42E-02 
519.3296 25-Hydroxy-24-epi-brassinolide Na+ C11050 1.96 7.21E-03 
527.1377 3-Fucosyllactose K+ HMDB02094 -2.53 1.15E-02 
535.3036 25-Hydroxy-24-epi-brassinolide K+ C11050 1.64 2.11E-02 
615.4948 1,2-di-(9Z-heptadecenoyl)-sn-glycerol Na+ LMGL02010021 -3.66 3.02E-02 
663.0984 Isoorientin 3'-O-glucuronide K+ LMPK12110311 -5.87 6.50E-04 
867.6961 PC(o-22:1(13Z)/20:4(8Z,11Z,14Z,17Z)) NH4




K+ LMGL03010067 28.39 1.34E-05 
203.0535 2S,4S,5R,6-tetrahydroxy-hexanoic acid Na+ LMFA01050392 -1.47 2.23E-02 
 
D-Glucose Na+ C00031 
  365.1075 Melibiose Na+ C05402,HMDB00048 -3.18 1.49E-04 
  Sucrose Na+ C00089 
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important conclusion from our work is that macronutrient-toxicant interactions are 
critical determinants of PCB 153’s effects on hepatic metabolites. Additional 
consideration must also be given to the PCB dosing protocol. PCBs were manufactured 
as mixtures, and multiple highly chlorinated PCB congeners have simultaneously 
bio-accumulated in humans primarily by ingestion[68]. This study investigated only a 
single congener (PCB 153), which is the single most abundant PCB in humans[1]. 
Because a metabolomics dose response curve has never been performed for any PCB, for 
this initial study a relatively high cumulative dose (200 mg/kg, administered to mice i.p., 
over 12 weeks) was selected based on a previously published National Toxicology 
Program Protocol (NTP TR 530, 210 mg/kg cumulative dose, administered to rats by 
gavage over 14-weeks.
 
The NTP protocol produced lipid-adjusted serum PCB levels 
approximately 10-fold higher than the most highly exposed subject from the Anniston, 
Alabama human cohort of highly-exposed residents living near a former PCB production 
facility[81]. Limitations regarding our PCB dosing protocol must be acknowledged and 
future studies investigating PCB mixtures at lower doses and more physiologic routes of 
administration (e.g. gavage) have been planned. However, the most important finding of 
this study is that even at a relatively high dose of PCB 153, no effects on hepatic 
metabolites were observed in the absence of high fat feeding. Therefore, the data suggest 
that the PCB-HFD interaction could be more important than the cumulative PCB dose. 
2.3.5. Ingenuity Pathway Analysis (IPA) 
As demonstrated by the spike-in experimental data, the analytical platform and the data 
analysis method employed in this study can introduce a certain level of technical 
variations. Such variations can cause both false-positive and false-negative discoveries. 
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On the other hand, the quantitative analysis was performed on the abundance of each 
individual metabolite. The inter-relationships between the various metabolites were not 
considered however, and thus, IPA was employed. IPA correlates specifically targeted 
metabolites with potential metabolic pathways for data analysis that helps researchers to 
model, analyze, and understand complex biological and chemical systems at the core of 
life science research[82]. Therefore, it is necessary to incorporate the analytical discovery 
with the metabolite pathway analysis to further filter and/or enrich the analytical 
discovery.  
All 14 metabolites recognized with significant abundance changes between the HFD 
group and the HFD+PCB 153 group were subjected to IPA for network analysis. Six 
metabolites were mapped into the IPA database. The most probable metabolite network 
reported by IPA contained 5 metabolites including creatine, glucosamine-6-phosphate, 
glutathione, L-histidine and uridine with a score of 14 (Figure 7). The IPA analysis 
resulted in that the top hepatotoxicity function is glutathione (GSH) depletion in liver and 
the top canonical pathway is glutamate metabolism. GSH, a tripeptide composed of 
glutamic acid, cysteine and glycine, is the major intracellular anti-oxidant in the liver, and 
its physiological function is to prevent damage to cellular components that may be caused 
by xenobiotic metabolites, reactive oxygen species (ROS) and free radicals[83]. In the 
liver, glutamate is the terminus for release of ammonia from amino acids, and the 
intrahepatic concentration of glutamate modulates the rate of ammonia detoxification into 
urea[83,84]. 
GSH (entry 7 of Table 1) had a 5.91-fold decrease in the HFD+PCB 153 group (p-value 
of 2.03×10
-3
) and its conjugate, S-(hydroxymethyl)glutathione (entry 6) had a 2.97-fold 
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decrease (p-value of 1.14×10
-2
).  Hepatic mitochondrial GSH depletion has been 
associated with the progression of alcoholic liver disease[85] and blood GSH depletion 
with obesity and diabetes[86]. Lower hepatic GSH content has also been reported in 
non-alcoholic steatosis[87]. Furthermore, Swenberg et al. reported the formation of 
oxidative DNA lesions in PCB 126-exposed rats which was likely due to ROS 
generation[88]. Therefore, the GSH depletion noted in the steatotic livers of mice treated 
with HFD+PCB 153 implies increased oxidative stress leading to extensive utilization of 
GSH which eventually decreased liver GSH stores. Further evidence for oxidative stress 
can also be accounted for by the increased levels of erythronic acid, the degradation 
product of vitamin C, another crucial anti-oxidant.  The mechanism by which PCB 153 
induces oxidative stress needs further investigation. PCB 153 is very poorly 






Figure 7. IPA proof-of-knowledge characterization of the metabolic networks in mouse liver 
affected by PCB 153.The dashed line indicates indirect interactions between metabolites 
while the solid line means a direct metabolite interaction. Filled circles represent metabolites 
discovered in this work and the color of each filled circle represents the direction and 





Unlike PCB 126, which is a potent Ah-receptor agonist strongly inducing CYP1A 
activity, PCB 153 is reported to have weak “Phenobarbital” activity[90] suggesting it will 
be a relatively poor inducer of CYP2B and thus is expected to have relatively poor ability 
to induce monooxygenase activity which could increase the levels of reactive compounds 
that reduce glutathione levels. However, it is possible that the depletion could be due to 
glutathione consumption by increased lipid peroxides which should have been generated 
within the steatotic livers of the HFD+PCB 153 group. It must also be noted that our 
results are consistent with the findings of Twaroski et al., as we observed no effects of 
PCB 153 on glutathione in the presence of a normal rodent chow diet[91]. PCB 
153-mediated glutathione depletion occurring only in the presence of HFD is not only 
innovative, but also probably the most important finding in this study. 
Regardless of its mechanism, the reduction in glutathione (entry 7 of Table 1) would 
diminish its availability for transformation into S-(hydroxymethyl)glutathione (entry 6), 
and should trigger the up-regulation of glutathione biosynthesis from glutamate, glycine, 
and cysteine, its component amino acids. Glutamate is made from the TCA cycle 
intermediate 2-oxoglutarate and ammonia, which could account for the decrease in 
measured D-glucosamine 6-phosphate (entry 4), either from its use as an ammonia source 
or from lowered production due to ammonia depletion. Histidine (entry 1) can also be 
rationalized as an ammonia source by decarboxylation and oxidation or as a source of 
both ammonia and glutamate via the pathway initiated by the action of histidine 
ammonia-lyase. The synthesis of uridine (entry 12) likely falls as ammonia is shunted 
into glutamate production. The degradation of creatine (entry 2) gives rise to glycine 
through the action of creatinase and sarcosine dehydrogenase. Interestingly, reduced 
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serum creatine levels in humans and mouse models has recently been reported in a 
metabolomic profiling studies of steatosis[92] and NAFLD progression[93].  Such a
 
simple accounting of glutathione consumption upon exposure of the liver to PCB 153, 
therefore, provides good rationalization of the observed reduction in metabolite levels 
(Table 1), centered on the glutamate metabolism.  
IPA mapped 7 of the 24 metabolites recognized with significant abundance changes 
between the CD+PCB 153 group and HFD+PCB 153 group. The most probable 
metabolite network reported by IPA contained 6 metabolites including adenosine, 
L-histidine, glutathione, D-glucose, melibiose and S-lactoylglutathione with a score of 16. 
The top hepatotoxicity function is glutathione depletion in liver and the top canonical 
pathway is also glutamate metabolism. D-glucose was detected with a 2.22-fold decrease 
in the HFD+PCB 153 group, indicating a significant decrease of D-glucose in the liver 
due to the exposure to PCB 153. D-glucose has been used as a biomarker for diagnosis of 
liver cancer[35]. GSH was detected with a 19.9-fold decrease in the HFD+PCB 153 
group, and this provides further evidence in the importance of HFD in PCB 153-mediated 
GSH depletion.  
Seven of the 25 metabolites with significant abundance changes between the CD group 
and HFD group were mapped to the IPA database. The most probable metabolite network 
reported by IPA has a score of 11 and contains 5 metabolites including 






Polychlorinated biphenyls (PCBs) are persistent environmental pollutants. The hepatic 
effects of PCB 153 in mice were investigated via a direct infusion nano-electrospray 
ionization linear trap quadrupole - Fourier transform ion cyclotron resonance mass 
spectrometry (DI-nESI-LTQ-FTICR MS). No difference was observed in the metabolite 
profile of mice a fed control diet with or without PCB 153 exposure. However, when 
mice fed a high fat diet were compared with mice fed a control diet, 15 metabolites were 
reduced and 10 metabolites were increased. Compared to the CD+PCB 153 group, 18 
metabolites were reduced while 6 metabolites were increased in the HFD+PCB 153 
group. Compared with the HFD group, 12 metabolites were reduced including 
glutathione and creatine and 2 metabolites were increased, most notably erythronic acid, 
in the HFD+PCB 153 group. These data indicate that PCB 153 had no observable effects 
on metabolites when administered to mice fed CD, which is consistent with the absence 
of histopathology. In contrast, when administered with HFD, PCB 153 produced 
significant metabolic changes (vs. HFD, or CD+PCB 153), which are consistent with 
worsened obesity/NAFLD pathology. Thus, the metabolic effects of PCB 153 were 
heavily dependent on macronutrient interactions with HFD. Antioxidant depletion is 
likely to be an important consequence of this interaction, as this mechanism has 










CHRONIC ALCOHOL EXPOSURE DISTURBS 
LIPID HOMEOSTASIS AT THE ADIPOSE-LIVER 
AXIS: ANALYSIS OF TRIACYLGLYCEROLS 
USING HIGH-RESOLUTION MASS 
SPECTROMETRY IN COMBINATION WITH IN 
VIVO METABOLITE DEUTERIUM LABELING 
 
3.1. Introduction 
It has been understood that dietary fats are digested in the intestinal epithelial cells, and 
then converted to triacylglycerols (TGs). TGs are assembled with apolipoproteins to form 
chylomicrons which are transported into the blood stream via the lymph system[94]. TGs 
are also synthesized by the liver where they are packaged as very low-density 
lipoproteins (VLDL) and secreted into the blood[94]. Upon arrival in the adipose and 
muscle tissues, lipoprotein lipase cleaves TG into free fatty acids and glycerol. Fatty 
acids are taken up by these tissues, and are used as energy sources via oxidation in 
muscles, or re-assembled into TGs to store excess energy in the white adipose tissue 
(WAT)[95]. Glycerol is transported to liver or kidneys where it is converted into 
dihydroxyacetone phosphate by glycerol kinase and glycerol-3-phosphate dehydrogenase.  
WAT plays an important role in regulation of whole body energy homeostasis. WAT 
stores excess energy in the form of TG under positive energy balance condition, and 
releases fatty acids for energy generation under negative energy balance condition[95]. 
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However, excess fatty acid release from the WAT may cause fatty acid overflux into the 
liver, leading to development of fatty liver[96]. Fatty liver is frequently associated with 
both alcohol abuse (alcoholic fatty liver, AFL) and obesity (nonalcoholic fatty liver, 
NAFL). Although previous studies have demonstrated similarities and differences in the 
pathogenesis of fatty liver between alcohol abuse and obesity, increased fatty acid uptake 
has been suggested to be a common mechanism for AFL and NAFL[97,98]. While 
hepatocytes isolated from both alcohol-fed and obese rats showed an increased fatty acid 
uptake[99], further investigation is needed to provide direct evidence that fatty acids 
released from the WAT are indeed deposited in the liver. 
Clinical studies have demonstrated that lower fat mass (lipodystrophy) was associated 
with higher liver fat in alcoholics[100,101]. Animal models of AFL also showed that 
reduction of WAT mass was associated with an increased fatty acid uptake by 
hepatocytes[102-104]. Our study demonstrated that alcohol exposure to mice caused 
more hepatic accumulation of TGs which were labeled before alcohol exposure[105]. We 
also found that alcohol exposure stimulated adipose lipolysis and fatty acid release from 
WAT[105,106]. These data suggest that alcohol exposure may cause an excess reverse 
fatty acid transport, thereby inducing fatty liver. Therefore, the animal model of AFL 
could be an ideal model to identify the importance of WAT in maintaining lipid 
homeostasis at the WAT-liver axis. Further determination of triacylglycerol homeostasis 
at the WAT-liver axis could reveal the direct link between WAT and liver, an 
organ-organ interaction mechanism, in the development of fatty liver. 
The objective of this work was to use high-resolution mass spectrometry in combination 
with metabolite deuterium labeling to test our hypothesis that alcohol exposure disturbs 
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lipid homeostasis at the WAT-liver axis towards triacylglycerol epitomic deposition in 
the liver. In order to differentiate the liver lipids synthesized using fatty acids from other 
sources from that synthesized using the fatty acids transported back from adipose tissue, a 
two-stage feeding experiment was performed, where all mice were first fed with 
deuterated water (
2
H2O) to ensure that the lipids stored in adipose tissue are deuterium 
labeled (stage one). The mice were then randomly grouped into two cohorts, the control 
cohort and the test cohort. Mice in the test cohort were fed an alcohol-containing liquid 
diet while mice in the control cohort were pair-fed an isocaloric maltose dextrin control 
liquid diet. The mice in both the control and test cohorts were then sacrificed at different 
times (stage two). Metabolite extracts from mouse liver, epididymal white adipose tissue 
(eWAT) and subcutaneous white adipose tissue (sWAT) were analyzed using linear trap 
quadrupole–Fourier transform ion cyclotron resonance mass spectrometer (LTQ-FTICR 
MS) via direct infusion electrospray ionization–mass spectrometry.  
3.2. Experimental  
3.2.1. Animals and Treatments 
Male C57BL/6N mice were obtained from Harlan (Indianapolis, IN, USA). All the mice 
were treated according to the experimental procedures approved by the University of 
Louisville Animal Care and Use Committee. To label lipids in adipose tissues, an 
approach using 
2
H2O as the metabolic tracer was followed[107]. Mice at two months old 
were given an initial priming dose of 99.8% 
2
H2O via an intraperitoneal injection to 
achieve 2.5% of body water enrichment, followed by administration of 5% 
2
H2O in the 
drinking water for five weeks (stage one, time point 0 week). The mice were then 
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randomly grouped into two cohorts, the control cohort and the test cohort, for a 4-week of 
alcohol exposure (stage two). The test cohort was fed a modified Lieber-DeCarli alcohol 
liquid diet which contained 1,000 kcal/L calories, 34% from alcohol, 18% from protein, 
34% from fat, and 14% from carbohydrate. The control cohort was fed a modified 
Lieber-DeCarli control liquid diet which also contained 1,000 kcal/L calories with 
replacement of the alcohol calories by isocaloric maltose dextrin. The alcohol-fed mice 
were free access to the alcohol diet, while the pair-fed mice were given the control diet in 
the same amount consumed by alcohol-fed mice in the previous day. The liquid diet 
feeding was conducted for 2 (time point of two weeks) or 4 (time point of four weeks) 
weeks. At the end of each feeding time point, mice were anesthetized, and liver, eWAT 
and sWAT tissues were collected from each mouse for measuring lipid components 
labeled by deuterium. There were 5, 5, 3 and 5, 7, 5 mice at time point 0, 2, 4 weeks for 
the control cohort and the test cohort, respectively. 
3.2.2. Tissue Sample Preparation 
Liver, eWAT and sWAT samples were weighed, homogenized for 2 min and stored at 
–80 °C until use. To extract metabolites from the homogenized tissue, 100 μL of 
homogenized tissue sample, 20 μL of butylatedhydroxytoluene (BHT) mixture (50 mg 
BHT into 1 mL methanol) and 2.0 mL chloroform–methanol (v/v = 2:1) were mixed and 
vortexed for 2 min followed by adding 420 μL of water and vortexing for 2 min. The 
mixture was then centrifuged at room temperature at 2,000 rpm for 8 min. 400 μL of the 
organic phase (bottom) was aspirated into another glass tube and dried using a nitrogen 
evaporator. The dried sample was then dissolved into 200 μL of chloroform–methanol 
(v/v = 2:1). 
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3.2.3. FT-MS and LTQ-MS/MS Analysis 
The direct infusion experiments were performed on a hybrid mass spectrometer, the 
so-called linear trap quadrupole – Fourier transform ion cyclotron resonance mass 
spectrometer (LTQ-FTICR MS or LTQ-FT MS) (Thermo Electron Corporation, Bremen, 
Germany) equipped with a chip-based nano-electrospray ionization (nESI) ion source 
(TriversaNanoMate) (Advion Biosciences, Ithaca, NY, USA). The mass spectrometer 
was operated in the positive ion mode. Each metabolite extract was measured for 5 min 
covering the m/z = 100-1,600 range. The mass spectra were recorded using the FTICR in 
profile mode and the resolving power (RP) was set at 400,000 @ m/z = 400. The 
maximum ion accumulation time was set at 1,000 ms. The ion optics was tuned for the 
sodium adduct of tricaprylin ([C27H50O6+Na
+
]) at m/z = 493.25 using the linear ion trap 
(LIT). The two most important nESI parameters were as follows: the spray voltage = 
+1.8 kV and the nitrogen gas pressure = 0.5 psi. The MS/MS spectrum of each metabolite 
ion was acquired on the LTQ. The parameters were set as follows: precursor ion m/z 
isolation window = ±0.3, spectrum accumulation time = 1 min. The normalized collision 
energy (NCE) is a molecule dependent parameter and ranged from 16 to 40%. 
3.2.4. Metabolite Quantification  
The experimental data were processed using software package MetSign[108]. After peak 
alignment, a contrast based method was employed for normalization[76,77]. Both the 
Fisher’s exact test and the pairwise two-tail t-test were used to study the concentration 
change of each metabolite between the two physiological conditions. The parameters 
used during the analysis are as follows: precursor ion m/z accuracy ≤ 5 ppm and the 
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q-value for false discovery rate (FDR) ≤ 0.2[109]. Temporal analysis as performed to 
study the correlation between time course trajectories measured by Pearson’s correlation 
coefficient and the distance measured by Fisher’s combined probability test[110,111].
 
3.2.5. Metabolite Identification 
Metabolite identification was achieved in two sequential steps, database search and 
MS/MS characterization. Such a metabolite identification process meets the requirement 
of Level 2 metabolite identification, i.e., putatively annotated metabolites[112]. The 
metabolite database search was accomplished by the MetSign software using the 
FTICR-MS data. Each of the measured metabolite ion m/z value and isotopic peak profile 
were compared to the corresponding theoretical information of metabolites recorded in 
the MetSign database, which was composed of all metabolites recorded in the Kyoto 
Encyclopedia of Genes and Genomes, LIPID MAPS, and the Human Metabolome 








To narrow down the metabolite candidates generated by database searching, the MS/MS 
spectra of metabolite peaks with significant concentration changes between two sample 
cohorts were acquired on LTQ-MS/MS. Each experimental MS/MS spectrum was 
compared to the in silico MS/MS spectra of all metabolite candidates using Mass Frontier 
6.0 (Thermo Scientific, FL, USA). The spectral similarity between the experimental 
MS/MS spectrum and the in silico MS/MS spectrum of the metabolite of interest was 
evaluated using Pearson’s correlation coefficient. The metabolite candidate(s) with the 




3.2.6. Measurements of Liver Steatosis and Routine Parameters   
Neutral lipids in the liver were detected by Oil red O staining. Liver cryostat sections 
were cut at 7 μM, fixed with 10% formalin for 5 min, and stained with Oil red O in 
2-propynal solution for 10 min. Plasma alanine aminotransferase (ALT) activity and 
triglyceride and cholesterol concentrations were determined using Infinity Reagents 
(Thermo Scientific, Middletown, VA). Plasma free fatty acids (FFA) were quantified 
using a FFA Quantification Kit (BioVision, San Francisco, CA). Statistical differences 
were analyzed by one-way ANOVA followed by Bonferroni post hoc comparison. The 
data are presented as mean ± SD and p values less than 0.05 were considered as 
significant. 
3.3. Results 
3.3.1. Metabolite Identification 
The metabolite initial assignment via database search was achieved using high-resolution 
FTICR-MS data. Figure 8 is a sample of putative identification of triacylglycerol 
TG(16:0/18:2/20:4)[iso6]. The m/z value of this metabolite was measured as 904.7407 by 
FTICR-MS. By searching the 43,245 database metabolites, this metabolite ion and its 
isotopic peak profile match the corresponding theoretical information of metabolites 







respectively. The number of deuterium atoms incorporated in these three metabolite 




Figure 8. An example of identifying a deuterium incorporated metabolite using MS/MS 
information.The metabolite ion m/z value was measured on FTICR-MS as 904.74066. (A) is 
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the experimental MS/MS spectrum of non-deuterated metabolite. (B) is the matching result 
of the non-deuterated metabolite between the experiment MS/MS spectrum and the 
theoretical MS/MS spectrum generated by Mass Frontier. The matched fragment ions are 
highlighted in red and the not matched ions in black. (C) is the MS/MS spectrum of 
deuterium incorporated metabolite. 
 
non-deuterium incorporated metabolites of these three metabolite candidates should be 
901.7407, 899.7407 and 898.7407, respectively. In order to confirm the initial assignment, 
LTQ-MS/MS experiments were performed to acquire MS/MS spectra for each of these 
metabolite ions. Figure 8A is the LTQ-MS/MS spectrum of the metabolite ion with a 
measured m/z = 901.57. The molecular structures of the candidate metabolites 
HMDB05391, HMDB10508, and HMDB13423 were then uploaded into Mass Frontier 
with corresponding adducts Na+, H+ and K+, respectively, to generate in silico MS/MS 
spectra for each of these three candidates. Each of the in silico spectra was then matched 
to the experimental LTQ-MS/MS spectrum. The in silico MS/MS spectrum of metabolite 
HMDB05391+Na+ has the best match with a Pearson’s correlation coefficient of  
0.9981 and therefore, this metabolite was considered as the metabolite present in the 
sample (Figure 8B).  
It should be pointed out that Mass Frontier software can only predict the m/z values of 
fragment ions, but not the fragment ion abundance. It then matches the m/z values of the 
predicted fragment ions to the m/z values of experiment mass spectrum. Therefore, a high 
value of Pearson’s correlation coefficient only refers to the matching quality of fragment 
ion m/z values between an in silico MS/MS and an experiment MS/MS spectrum.  
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The incorporated deuterium atoms in a metabolite do not significantly affect the 
metabolite fragmentation during MS/MS analysis, resulting in similar MS/MS spectra 
between the deuterium incorporated metabolite and the corresponding non-deuterium 
incorporated metabolite. The only difference between the MS/MS spectra is m/z values 
of the fragment ions that carry deuterium atoms. The difference in the m/z values 
between the corresponding fragment ions in the two spectra may range from zero to the 
mass of all incorporated deuterium atoms. Figure 8C is the LTQ-MS/MS spectrum of a 
deuterium incorporated version of metabolite HMDB05391 with a measured metabolite 
ion m/z = 904.80. The corresponding fragment ions between the deuterium incorporated 
fragment ions and the non-deuterium incorporated fragment ions are (904.80, 901.57), 
(887.99, 883.62), (648.45, 645.39), (624.40, 621.37), (622.39, 619.44), (602.45, 599.44) 
and (600.46, 597.47). The number of incorporated deuterium atoms in each fragment ion 
is 3, 3, 3, 3, 3, 3 and 3, respectively. The spectral similarity between the spectrum of a 
deuterium incorporated metabolite (Figure 8C) and the spectrum of the corresponding 
non-deuterium incorporated metabolite (Figure 8A) was evaluated using Pearson’s 
correlation coefficient, after recognizing the pairs of fragment ions between the spectrum 
of a deuterium incorporated metabolite and the spectrum of a non-deuterium incorporated 
metabolite. The Pearson’s correlation coefficient between the top 10 abundant fragment 
ions in the two spectra displayed in Figures 8A and 8C is 0.8744, showing the high 




3.3.2. Statistical Significance Tests 
Figure 9 depicts peak area distribution of triacylglycerol TG(16:0/18:2/20:4)[iso6] at time 
two weeks among the samples of the test and control cohorts. It can be seen that this 
molecule is significantly increased with a 2.8-fold change in the test cohort compared to 
its level in the control cohort. The fold change was defined as the ratio of the average 
peak area of a metabolite measured in the test cohort divided by the average peak area of 





Figure 9. Sample concentration changes of metabolite in two different physiological 
conditions.The abundance test (pair-wise two-tail t-test) shows that the concentration of this 
metabolite in the test cohort is increased with a fold change of 2.8 and a p-value of 1.4×10-5. 


























































Table 4 lists all of the metabolites identified with significant concentration changes in 
liver between the control cohort and the test cohort at two and four weeks. All of these 
metabolites were identified as deuterium incorporated TGs even though all the 43,245 
metabolites were searched for the metabolite identification. Secondly, the deuterium 
incorporated TGs, 13 at 2 weeks and 10 at 4 weeks, were all increased in the test cohort 
with a 1.7 to 6.3-fold change. Tables 5 list all of the metabolites identified with 
significant concentration changes between the control cohort and the test cohort at two 
and four weeks in the eWAT and sWAT. These metabolites are all deuterium labeled and 
identified as TGs. The number of deuterated TGs was more in the eWAT (10 TGs) 
compared to the sWAT (4 TGs). All these deuteraed TGs were reduced by alcohol 
exposure at either two weeks or four weeks with a fold-change ranged from 0.19 to 0.77. 
Table 4. List of triacylglycerols in liver identified with significant concentration changes 










2 878.7338 7.8×10-3 2.1 TG(16:1/18:2/20:4)[iso6] H+ 1 
2 902.7352 1.0×10-4 8.1 TG(16:0/18:2/20:4)[iso6] Na+ 1 
2 904.7407 1.4×10-5 2.8 TG(16:0/18:2/20:4)[iso6] Na+ 3 
2 907.7698 2.8×10-3 2.8 TG(16:0/18:0/20:4)[iso6] Na+ 4 
    TG(16:0/20:4/20:4)[iso3] H+ 4 
2 926.7360 6.9×10-3 4.2 TG(16:0/20:4/20:4)[iso3] Na+ 1 
    TG(18:3/18:2/22:6)[iso6] H+ 1 
2 927.7376 2.3×10-3 1.9 TG(16:0/20:4/20:4)[iso3] Na+ 2 
2 928.7407 5.7×10-3 1.9 TG(16:0/20:4/20:4)[iso3] Na+ 3 
2 929.7534 1.6×10-2 1.7 TG(16:0/20:4/20:4)[iso3] Na+ 4 
    TG(18:3/18:2/22:6)[iso6] H+ 4 
2 930.7666 3.1×10-2 3.1 TG(18:3/18:3/20:0)[iso3] Na+ 1 
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2 952.7521 8.6×10-3 6.3 TG(18:1/20:4/20:4)[iso3] Na+ 1 
    TG(18:3/20:4/22:6)[iso6] H+ 3 
2 954.7666 9.1×10-3 3.0 TG(20:4/18:1/22:6)[iso6] H+ 1 
2 903.7797 7.2×10-3 na b TG(16:0/18:0/18:0)[iso3] K+ 2 
2 905.7533 4.8×10-3 nab TG(16:0/18:2/20:4)[iso6] Na+ 4 
    TG(16:0/20:4/20:4)[iso3] H+ 2 
4 902.7352 2.1×10-3 3.8 TG(16:0/18:2/20:4)[iso6] Na+ 1 
4 904.7407 4.4×10-2 1.7 TG(16:0/18:2/20:4)[iso6] Na+ 3 
4 926.7360 1.8×10-3 2.7 TG(16:0/20:4/20:4)[iso3] Na+ 1 
    TG(18:3/18:2/22:6)[iso6] H+ 1 
4 927.7376 3.8×10-3 2.5 TG(16:0/20:4/20:4)[iso3] Na+ 2 
4 928.7407 3.6×10-2 1.7 TG(16:0/20:4/20:4)[iso3] Na+ 3 
4 929.7534 2.2×10-2 1.9 TG(16:0/20:4/20:4)[iso3] Na+ 4 
    TG(18:3/18:2/22:6)[iso6] H+ 4 
4 930.7666 3.2×10-2 2.8 TG(18:3/18:3/20:0)[iso3] Na+ 1 
4 952.7521 2.8×10-2 3.6 TG(18:1/20:4/20:4)[iso3] Na+ 1 
    TG(18:3/20:4/22:6)[iso6] H+ 3 
4 953.7545 2.5×10-2 2.7 TG(18:3/20:4/22:6)[iso6] H+ 4 
4 954.7666 5.3×10-3 3.3 TG(20:4/18:1/22:6)[iso6] H+ 1 
a. Fold-change is the ratio of average peak area of a metabolite in the test cohort (T) to 
that in the control cohort (C). 
b. na refers to a metabolite that was detected only in the test cohort. Therefore, the values 
of fold change for these metabolites are not available. 
 
 
3.3.3. Temporal Analysis 
Even though the statistical significance tests support the hypothesis of reverse fatty acid 
transport, it is still necessary to investigate the trajectory of each metabolite in the time 
course. Figure 10 shows three sample time course trajectories in liver, eWAT and sWAT, 
respectively. Figure 10A displays the time course trajectory of triacylglycerol 
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TG(16:0/18:2/20:4)[iso6] with one 
2
H label and one Na+ as adduct ion in liver samples. 
While this TG molecule was not significantly increased in control cohort, it was 
significantly increased in test cohort at 2 weeks and a further elevation was found at 4 
weeks. Figures 10B and 10C show the time course trajectories of 
TG(16:0/16:1/16:1)[iso3] with one 
2
H label and an adduct ion of Na+ in eWAT samples, 
TG(16:0/16:0/18:1)[iso3] with one 
2
H label and an adduct ion of Na+ in sWAT samples, 
respectively. In contrast to the increase in the liver of test cohort, a decrease in 
deuterium-labeled TGs was observed in both the eWAT and sWAT of test cohorts. The 
deuterium-labeled TG(16:0/16:1/16:1)[iso3] in eWAT significantly declined at 2 weeks 
and a further decrease was found at 4 weeks. While deuterium-labeled 
TG(16:0/16:0/18:1)[iso3] in sWAT significantly declined at 2 weeks, no further decrease 
was found at 4 weeks. Time course changes for other deuterium-labeled TGs in liver and 
WAT were listed in Table 4 and Table 5, respectively. 
Figure 11 shows that the time course trajectory of triacylglycerol 
TG(16:0/18:2/20:4)[iso6] without 
2
H label in liver samples of control cohort and test 
cohort. This TG molecule represents hepatic TGs which are synthesized from the dietary 
fats or from de novo lipogenesis, because it did not incorporate any deuterium. In the 
liver of control cohort, this TG molecule did not change at 2 weeks but increased at 4 
weeks. Surprisingly, the test cohort showed a remarkable increase at 2 weeks compared 
to time 0, and a further increase at 4 weeks. The abundance of this TG molecule in the 




Figure 10. Sample time course trajectories of deuterium labeled triacylglycerols detected in 
liver, eWAT and sWAT samples.(A) TG(16:0/18:2/20:4)[iso6] with one 2H label and one 
Na+ as adduct ion in liver samples. (B) TG(16:0/16:1/16:1)[iso3] with one 2H label and an 
adduct ion of Na+ eWAT samples. (C) TG(16:0/16:0/18:1)[iso3] with one 2H label and an 
adduct ion of Na+ in sWAT samples 
 
Figure 11. Time course trajectory of triacylglycerol TG(16:0/18:2/20:4)[iso6] without any 
deuterium labeling in liver samples. 

























3.3.4. Alterations of Hepatic Neutral Lipid and WAT Mass 
To determine an overall change in lipid homeostasis at the liver-WAT axis, neutral lipid 
in the liver and WAT mass were measured. As shown in Figure 12, oil red O staining of 
neutral lipid on cryostat liver sections clearly demonstrated accumulation of lipid droplets 
in the hepatocytes of alcohol-fed mice at 2 weeks. Further increases in number and size 
of the lipid droplets were observed at 4 weeks. In contrast to neutral lipid accumulation in 
the liver, WAT mass was significantly lower in the alcohol-fed mice compared to the 
controls (Figure 13). The weights of both eWAT and sWAT from control mice were 
increased at 2 weeks and a further increase was found at 4 weeks. However, the weights 
of both eWAT and sWAT from alcohol-fed mice did not change at either 2 weeks or 4 
weeks, leading to an increased difference between the control and alcohol mice along the 
4 weeks of experiment. The time course changes in WAT to body weight ratio showed 




Figure 12. Time course changes of hepatic lipid content. Hepatic neutral lipid detected by Oil 
red O staining of cryostat liver sections. Alcohol exposure increased hepatic neutral lipid 




Figure 13.  Time course changes of WAT tissues.(A) WAT mass. The weights of both 
eWAT and sWAT in control mice increased gradually during the 4 weeks of experiment. 
However, the alcohol-fed mice did not show weight change in both eWAT and sWAT at 
either 2 weeks or 4 weeks. (B) WAT to body weight ratio (%). Data are expressed as mean ± 
SD (n=6-8). Statistical differences were analyzed by ANOVA followed by Bonferroni post 









Table 5. List of triacylglycerols in sWAT and eWAT identified with significant concentration 
changes between the control cohort and the test cohort at two and four weeks. 
WAT Time 
(Week) 
m/z p-value Fold change   
(T/C)a 




2 879.7446 2.1×10-2 0.74 TG(16:1/18:2/20:4)[iso6] H+ 2 
2 880.7507 3.9×10-2 0.69 TG(16:0/18:1/18:2)[iso6] Na+ 1 
4 826.7013 1.7×10-3 0.28 TG(16:0/16:1/16:1)[iso3] Na+ 1 
4 879.7446 1.5×10-2 0.74 TG(16:1/18:2/20:4)[iso6] H+ 2 
eWAT 
2 826.7017 4.1×10-4 0.38 TG(16:0/16:1/16:1)[iso3] Na+ 1 
2 850.7013 1.3×10-2 0.68 TG(16:1/16:1/18:2)[iso3] Na+ 1 
2 854.7334 2.7×10-3 0.58 TG(16:0/16:1/20:4)[iso6] H+ 1 
2 855.7378 1.9×10-2 0.70 TG(16:0/16:0/18:2)[iso3] Na+ 2 
4 828.7174 1.6×10-2 0.19 TG(16:0/16:1/16:1)[iso3] Na+ 3 
4 854.7334 1.5×10-2 0.54 TG(16:0/16:1/20:4)[iso6] H+ 1 
4 855.7378 4.4×10-2 0.48 TG(16:0/16:0/18:2)[iso3] Na+ 2 
4 856.7482 2.2×10-3 0.49 TG(16:0/16:0/18:1)[iso3] Na+ 1 
4 879.7445 1.5×10-2 0.73 TG(16:1/18:2/20:4)[iso6] H+ 2 
4 880.7498 7.7×10-3 0.77 TG(16:0/18:1/18:2)[iso6] Na+ 1 
a. Fold-change is the ratio of average peak area of a metabolite in the test cohort (T) to 
that in the control cohort (C). 
 
3.3.5. Routine Parameters 
Table 6 listed the results of routine parameters including body weight, liver weight, liver 
to body weight ratio, and plasma ALT activity and FFA concentration. The test cohort 
showed a lower body weight but a higher liver weight, leading to a significant increase in 
liver/body weight ratio at both 2- and 4-week time points. The plasma ALT activity level, 
an indicator of liver injury, was elevated in the test cohort at both time points. The plasma 
triacylglycerol level was also increased in the test cohort at 4-week. However, plasma 




Table 6. Body weight, liver weight and plasma parameters of the control cohort and the test 
cohort at two and four weeks. 
                          2 weeks                    4 weeks                                       
                     Control         Test       Control          Test 
Body weight (BW, g)  28.6±0.9 a 26.9±1.3 a 32.4±2.7 b 27.9±1.2 a 
Liver weight (g)  1.06±0.04 a 1.16±0.05 b 1.10±0.04 ab 1.32±0.08 c 
Liver/BW ratio (%)  3.69±0.22 a 4.33±0.30 b 3.41±0.16 a 4.77±0.21 c 
ALT (U/L)  20.4±9.1 a 48.2±9.1 b  25.6±3.1 a  58.6±12.6 b 
Triacylglycerol (mg/dL)  93.2±10.4 a 130.5±24.7 ab 110.4±11.3 a  171.9±47.7 b 
Cholesterol (mg/dL)  121.7±19.6 107.1±14.8 110.7±10.3 101.4±10.3 
FFA (mg/dL)  0.36±0.02  0.31±0.05  0.34±0.05 0.33±0.07 
     
Data are expressed as mean ± SD (n=6-8). Statistical differences were analyzed by 
ANOVA followed by Bonferroni post hoc comparison, and means without a common 
letter differ at p<0.05. 
 
3.4. Discussion 
TGs are the group of most abundant lipids in liver, eWAT and sWAT. Analysis of the 
abundance changes of TGs is enough for us to test our hypothesis. Therefore, the 
methanol/water phase of metabolite extract from mouse tissues was discarded during the 
process of metabolite extraction, while the organic phase was used for analysis. It is 
possible that the regulations of other types of metabolites are also changed besides TGs 
during the mouse feeding period. However, the changes of these metabolites are not in 




3.4.1. Biological Experiment Design  
A two-stage animal feeding experiment was performed in this study to differentiate the 
hepatic lipids synthesized from the fatty acids transported back from adipose tissue from 
that synthesized using fatty acids from de novo lipogenesis. It is expected that majority of 
the lipids synthesized in the stage-one experiment were incorporated with a certain 
number of deuterium atoms, and most of them were transported and stored in WAT. The 
purpose of the stage-two experiment was to induce fatty liver in the test cohort and to use 
the mice in the control cohort as reference to monitor the lipid concentration change in 
the mice of the test cohort.  
During the stage-two experiment, lipids were continuously synthesized in the mouse 
livers in both the test and the control cohorts. The lipids synthesized from the uptake of 
dietary fats should not incorporate any deuterium atoms, except a very small fraction of 
naturally occurring deuterium in the dietary fats. Therefore, two forms of lipids should be 
present in mouse liver: deuterium incorporated lipids and non-deuterium incorporated 
lipids. In case of the control cohort, the deuterium incorporated lipids were synthesized 
during the stage-one experiment while the non-deuterium incorporated lipids were 
synthesized in the stage-two experiment.  
3.4.2. Statistical Significance Tests 
Compared to the levels of deuterium incorporated TGs in the control cohort, the 
significant increase of the deuterium incorporated TGs in the test cohort of liver samples 
(Table 4) indicates that extra deuterium incorporated fatty acids were used for the 
synthesis of TGs in alcoholic fatty liver at 2 and 4 weeks. The only source of the extra 
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deuterium incorporated fatty acids is the WATs, where the deuterium incorporated fatty 
acids were stored in the form of TGs during the stage-one experiment. Therefore, a 
reasonable explanation to the increase of deuterium incorporated TGs in alcoholic fatty 
liver in the test cohort is that the deuterium incorporated fatty acids were transported back 
from the WAT after lipolysis due to alcohol consumption. Indeed, such an explanation is 
further substantiated by the decrease of deuterated TGs in eWAT and sWAT, 
respectively (Table 5). This supports our hypothesis, i.e., alcohol consumption  
stimulates lipolysis in the WAT of mice, leading to release of fatty acids, which are 
transported back and deposited in the liver for the synthesis of TGs. 
3.4.3. Temporal Analysis 
Figures 10A demonstrates that portions of the accumulated TGs in fatty liver were 
synthesized using deuterium incorporated fatty acids that were transported back from the 
WAT due to lipolysis, while Figure 10B and 10C demonstrate a significant abundance 
decrease of the deuterated TGs in eWAT and sWAT, respectively. These results reveal a 
direct link between WAT fatty acid release and hepatic TG deposition in the development 
of alcoholic fatty liver. A previous study also demonstrated that diminishing lipid storage 
function in WAT by over-expressing leptin-receptor b (lpr-b) on the aP2-lpr-b promoter 
(aP2lepr-b transgene) in db/db mice attenuated obesity after high fat feeding[113]. 
However, the aP2lepr-b transgene significantly increased liver weight and triglyceride 
concentrations, and accelerated the development of diabetes. Therefore, WAT 
dysfunction in lipid storage could be an important determinant in the pathogenesis 
alcoholic or nonalcoholic fatty liver. 
61 
 
Figure 11 displays the time course trajectory of triacylglycerol TG(16:0/18:2/20:4)[iso6] 
without any deuterium labeling in liver samples. This TG molecule is synthesized by 
using fatty acids from dietary source and/or hepatic de novo lipogenesis rather than by 
using fatty acids transported back from the WAT. The time dependent abundance of this 
metabolite in the test sample is always higher than its abundance in the control sample at 
both 2 weeks and 4 weeks. These data indicate that fatty acids from the WAT are not the 
sole source of TG synthesis, and fatty acids from diet and/or de novo synthesis also 
contribute to the development of alcoholic fatty liver.  
3.4.4. WAT Dysfunction and Fatty Liver 
Time course changes in WAT weight (Figure 13) demonstrated that WAT mass in 
control mice significantly increased along the 4 weeks of feeding. Surprisingly, the WAT 
mass of alcohol fed mice did not changed at either 2 weeks or 4 weeks compared to time 
0, indicating a loss of the lipid storage function. A previous study has reported that 
alcohol feeding to rats reduced total body fat content due to an increase of TG turnover in 
rats, as indicated by a 2.3-fold increase in TG degradation with no significant change in 
TG synthesis[102]. Our previous report also showed that alcohol exposure activates 
lipolysis pathways in WAT, thereby accelerating fatty acid release[105]. Adipose 
lipolysis is regulated positively by catecholamine and negatively by insulin[114]. 
Previous studies suggested that alcohol-increased lipolysis is most likely through 
disturbing insulin signaling rather than enhancing catecholamine-mediated 
lipolysis[102,105,115]. Insulin negatively regulates lipolysis, and phosphodiesterase 4 
(PDE4) and activating protein phosphatase 1 (PP1) mediate insulin signaling via reducing 
cellular cAMP level and dephosphorylating hormone sensitive lipase (HSL), 
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respectively[114].  Although the adipose PDE4 was not affected in the WAT of 
alcohol-fed rats[102], our previous study showed that PP1 protein level was reduced in 
the WAT of alcohol-fed mice[105]. We also found that chronic alcohol exposure 
up-regulated negative regulators of insulin signaling, including phosphatase and tensin 
homolog (PTEN) and suppressor of cytokine signaling 3 (SOC3). In addition to lipid 
storage dysfunction, alcohol exposure also inhibited expression and secretion of 
adipokines including adiponectin and leptin in WAT[116-118]. Both adiponectin and 
leptin critically modulate hepatic lipid metabolism toward reduction of lipid content in 
the liver. Normalizing plasma adiponectin or leptin level was associated with attenuation 
of alcoholic fatty liver[119-121]. Therefore, adipose tissue dysfunction may contribute to 
the development of alcoholic fatty liver by directly supplying fatty acids for hepatic TG 
synthesis or indirectly disturbing adipokine regulation of hepatic lipid metabolism.       
3.4.5. Alcohol-induced Hepatic Lipid Dyshomeostasis 
Alcohol exposure may disturb hepatic lipid metabolism in multiple pathways, including 
fatty acid uptake, fatty acid oxidation, de novo lipogenesis and lipid export[116,122].  
The present study demonstrated that alcohol exposure causes a reverse transport of TGs 
from WAT to the liver. Liver plays a central role in lipid metabolism, but it does not store 
lipid at physiological condition. Balance between TG synthesis and export is a key 
determent of hepatic lipid homeostasis[123,124]. Fatty acids from either blood or de novo 
synthesis are converted to TGs which are exported to the blood in the form of very low 
density lipoproteins (VLDL) for use or storage by the peripheral organs. Even though 
alcohol induces hepatic influx of fatty acids, fatty liver should not be developed as long 
as the liver can efficiently secrete TGs into the blood. Therefore, impaired VLDL 
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secretion should co-exist with hepatic fatty acid influx in the development of alcoholic 
fatty liver. The present study shows that the liver of alcohol-fed mice accumulated TGs 
synthesized by using fatty acids of both deuterium labeled from WAT source and 
non-deuterium labeled from dietary fats or de novo lipogenesis. These data suggest that 
alcohol blunted lipid export. The authors believe that the increased blood TG levels in the 
test cohort at 4 weeks may indicate an impaired TG uptake from VLDL in WATs, rather 
than an increased hepatic TG secretion. Indeed, our previous study demonstrated that 
alcohol exposure significantly reduced the rate of VLDL-TG secretion from the liver to 
the blood[104, 106]. Disruption of VLDL secretion is likely an important mechanism 
underlying alcoholic fatty liver, because improvement of VLDL secretion was associated 
with attenuation of alcoholic fatty liver by zinc, betaine or hepatocyte growth 
factor[104,125,126]. Further investigations are required to determine the mechanisms of 
how alcohol exposure suppresses lipid export function of the liver.  
3.5. Conclusions 
We used an analytical method of employing high-resolution mass spectrometry in 
combination with metabolite deuterium labeling for the analysis of triacylglycerol. A 
two-stage mouse feeding schema was designed, where all mice were first fed with 
deuterated water to label WAT TGs (stage one), followed by pair-feeding an alcohol or 
isocaloric maltose dextrin control liquid diet for two or four weeks. Hepatic lipids 
extracted from the livers, eWAT and sWAT tissues were detected by FTICR–MS and 
LTQ-MS/MS. All observations in this study, including the increase of TGs in the test 
cohort of liver, the simultaneous decrease of TGs in the test cohort of eWAT and sWAT, 
and the agreement between the metabolomics data and the histological data demonstrate 
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that chronic alcohol exposure disturbs lipid homeostasis at the adipose tissue-liver axis 
and therefore, support our hypothesis, that is, alcohol consumption stimulates lipolysis of 
the WAT and leads to an excess release of fatty acids which are transported to the liver 
and deposited as TGs. Furthermore, accumulation of TGs synthesized from fatty acids 


























THE EFFECTS OF CHRONIC ARSENIC 
EXPOSURE IN A MOUSE MODEL OF 
DIET-INDUCED FATTY LIVER DISEASE 
 
4.1. Introduction 
Diet-environment interactions play an important role in the development and progression 
of many human diseases, including fatty liver disease (FLD). According to the prevailing 
two hit hypothesis[127], dietary factors such as excessive fat consumption contribute to the 
formation of fatty liver, which makes the liver susceptible to a second hit which promotes 
the progression to more severe liver injury. Several factors have been shown to mediate the 
progression from simple steatosis (fatty liver) to steatohepatitis (fatty liver with 
inflammation and cell death)[128] and environmental agents that activate these factors can 
contribute to the extent of liver injury[129,130]. For example, arsenic was recently shown 
to contribute to the progression of diet-induced fatty liver disease by increasing 
inflammatory mediators in mouse liver[131]. 
Although several regions in the United States where municipal water supplies and private 
artesian wells have arsenic concentrations exceeding the Maximum Contaminant Level of 
10 parts per billion (ppb) set by the World Health Organization and the Environmental 
Protection Agency, arsenic concentrations can reach much higher concentrations in 
places like Bangladesh and West Bengal[132]. Epidemiological studies in these 
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highly-exposed populations have revealed strong links between arsenic exposure and skin 
lesions, hypertension, cardiovascular disease, respiratory disease, and cancer[133].  In 
the liver, high arsenic exposure results in hepatomegaly, portal hypertension, 
non-cirrhotic portal fibrosis and cancer[134]. It is unclear whether the liver is a primary 
target of toxicity in people exposed to lower levels of arsenic, such as those seen in the 
United States. It is more likely that the adverse effects of arsenic on the liver will depend 
on the presence of other sensitizing factors like fatty liver disease. 
It has been reported that mice fed a diet high in fat and cholesterol (the so-called Western 
Diet) for 10 weeks developed steatosis, while simultaneous exposure to drinking water 
contaminated with arsenic resulted in much more inflammation and cell death[131]. In 
that study, 5 parts per million (ppm) arsenic had no effect on the livers of mice fed a low 
fat control diet. While this concentration is higher than those to which produce 
hepatotoxicity in human populations[134] the absorption, distribution and metabolism of 
arsenic is much different in mice than in humans. Indeed, a recent report showed that it 
took 10 times higher concentrations of drinking water (arsenic 50 ppm) to achieve liver 
arsenic concentrations similar to those seen in humans exposed to arsenic in West Bengal 
[135]. 
To better understand the interactions between arsenic and diet-induced fatty liver disease, 
we employed high throughput comprehensive two-dimensional gas chromatography 
time-of-flight mass spectrometry (GC×GC–TOF MS) to analyze liver metabolites altered 
by arsenic, a high fat diet, and the combination of the two. GC×GC–TOF MS is one of 
the most powerful analytical platforms for metabolomics analyses. It is an emerging 
technology that provides considerably more chemical selectivity than GC-MS. It uses two 
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capillary GC columns connected via a thermal modulator to achieve a high degree of 
separation of metabolites[136-138]. Compared to the 15–60 m length of the first 
dimension column, the length of the second dimension column is very short, in general 
only 0.5–2 m. These two GC columns usually have different stationary phases to 
maximize the orthogonality of the two-dimensional separation system to achieve high 
peak capacity. The analytes co-eluted from the first column are further separated in the 
second column because of the difference of column temperature and the chromatographic 
polarities. The further separated analytes are directed to a high capacity time-of-flight 
mass spectrometry system for detection. The GC×GC–TOF MS platform offers 
significant advantages over other metabolomics platforms for analysis of complex 
samples, including an order-of-magnitude increase in separation capacity, significant 
increase in signal-to-noise ratio and dynamic range, and improvement of mass spectral 
deconvolution and similarity matches[139,140]. Presently, GC×GC-MS has not been 
widely used for large-scale broad-spectrum biomarker discovery most likely due to the 
increased difficulty of data analysis. New bioinformatics tools have recently emerged that 
greatly decrease the personnel time necessary to properly process the GC×GC-MS 
data[141-143] making this approach feasible for large-scale metabolomics studies[3, 5]. 
Our in-house developed bioinformatics tools MetPP combined with GC×GC-MS 





4.2.1. Materials and Reagents 
Chemicals used in this experiment include organic solvents (methanol, chloroform and 
pyridine), amino acids (glycine, L-serine, L-proline, L-phenylalanine, L-threonine, 
L-methionine, L-aspartic acid, L-glutamic acid, L-lysine, L-histidine, and L-alanine), 
organic acids (adipic acid, fumaric acid, malonic acid, oxalic acid, succinic acid), fatty 
acids (butyric acid, dodecanoic acid, hexadecanoic acid, heptadecanoic acid, heptanoic 
acid, nonanoic acid, octadecanoic acid, pentadecanoic acid, tetradecanoic acid, 
tridecanoic acid), oximation and derivatization reagents (tert-butyldimethylchlorosilane 
(TBDMSCI) and N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA)). 
All of these chemicals were purchased from Sigma-Aldrich Corp. (St. Louis, MO, US). A 
deuterated semi-volatile internal standard (ISTD) mixture containing acenaphthene-d10, 
chrysene-d12, 1,4-dichlorobenzene-d4, naphthalene-d8, perylene-d12, phenanthrene-d10 
was purchased from Restek Corp. (Bellefonte, PA, US) 
4.2.2. Spiked-in Samples 
To extract metabolites from mouse liver, a 200 μL aliquot of homogenized liver sample 
was mixed with 800 μL of methanol and vortexed for 1 min, followed by centrifugation 
at 4 °C for 10 min at 15,000 rpm. 0.8 mL of the top solution was aspirated into a plastic 
tube and dried by N2 flow. After dissolving the dried sample with 100 μL of pyridine, 
100 μL of MTBSTFA was added and the derivatization was lasted for 1 hour at 70 °C. 
A mixture of 28 acid standards was prepared at a concentration of 100 μg/mL per acid. 
The acids included glycine, L-alanine, L-proline, L-cystine, L-histidine, L-phenylalanine, 
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L-tyrosine, L-lysine, L-glutamic acid, L-methioneine, L-proline, L-serine, L-threonine, 
L-tryptophan, L-valine, L-leucine, adipic acid, butyric acid, fumaric acid, malonic acid, 
oxalic acid, succinic acid, dodecanoic acid, docosanoic acid, hexadecanoic acid, 
heptadecanoic acid, octadecanoic acid, tetradecanoic acid, nonadecanoic acid, tridecanoic 
acid,  hepadecanoic acid, heptanoic acid, nonanoic acid and pentadecanoic acid. 100 μL 
of the acid mixture was added to 100 μL MTBSTFA at 70 °C and kept 1 hour for 
derivatization.  
Ten μL of the acid mixture was added to the first vial, while 20, 40, 50 and 80 μL of the 
acid mixture were added to the other vials, respectively. Twenty μL of derivatized liver 
extract sample and 5 μL of ISTD at a concentration of 200 μg/mL were added to each of 
the five vials, respectively. Pyridine was then added to each of the 5 vials to make the 
total volume of each aliquot to 105 μL. This resulted in five samples with spiked-in acid 
standards. The acid concentration of the amount of spiked-in acid in the 5 samples is 
approximately 6.4 μg/mL, 12.8 μg/mL, 25.6 μg/mL, 32.0 μg/mL and 51.2 μg/mL, 
respectively. The ratio of the concentrations is 1:2:4:5:8 in terms of the amount of 
spiked-in standards. A blank sample was also prepared in parallel without adding acid 
standards and liver extract. Each of the five samples was injected 6 times on the 
GC×GC-TOF MS instrument to generate one sample group, respectively.  
Of these 28 acids, 23 of them already exist in mouse liver including adipic acid, fumaric 
acid, malonic acid, oxalic acid, dodecanoic acid, hexadecanoic acid, heptadecanoic acid, 
decanoic acid, nonanoic acid, octadecanoic acid, pentadecanoic acid, tetradecanoic acid, 
glycine, L-alanine, L-glutamic acid, L-leucine, L-lysine, L-methionenine, L-phenylanine, 
L-proline, L-serine, L-threonine, and L-valine. The concentration ratio of these metabolites 
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among the five sample groups is not 1:2:4:5:8, due to the presence of these metabolites in 
the mouse liver extract. 
4.2.3. Animals and Diets 
Four week old male C57Bl/6J mice were purchased from The Jackson Laboratory (Bar 
Harbor, ME). Mice were housed in a pathogen-free barrier facility accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care. Food and tap 
water were allowed ad libitum. The procedures of animal care were approved by the 
University of Louisville Institutional Animal Care and Use Committee.  
All mice were fed AIN-76A Purified diet (Harlan Laboratories, Madison, WI) for one 
week to minimize the potential confounding factor of arsenic present in standard 
laboratory chow [144].  Mice were exposed to sodium arsenite (5 ppm in tap water) or 
tap water for one week prior to initiating feeding with either low fat diet (13% of calories 
from fat) or high fat diet (42% of calories from fat) (diets TD.08485 and TD.88137, 
Harlan Laboratories, Madison, WI) for 10 weeks. This exposure level of arsenic was 
shown in literature[131] to cause no overt liver damage in mice fed low-fat diet, but to 
exacerbate high fat diet-induced liver injury. Four different treatment groups were 
evaluated in this study: 6 mice fed a low fat diet and tap water (sample group LFD); 6 
mice fed a low fat diet and tap water containing sodium arsenite (sample group LFD+As); 
5 mice fed a high fat diet and tap water (sample group HFD); 6 mice fed a high fat diet 
and tap water containing sodium arsenite (sample group HFD+As). Food and water 
consumption were measured twice a week. Body weight was measured once a week. For 
termination, mice were anesthetized with ketamine/xylazine (100/15 mg/kg i.m.). 
Portions of liver tissue were frozen immediately in liquid nitrogen.  
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4.2.4. Metabolite Sample Preparation from Mouse Liver 
The liver tissue of each mouse was weighed and then homogenized for 2 min after adding 
water at a ratio of 100 mg liver tissue/mL water. The homogenized sample was then 
stored at –80 °C until use. A 100 µL aliquot of the homogenized liver sample and 400 µL 
methanol were mixed and vortexed for 1 min followed by centrifugation at room 
temperature for 10 min at 15000 rpm. 400 µL of the supernatant was aspirated into a 
plastic tube and dried by N2 flow. The metabolites extracts were then dissolved in 40 µL 
ethoxyamine hydrochloride solution (30 mg/mL) and vigorously vortex-mixed for 1 min. 
Methoxymation was carried out at 70 °C for 1 hour. After adding 40 µL MTBSTFA 
mixed with 1% TBDMSCI, derivatization was carried out at 70 °C for 1 hour. Stock 
solutions were then transferred to GC vials for analysis. The methoxymation and 
derivatization were prepared just before GC×GC–TOF MS analysis.  
4.2.5. GCGC–TOF MS Analysis  
The LECO Pegasus 4D GC×GC –TOF MS instrument was equipped with an Agilent 
6890 gas chromatograph and a Gerstel MPS2 auto-sampler (GERSTEL Inc., Linthicum, 
MD), featuring a LECO two-stage cryogenic modulator and secondary oven. The primary 
column was a 60 m × 0.25 mm 
1
dc × 0.25 μm 
1
df, DB-5ms GC capillary column (phenyl 
arylene polymer virtually equivalent to a (5%-phenyl)-methylpolysiloxane). A second 
GC column of 1 m × 0.25 mm 
1
dc × 0.25 μm 
2
df, DB17ms 
((50%-phenyl)-methylpolysiloxane) was placed inside the secondary GC oven after the 
thermal modulator. Both columns were obtained from Agilent Technologies (Agilent 
Technologies J&W, Santa Clara, CA). The helium carrier gas (99.999% purity) flow rate 
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was set to 1.0 mL/min at a corrected constant flow via pressure ramps. The inlet 
temperature was set at 280 °C. The primary column temperature was programmed with 
an initial temperature of 60 °C for 0.5 min and then ramped at 5 °C /min to 280 °C and 
maintained for 12 min. The secondary column temperature program was set to an initial 
temperature of 70 °C for 0.5 min and then also ramped at the same temperature gradient 
employed in the first column to 280 °C, accordingly. The thermal modulator was set to 
+20 °C relative to the primary oven, and a modulation time of PM = 2.5 s was used. The 
mass range was set as 45−1000 m/z with an acquisition rate of 200 mass spectra per 
second. The ion source chamber was set at 230 °C with the transfer line temperature of 
280 °C, and the detector voltage was 1680 V with electron energy of 70 eV. The 
acceleration voltage was turned on after a solvent delay of 775 s. The split ratio was set at 
40:1. 
4.2.6. Data Analysis 
The GC×GC–TOF MS data were processed using LECO’s instrument control software 
ChromaTOF for peak picking and tentative metabolite identification, followed by 
retention index matching, peak merging, peak list alignment, normalization, and 
statistical significance test. For metabolite identification using ChromaTOF, each 
chromatographic peak was tentatively assigned to a metabolite if its experimental mass 
spectrum and a database spectrum have a spectral similarity score no less than 600. Note 
that the maximum spectral similarity score is 1000. Peak merging and peak list alignment 
were carried out using DISCO software[17], while the retention index matching was 
performed using iMatch software with the p-value threshold set as p ≤ 0.001[18]. The 
pairwise two-tail t-test was used to determine whether a metabolite has a significant 
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abundance difference between sample groups by setting the threshold of false discovery 
rate q ≤ 0.2. 
To further verify the identification of metabolites detected with significant abundance 
difference between sample groups, commercially available authentic standards of these 
metabolites were analyzed on GC×GC–TOF MS under the same experimental conditions 
as the biological samples analyzed. A tentative metabolite assignment was considered as 
a correct identification only if the experimental information of the authentic metabolite 
agreed with the corresponding information of the chromatographic peak in the biological 
samples, i.e., difference of the first dimension retention time ≤ 10 s, difference of the 
second dimension retention time ≤ 0.06 s, and the mass spectral similarity ≥ 700.  
4.2.7. Metabolite Relative Quantification 
To measure the accuracy of recognizing the spiked-in metabolites from the experimental 
data, the receiver operating characteristic (ROC) curve is applied, which is created by 
plotting the true positive rate (TPR) vs. the false positive rate (FPR) at various threshold 
settings. TPR, PPV and their harmonic mean F1 score are calculated as follows:     


















           (4.3) 




where TP (true-positive) is the number of spiked-in metabolites that were detected as 
molecules with significant peak area changes between two testing sample groups by 
statistical analysis, FP (false-positive) is the number of molecules that were not the 
spiked-in metabolites but detected as molecules with significant peak area changes, and 
FN (false-negative) is the number of spiked-in metabolites that were not detected as 
molecules with significant peak area changes. TPR is called recall and PPV precision and 
their harmonic mean F1 score can be used as an accuracy of the statistical significant test. 
Furthermore, the area under curve (AUC) in the ROC curve is equal to the probability of 
positive outcomes being higher than the negative ones. The higher the AUC score is, the 
better the observed accuracy of the test for statistical significance. 
4.3. Results 
Figure 14 depicts the analysis workflow of this study. Metabolites were first extracted 
from mouse liver using solvent of methanol and water. The extracted metabolites were 
then analyzed on GC×GC–TOF MS instrument after derivatization. A suite of 
bioinformatics tools were then employed for metabolite identification, quantification and 
pathway analysis.  
GC×GC–TOF MS instrument data provide four pieces of information for each metabolite, 
the first dimension retention time 
1
tR, the second dimension retention time 
2
tR, fragment 
ion m/z, and peak height of each fragment ion. The information of fragment ion m/z and 
peak height forms the mass spectrum of the metabolite. Figure 15 is a contour plot of the 
GC×GC–TOF MS data acquired from a sample randomly selected from the sample group 





Figure 14.  Workflow of metabolomics Study by GC×GC-TOF MS. 
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    Figure 15. Sample GC×GC–TOF MS chromatograms of metabolite extract from mouse 
liver. The x-axis is the first dimension retention time 1tR in seconds. The y-axis is the second 
dimension retention time 2tR in seconds. The color bar shows the signal intensity of each peak 
plotted on the chromatogram in total ion current.  
 
The instrument data were first processed using commercial software ChromaTOF for 
peak picking and initial compound identification using the vendor recommended 
parameters, and the information of the top 1500 abundant chromatographic peaks were 
reported. By setting the threshold of spectral similarity ≥ 600, about 570-730 
chromatographic peaks were assigned to compounds in each sample, while the remaining 
chromatographic peaks were assigned as unknowns. The average peak area of the 
chromatographic peaks with initial identification results is about 6 times larger than the 
average peak area of the chromatographic peaks assigned as unknowns. The 
chromatographic peaks with positive identifications were further subjected for retention 
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index matching using iMatch algorithm. By setting the threshold p ≤ 0.001, about 
380-520 compounds had correct retention index values in each sample and the remaining 
chromatographic peaks were re-assigned as unknowns. All retention index matched 
compounds were used for alignment using DISCO algorithm. A total of 402 peaks were 
aligned.  The aligned metabolites were further filtered by removing compounds detected 
in the blank samples as well as the compounds that detected in less than 75% of samples 
in each sample group. By doing so, about 100 metabolites left between two sample 
groups for statistical significance test and FDR analysis. 
The ability of the platform to accurately identify metabolites with significant abundance 
differences between two sample groups was assessed by spiking different concentrations 
of a mixture of standards into a sample. Figure 17 shows the receiver operator curves 
produced by these spike-in experiments. A large value of area under curve (AUC) in the 
receiver operating characteristic (ROC) curve demonstrates that the analytical platform 
and the data analysis methods used in this study are effective in recognizing the 
metabolites with significant differences.  
4.3.1. Metabolite Identification 
Metabolite identification was done in three sequential steps in this study: mass spectral 
matching, retention index matching, and comparison with authentic standards. It is 
common that multiple distinct chromatographic peaks can be assigned to the same 
metabolite by mass spectral matching, due to limited accuracy of the identification 
algorithm[139,140]. For example, glycine, N-(tert-butyldimethylsilyl)-, 
tert-butylsimethylsilyl ester was assigned to three distinct chromatographic peaks with 
two-dimensional retention times of (1655 s, 1.155 s), (1845 s, 1.055 s) and (1850 s, 1.045 
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s), respectively. The spectral similarity of these three assignments to the mass spectra in 
the NIST11 database was 872, 731 and 787, respectively. In order to reduce the rate of 
false identification, we employed a second round of retention index matching to remove 
the false positive identifications. By setting the threshold p ≤ 0.001 in iMatch software, 
the chromatographic peaks with the two-dimensional retention time values of (1845 s, 
1.055 s) and (1850 s, 1.045 s) were recognized as false identifications and excluded from 
the downstream analysis, due to large retention index difference.  
Metabolite identifications based on retention index matching were further confirmed by 
comparison to authentic standards. For example, glycine was detected as a metabolite 
with significant abundance changes between different sample groups. The retention time 
values for the metabolite identified as glycine in the biological samples were (1655 s, 
1.155 s). The authentic standard of glycine that was derivatized and analyzed on 
GC×GC–TOF MS under the same conditions as the biological samples eluted at 
1
tR = 
1655 s and 
2
tR = 1.165 s, which is very similar to the peaks eluted in the biological 
sample with identical 
1
tR and a difference of 0.01 s in 
2
tR. The mass spectral similarity 
between the authentic standards and the biological sample was 970, demonstrating the 
correct identification of glycine from the biological samples.  
Some metabolites tentatively assigned by mass spectrum matching and retention index 
filtering were not compared to authentic standards because they were not available in our 
laboratory. Because this technical verification was not performed, their identification 
remained tentative. Tentatively-identified metabolites were considered as false 
identifications and removed from the identification list, if they were recognized as drugs 
or from non-mammalian animals during metabolic network analysis by the Ingenuity 
79 
 
Pathway Analysis (IPA) software (Ingenuity Systems, Inc., Redwood City, CA). The 
remaining tentatively-identified metabolites were included in subsequent analyses, but 
they have been labeled as tentative in Tables 7 through 9. 
4.3.2. Metabolite Quantification 
About 500-800 metabolites were identified in each mouse liver sample via mass spectral 
matching. By setting p ≤ 0.001, 18.6% of the identified metabolites were confirmed by 
the first dimension retention index matching and 51.8% were preserved due to the lack of 
retention index information in the NIST11 database. However, 29.5% of the mass 
spectral matched metabolites were removed due to the large first dimension retention 
index deviation from the database values. The mean absolute deviation between the 
database value and experimental retention index of the removed metabolites is 318 i.u. 
with a standard deviation of 267 i.u. The corresponding values of the preserved 
metabolites are 21 ± 16 i.u. 
After the retention time filtering, about 300–500 peaks were left in each sample for 
alignment. Among the aligned peaks, the maximum value of the RSD for the first 
dimensional retention time and the second dimensional retention time was only 3.15% 
and 3.30%, respectively. 
To study the abundance change of a metabolite between two testing sample groups, the 
pairwise two-tail t-test was employed by setting the threshold of false discovery rate as q 
≤ 0.2. A term fold-change was defined as the ratio of the large abundance value (peak 
area) of a metabolite in one group divided by the small abundance value of the same 
metabolite in the other group. A positive sign and a negative sign indicate the abundance 
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increase and decrease in the testing sample group compared to the reference sample 
group, respectively.  
Figure 16 depicts a sample abundance distribution of metabolite glycine in sample groups 
HFD and HFD+As. Glycine was detected by the statistical significance test as one of the 
metabolites that have significant abundance changes between these two sample groups. 
Compared with its abundance in the HFD group, glycine is 1.7-fold lower in the 




Figure 16.  Abundance distribution of metabolite glycine in the samples of HFD+As group 
and HFD group.The abundance test (pairwise two-tail t-test) shows that the regulation of this 
metabolite in the HFD+As group is decreased with a fold change of 1.7 and a p-value of 
5.0×10-3 comparing with HFD group. 
 
Mice fed a high fat diet develop steatotosis[131]. To establish the metabolomic changes 
that accompany this liver injury, the metabolites with significant differences in 
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abundance between the HFD group and the LFD group were determined (Table 7). Eight 
metabolites were increased and one metabolite was decreased in the HFD group relative 
to the LFD group. As would be expected when comparing mice fed a diet high in fat to 
mice fed a low fat diet, two of the increased metabolites were fatty acids, whereas none 
of the decreased metabolite was fatty acids. 
Table 8 shows the effects of arsenic in mice fed the low fat diet (LFD+As vs. LFD). 
There were no signs of liver injury in either of these groups, but there were significant 
metabolic differences resulting from arsenic exposure. The abundance of one metabolite 
was decreased while seven metabolites were increased in the LFD+As group compared to 
the LFD group. Three fatty acids were detected with significant regulation changes by 
arsenic. The levels of two fatty acids were increased while one was decreased. 
Table 9 presents the results of arguably the most important comparison in this study: the 
metabolic differences between the HFD and HFD+As groups. Whereas the HFD 
produces mild liver injury in the form of steatosis, co-exposure to arsenic results in even 
more severe liver injury, with elevated markers of inflammation and cell death[131]. The 
combination of arsenic and a high fat diet (HFD+As) resulted in abundance changes in 
nine metabolites relative to the effect of a high fat diet alone (HFD), with six metabolites 
decreasing and three metabolites increasing. The metabolites that were lower in the 
HFD+As group were short-chain fatty acids, medium-chain fatty acids, the two acidic 
amino acids, aspartate and glutamate, and the anti-inflammatory amino acid glycine. The 
metabolites that were higher in the HFD+As group were the amino acids cysteine and 

















 2323.8 1.228 544-63-8 1.5 
Pentadecanoic acid 1.4×10
-4
 2432.6 1.243 1002-84-2 2.3 
L-Cysteine 3.0×10
-5
 2440.0 1.262 7048-04-6 1.7 
L-Threonine 2.4×10
-2
 1900.5 1.208 72-19-5 2.1 
L-Lysine 5.2×10
-4







 2205.1 1.363 6628-79-1  1.2 
L-Methionine 1.3×10
-2
 2177.5 1.280 63-68-3 1.4 
L-Glutamic acid 2.4×10
-2
 2510.0 1.244 56-86-0 1.5 
Taurine 3.8×10
-6
 2117.5 1.351 107-35-7 4.5 
a The sample group LFD is the reference group. “+” sign refers to abundance increase in 
sample group HFD, while “ –” sign refers to abundance decrease in HFD group. 











Table 8.  Metabolites with significance abundance difference between sample groups 












 1397.5 1.158 111-14-8 -1.4 
Dodecanoic acid 3.5×10
-3
 2089.3 1.204 143-07-7 1.7 
Pentadecanoic acid 3.3×10
-2
 2432.6 1.243 1002-84-2 1.3 
L-Proline 1.2×10
-2
 1935.1 1.235 147-85-3 1.2 
L-Cysteine 3.0×10
-2
 2440.0 1.262 7048-04-6 1.3 
L-Methionine 3.0×10
-3










 2205.1 1.363 6628-79-1  1.8 
a The sample group LFD is the reference group. “+” sign refers to abundance increase in 
sample group LFD+As, while “ –” sign refers to abundance decrease in LFD+As group. 










Table 9.  Metabolites with significance abundance difference between sample groups 












 2089.3 1.204 143-07-7 -1.3 
Glycine 5.0×10
-3





 1686.9 1.166 594-61-6 -1.6 
L-Glutamic acid 4.2×10
-3
 2510.0 1.244 56-86-0 -1.4 
2-Hydroxybutyric acid 4.9×10
-2
 1642.4 1.135 600-15-7 -1.4 
L-Aspartic acid 4.6×10
-2
 2385.0 1.225 56-84-8 -1.2 
L-Cysteine 1.5×10
-2





 2911.1 1.593 77-92-9 1.7 
L-Lysine 6.0×10
-2
 2625.7 1.272 56-87-1 1.7 
a The sample group HFD is the reference group. “+” sign refers to abundance increase in 
sample group HFD+As, while “ –” sign refers to abundance decrease in HFD+As group. 
b Tentative identification without technical verification using authentic standards. 
 
4.3.3. Analysis of Spike-in Samples 
A total of 30 samples were analyzed on GC×GC-TOF MS. Manual review of the peak 
lists generated by ChromaTOF shows that the 28 spiked-in metabolites were correctly 
identified in every sample. Of the 28 spiked-in metabolites, 23 metabolites were 
originally present in mouse liver extract. Therefore, the concentrations of these 23 
metabolites are different from the other 5 spiked-in metabolites in each sample group.  
About 300 peak entries in each sample were assigned to a metabolite name via mass 
spectral matching. For retention index matching, the confidence interval of the empirical 
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distribution function of the absolute retention index deviation to its mean value was set as 
p ≤ 0.001. 20.7% of the identified metabolites were confirmed by the first dimension 
retention index matching and 53.5% were also preserved due to the lack of retention 
index information in the NIST11 retention index database. However, 25.8% of the mass 
spectral matched metabolites were removed due to the large first dimension retention 
index deviation from the database values. The mean absolute deviation between the 
database value and experimental retention index of the removed metabolites is 308 index 
units (i.u.) with a standard deviation of 257 i.u. The corresponding values of the 
preserved metabolites are 28 ± 12 i.u. All 28 spiked-in metabolites are preserved in each 
of the 30 samples after the retention index matching. Metabolites butyric acid and 
L-tryptophan were preserved due to the lack of retention index values in the NIST11 
database while the others were preserved by correct retention index match. 
About 200–400 peaks were left in each sample for alignment. Peak picking is likely the 
primary cause for such variation. By manual validation, all 28 spiked-in metabolites were 
present in all 30 samples with a relative standard deviation (RSD) of the first and second 
dimensional retention times of 0.07% and 0.55%, respectively, demonstrating a very 
good stability of the instrument during the two-dimensional GC separation and a high 
accuracy of ChromaTOF in determining peak location in the two-dimensional gas 
chromatograms. 
Figure 17 depicts the peak area distribution of the 28 spiked-in metabolites in G10 before 
and after peak area conversion. A large variation in each box represents the peak area 
variation of the same compound between the 6 samples. By design, each compound 




Figure 17.  Boxplot of peak area of the 28 spiked-in metabolites in G10 before reference 
spectrum-based peak area conversion (A) and after the reference spectrum-based peak area 






only the peak area of a quant mass (a fragment ion that has the highest quality for 
quantification), and it often chooses different quant mass for the same metabolite, 
depending on the data. Of the 28 metabolites, 10 metabolites in at least one of the 6 
samples have quant mass different from the other samples. For instance, compound 4 
(oxalic acid) in Figure 17(A) has 2 quant mass values and the value of peak area has a 
large deviation, ranging from 1,041,108 to 3,206,235. After reference spectrum-based 
peak area conversion, the span of peak area is greatly reduced to 1,329,043–1,935,698 
(Figure 17(B)), demonstrating the effectiveness of the reference spectrum-based peak 
area conversion. The converted peak area values not only reduced the variation in peak 
area, but also guarantee the consistency of the values of peak area across samples for the 
downstream statistical analysis. 
To demonstrate whether the concentration differences of the spiked-in metabolite 
standards can be recognized from the alignment table, a two-tailed t-test was used to 
check the mean difference of the peak area of each compound between sample groups 
through different p-value settings. The true positive rate (TPR) and the false positive rate 
(FPR) are used as measures for metabolite relative quantification. Figure 18 depicts the 
ROC curve of recognizing the concentration difference of the spiked-in metabolite 
standards between sample groups using the alignment results. As expected, the FPR 
increases with the increase of TPR. The TPR levels off at 1.0 when the FPR reaches 0.9 




Figure 18.  The receiver operating characteristic (ROC) curve of the spike-in data. The area 
under curve (AUC) of the three comparisons is 0.87, 0.71, and 0.81 for G20 vs. G10, G40 vs. 
G10 and G40 vs. G20, respectively. 
 
0.87, while the AUC of the ROC curve of G20 vs. G40 and G10 vs. G40 is 0.71 and 0.81, 
respectively. A high value of AUC indicates a high accuracy of recognizing the 
concentration difference of the spiked-in compounds between sample groups, which is 
achieved on the basis of correct alignment of the spiked-in compounds. Moreover, it is 
worth mentioning that the spiked-in metabolites that were not recognized as metabolites 
with significant concentration difference between the two testing sample groups are all 
present in the mouse liver extract before the addition of the mixture of authentic 
standards. This means that the concentration differences of these metabolites between 
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sample groups may be much smaller than 2:1 or 4:1, depending on the amount of the 
metabolites in each sample of mouse liver extract. 
4.4. Discussion 
Multiple data analysis steps were involved in analysis of the GC×GC–TOF MS data in 
this study. In order to control the false discovery rate, the experimental data were 
analyzed using different values of FDR threshold including q ≤ 0.05, 0.1, 0.15, 0.2 and 
0.3. The numbers of metabolites detected with significant abundance change between two 
sample groups are listed in Table 10. It is generally known that the statistical power 
increases as the FDR increases at a fixed sample size, while the power increases as the 
sample size increases at a fixed FDR[145]. Consequently, a larger FDR threshold is 
required to achieve a desirable power when the sample size is small. For this reason, we 
selected q ≤ 0.2 to achieve a reasonable power due to the small sample size in this study. 
Figure 19 depicts the clustering results of the four sample groups. The results presented 
here demonstrate that both high dietary fat intake and environmental arsenic exposure 
exert effects on liver metabolism, and that the combination of the two exposures yields a 
unique metabolite profile that may offer some insight into the mechanisms of liver injury. 
Previously, we showed that mice fed the so-called Western diet (a diet high in milk fat 
and cholesterol) for 10 weeks gained more weight and had significantly more fat in their 
livers than mice fed a low fat diet[131], consistent with other studies using this 
diet[146,147]. Importantly, co-exposure to arsenic-containing drinking water resulted in 
significantly greater inflammatory liver injury in this model[131], suggesting that arsenic 





Figure 19.  Clustering analysis of the four sample groups using fuzzy C mean algorithm. 
The input data were the abundance of all metabolites that were detected with significant 
regulation changes between two or more sample groups when the FDR threshold q≤0.2.  
(A) depicts the clustering results of all four sample groups. The overall clustering accuracy 






Table 10.  The number of metabolites with significant differences between sample groups 
with different values of FDR threshold. It should be noted that the number of metabolites 
detected with significant difference between sample groups are different from these listed in 
Tables 7, 8, 9. The number of metabolites listed in this table was directly calculated from the 
alignment table. That is the identifications of these compounds were not yet confirmed using 
the methods described in section 4.3.1. 
 








q ≤ 0.05 9 8 0 25 
q ≤ 0.1 14 12 6 30 
q ≤ 0.15 15 20 10 31 
q ≤ 0.2 25 20 12 36 




In the context of the two hit hypothesis of steatohepatitis[127], one should consider how 
the metabolic changes elicited by the first hit (high fat diet) are affected by the second hit 
(arsenic). The high fat diet significantly altered nine metabolites (Table 7), and the 
addition of arsenic resulted in further alterations in three of these metabolites (Table 9). 
The HFD-induced increase in cysteine was amplified, whereas the increase in glutamate 
was blocked, by co-exposure to arsenic. Also, the HFD-induced decrease in lysine was 
reversed by arsenic. Furthermore, six additional metabolites were changed by the 
combination of the high fat diet and arsenic that were not altered by the high fat diet 
alone. Among these, glycine was decreased by the combination of arsenic and a high fat 
diet. Therefore, all three of the amino acids that constitute the antioxidant glutathione 
(glutamate, cysteine and glycine) were altered, with glutamate and glycine levels lower 
and cysteine levels higher. Under normal conditions, cysteine concentrations are near the 
Km for the rate-limiting enzyme glutathione synthesis[148], and an increase in cysteine 
would be expected to increase the rate of synthesis. Indeed, Literature reported that mice 
exposed to arsenic for 8 weeks had elevated levels of hepatic glutathione[149]. Thus, 
arsenic exposure may evoke a compensatory increase in glutathione synthesis in the liver, 
at least in response to these relatively short exposures. The increase in cysteine observed 
in the current study could reflect increased uptake of this rate-limiting amino acid in an 
attempt by the liver to compensate for an increased demand for glutathione synthesis. 
Cysteine is taken up by the cystine/glutamate antiporter, which exchanges extracellular 
cystine for intracellular gluatamate. The expression of this transporter is induced by 
oxidants, electrophiles and inflammatory mediators. Therefore, the increase in cysteine 
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and decrease in glutamate observed in the present study may reflect increased activity of 
this transporter.   
In addition to altered glycine, alterations in five other metabolites were specific to the 
HFD+As group. Three of these were fatty acids or fatty acid metabolites, and each of 
these was found to be decreased relative to the high fat diet alone. The high fat diet used 
in this study contained 21% (w/w) milk fat. The major fatty acids found in milk fat are 
palmitic acid (C16:0, 30% of the fatty acids), stearic acid (C18:0, 12%), myristic acid 
(C14:0, 11%) and lauric acid (C12:0, 3.3%) [150]. We observed an increase in myristic 
acid in the livers of mice fed a high milk fat diet when compared to the mice fed the low 
fat control diet, but not palmitic, stearic or lauric acids.  
Interestingly, when mice were co-exposed to arsenic and a high fat diet, there was a 
decline in hepatic lauric acid levels. Diets high in saturated medium chain fatty acids, 
such as lauric acid, protect against inflammatory liver injury caused by chronic alcohol 
ingestion[151]
 
or acute endotoxin administration[152]. Recently, in a model of 
non-alcoholic fatty liver disease where rats were fed diets supplying 70% of calories from 
fat, replacing fat from corn oil with fats enriched in medium-chain triglycerides 
decreased steatosis and liver injury[153]. The mechanisms by which medium-chain lipids 
in general and lauric acid in particular inhibit inflammatory liver injury are not clear. In 
fact, some in vitro studies have found that lauric acid can by pro-inflammatory. For 
example, lauric acid increased inflammatory cytokine production by astrocytes and 
macrophages via activation of TLR4 signaling[154,155], but it had no effect on cytokine 
production by adipocytes or endothelial cells[156,157]. It is possible that hepatic lauric 
acid contributes to inflammatory liver injury independently of any effects on cytokine 
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production; its levels may influence responses to cytokines, or it may be a marker of 
alterations in other critical pathways like mitochondrial fatty acid oxidation[158]. 
Additional studies will be needed to determine how arsenic and a high fat diet contribute 
to the down-regulation of lauric acid, and whether this down-regulation contributes to 
increased inflammation and/or injury in this model.  
Two other fatty acid metabolites were decreased in the livers of mice fed arsenic and a 
high fat diet: 2-hydroxybutyrate and 2-aminobutyrate. Both of these compounds can be 
produced by the catabolism of threonine, and 2-hydroxybutyrate can also be formed in 
the conversion of methionine to cysteine in the transsulfuration pathway. A decrease in 
serum 2-hydroxybutyrate was recently reported in children with cystic fibrosis[159], a 
disease associated with increased inflammation.  It remains to be determined whether 
decreases in these metabolites are common to early stages of inflammatory tissue injury.   
The decrease in glycine in the HFD+As group relative to the HFD group may be an 
important clue as to the mechanism by which the combination of arsenic and a high fat 
diet leads to inflammatory liver injury. Glycine supplementation protects the liver in a 
number of inflammatory injury models[160,161] by acting on glycine-gated chloride 
channels on Kupffer cells to inhibit inflammatory cytokine production[160,162,163]. The 
glycine deficiency in our model may have promoted pro-inflammatory signaling. In 
support of this, we observed a dramatic increase in the number of activated Kupffer cells, 
as determined by F4/80 staining, in response to arsenic exposure in the HFD group[131].  
It is unclear how arsenic and a high fat diet deplete hepatic glycine, but altered glycine 
metabolism could play a role. Threonine dehydratase is inhibited by cysteine[164], which 
is elevated by arsenic and a high fat diet, both alone and in combination. Serine 
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hydroxymethyltransferase has an active site cysteine as well as two closely-spaced 
(vicinal) surface-exposed cysteines that can alter activity when modified by sulfhydryl 
reagents[165, 166]. Arsenic binds to vicinal dithiols[167], but it is not known whether 
serine hydroxymethyltransferase is a target of arsenic binding. 
Metabolomics is a powerful approach for the discovery of pathways altered by 
environmental and dietary exposures related to disease. When used to investigate the 
combined effects of a high fat diet and arsenic in producing fatty liver with inflammation 
and cell death, metabolomic analyses revealed significant changes in the metabolism of 
short-chain and medium-chain fatty acids, as well as alterations in the pathways 
producing the anti-inflammatory amino acid glycine. Further investigations into the 
mechanisms by which these pathways are altered and the specific roles they play in the 
progression of non-alcoholic fatty liver disease are warranted.  
Metabolites in mouse liver can have very diverse chemical characteristics. In this work, 
metabolites were extracted by water and methanol. Most of the nonpolar metabolites 
were lost during this analytical step. The extracted metabolites were then analyzed on 
GC×GC-TOF MS. Even though the GC×GC-TOF MS has a large separation power, it may 
not be enough to resolve all metabolites, resulting overlapping chromatographic peaks that 
introduces significant challenges for metabolite identification and quantification. In this 
work, metabolite identification was first achieved by matching the experimental mass 
spectra to the mass spectra recorded in the NIST mass spectral library. The incompleteness 
of the existing mass spectral library does not only introduce a certain degree of 
false-positive identifications, but also leaves a number of chromatographic peaks without 
any compound identification. All of these technical limitations in the current study prevent 
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us from seeing the entire picture of the metabolite profile in mouse liver. Further studies 
such as using different extraction methods, combining both GC×GC-TOF MS and 2D 
LC-MS, and applying multiple mass spectral libraries for metabolite identification may 
provide more comprehensive results. Further studies with a larger sample size will be also 
necessary to confirm the results in this study. 
The high accuracy of clustering between sample groups HFD vs. LFD, HFD+As vs. HFD 
and LFD+As vs. LFD indicates that the high-fat diet and arsenic contaminated water can 
significantly change the metabolite profile in mouse liver. Comparing the clustering 
accuracy of (A) and (B), the low value of overall clustering accuracy for clustering all four 
sample groups in (A) was mainly caused by a ceartin degree of similarity of metabolite 
profile between sample groups LFD+As and HFD+As. 
4.5. Conclusions 
GC×GC-TOF MS was used to identify metabolites that were significantly increased or 
decreased in the livers of mice fed a Western diet (a diet high in fat and cholesterol) and 
co-exposed to arsenic-contaminated drinking water, to investigate potential mechanisms of 
this diet-environment interaction. The results showed that there are distinct hepatic 
metabolomic profiles associated with eating a high fat diet, drinking arsenic contaminated 
water, and the combination of the two. Among the metabolites that were decreased when 
arsenic exposure was combined with a high fat diet were hepatoprotective short chain and 
medium-chain fatty acid metabolites and the anti-inflammatory amino acid glycine. 
These results are consistent with the observed increase in inflammation and cell death in 
the livers of these mice and point to potentially novel mechanisms by which these 
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HEPATIC AND FECAL METABOLOMIC 
ANALYSIS OF THE EFFECTS OF 
LACTOBACILLUS RHAMNOSUS GG ON 
ALCOHOLIC FATTY LIVER DISEASE IN MICE  
5.1. Introduction 
Lactobacillus rhamnosus GG (LGG), a strain of the bacterium, Lactobacillus rhamnosus, 
has a great affinity for human intestinal mucosal cells. Previous studies in our laboratory 
and others demonstrated that LGG is effective in the treatment of alcohol-induced liver 
injury in rodents[168-171].
 
More recently, we have shown that LGG culture supernatant 
(LGGs) is effective in prevention of acute and chronic alcohol exposure-induced fatty 
liver[172,173]. LGGs administration markedly attenuates the effects of alcohol exposure 
on intestinal barrier dysfunction, by increasing intestinal mucus factors and epithelial 
tight junction protein expression, leading to decreased circulation endotoxin levels. In 
addition, LGGs activates hepatic 5' adenosine monophosphate-activated protein kinase-α 
(AMPKα) phosphorylation, which is critical for liver lipid degradation[174]. 
To gain insight into the metabolic mechanisms by which LGGs exerts an influence in 
alcoholic liver disease (ALD), investigation of metabolome alteration using high 
throughput metabolomics analysis is needed. Comprehensive two-dimensional gas 
chromatography time-of-flight mass spectrometry (GC×GC–TOF MS) is a powerful 
analytical platform in metabolomics. It uses two distinctly different capillary GC columns 
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of different polarities connected via a thermal modulator[137,138,175]. The analytes 
co-eluted from the first column are further separated in the second column because of the 
difference of column temperature and the chromatographic polarities. The further 
separated analytes are detected by a time-of-flight mass spectrometer. The GC×GC–TOF 
MS platform has significant advantages for complex sample analysis including: an 
order-of-magnitude increase in separation capacity, significant increase in signal-to-noise 
ratio and dynamic range and improvement of mass spectral deconvolution and similarity 
matches[176-178]. 
The objectives of this study were to determine if the beneficial effects of LGGs 
administration on the prevention of ALD are associated with alterations in metabolic 
profiles in the liver and fecal metabolome. Male C57BL/6 mice were pair-fed either an 
isocaloric control diet (PF) or alcohol-containing diet (AF) for 4 weeks with or without 
LGGs co-exposure. Liver and fecal samples were collected at the end of the experiments. 
The metabolite extracts from mouse livers and feces were analyzed on GC×GC–TOF MS 
for metabolic profiling.  
5.2. Experimental Methods 
5.2.1. Animals and Diets 
C57BL/6 male mice obtained from Harlan (Indianapolis, IN) were fed a modified 
Lieber-DeCarli liquid diet (Research Diet, New Brunswick, NJ). Mice were fed 
EtOH-containing diets (35% of total calories, AF) ad libitum for 4 weeks. Control mice 
were pair-fed isocaloric diet in which EtOH was replaced with maltose-dextrin. LGG was 
cultured following the instruction provided by ATCC (Manasses, VA). The culture 
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supernatant was collected when LGG bacterial growth reached 10
9
 CFU/ml. The LGG 
supernatant (LGGs) was added to the liquid diet at a dose equivalent to 10
9
 
CFU/mouse/day. At the end of the experiment, the mice were anesthetized, and the fecal 
samples and liver samples were harvested. A portion of liver samples was fixed in 
formalin, while the rest of the liver samples and the fecal samples were frozen 
immediately in liquid nitrogen and stored at -80 ºC for later assays. The animal protocol 
was approved by the University of Louisville Institutional Animal Care and Use 
Committee.  
5.2.2. Liver Oil Red O Staining and Liver Total Free Fatty Acid 
Analysis 
Frozen liver sections were processed for staining with Oil red O and then studied by light 
microscopy. Hepatic free fatty acid levels were measured using Infinity kits (Thermo 
Scientific, Waltham, MA). 
5.2.3. Metabolite Sample Preparation 
Fecal sample was first weighed and ground on ice. Each grounded fecal sample was 
added ice cold 80% methanol with a ratio of 50 mg feces in 1 mL 80% methanol. The 
mixture was vortexed for 10 min followed by centrifugation for 10 min at 16000 rpm.   
The supernatant 200 µL was aspirated into a plastic tube and dried by SpeedVac 
overnight. The dried metabolite extracts were dissolved in 30 µL ethoxyamine 
hydrochloride solution (30 mg/mL) and vigorously vortex-mixed for 1 min. 
Ethoxymation was carried out at 70 °C for 1 hour. After adding 30 µL 
N-(tert-butyldimethylsilyl)-N methyltrifluoroacetamide (MTBSTFA) mixed with 1%  
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tert-Butyldimethylchlorosilane (TBDMSCI), derivatization was carried out at 70 °C for 1 
hour.  
To prepare liver samples, a sample of liver tissue was weighed and then homogenized for 
2 min after adding water at a ratio of 100 mg liver tissue/mL water. The homogenized 
sample was then stored at –80 °C until use. A 100 µL aliquot of the homogenized liver 
sample and 400 µL methanol were mixed and vortexed for 1 min followed by 
centrifugation at room temperature for 10 min at 15000 rpm. 400 µL of the supernatant 
was aspirated into a plastic tube and dried by N2 flow. The metabolites extracts were then 
dissolved in 40 µL ethoxyamine hydrochloride solution (30 mg/mL) and vigorously 
vortex-mixed for 1 min. Ethoxymation and derivatization were achieved in the same way 
as for the fecal samples.  
In order to verify the compound identification, a total of 61 compound standards were 
prepared in equal molarity and analyzed on GCGC–TOF MS. The ethoxymation and 
derivatization of the fecal sample, liver sample, and compound standards were carried out 
right before GCGC–TOF MS analysis, respectively.  
5.2.4. GCGC–TOF MS Analysis  
The LECO Pegasus 4D GC×GC–TOF MS instrument was equipped with an Agilent 
6890 gas chromatograph and a Gerstel MPS2 auto-sampler (GERSTEL Inc., Linthicum, 
MD), featuring a LECO two-stage cryogenic modulator and secondary oven. The primary 
column was a 60 m × 0.25 mm 
1
dc × 0.25 μm 
1
df, DB-5ms GC capillary column (phenyl 
arylene polymer virtually equivalent to a (5%-phenyl)-methylpolysiloxane). A second 
GC column of 1 m × 0.25 mm 
1
dc × 0.25 μm 
2
df, DB17ms 
((50%-phenyl)-methylpolysiloxane) was placed inside the secondary GC oven after the 
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thermal modulator. Both columns were obtained from Agilent Technologies (Agilent 
Technologies J&W, Santa Clara, CA). The helium carrier gas (99.999% purity) flow rate 
was set to 2.0 mL/min at a corrected constant flow via pressure ramps. The inlet 
temperature was set at 280 °C. The primary column temperature was programmed with 
an initial temperature of 60 °C for 0.5 min and then ramped at 5 °C /min to 280 °C and 
kept for 15 min. The secondary column temperature program was set to an initial 
temperature of 70 °C for 0.5 min and then also ramped at the same temperature gradient 
employed in the first column to 280 °C accordingly. The thermal modulator was set to 
+15 °C relative to the secondary oven, and a modulation time of PM = 2 s was used. The 
mass range was set as 29−800 m/z with an acquisition rate of 200 mass spectra per second. 
The ion source chamber was set at 230 °C with the transfer line temperature set to 280 °C, 
and the detector voltage was 1450 V with electron energy of 70 eV. The acceleration 
voltage was turned on after a solvent delay of 675 s. The split ratio was set at 40:1 for 
liver samples and 10:1 for fecal samples. 
5.2.5. Data Analysis 
The GC×GC–TOF MS data were processed using LECO’s instrument control software 
ChromaTOF for peak picking and tentative metabolite identification, followed by peak 
merging, retention index filtering, peak list alignment, normalization, and statistical 
significance test using MetPP[141]. Two-way ANOVA test with a threshold of false 
discovery rate p < 0.05 was used to determine whether a metabolite has a significance 
difference of abundance level between sample groups. 
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For metabolite identification using ChromaTOF, each chromatographic peak was 
tentatively assigned to a metabolite if its experimental mass spectrum and a NIST11 MS 
library spectrum have a spectral similarity score higher than 600 (the maximum value of 
spectral similarity was defined as 1000 in ChromaTOF). If a chromatographic peak was 
tentatively assigned to a metabolite by mass spectral matching, the other top four ranked 
metabolite candidates were considered as the identification results of mass spectral 
matching for this chromatographic peak. The tentatively assigned metabolites were 
further filtered by retention index matching using iMatch software with a p-value 
threshold of p < 0.001[179]. To further verify the identification of metabolites detected 
with significant abundance difference between sample groups, the authentic standards of 
these metabolites, if commercially available, were analyzed on GC×GC–TOF MS under 
the same experimental conditions as the biological samples analyzed. A tentative 
metabolite assignment was considered as a correct identification only if the experimental 
information of the authentic metabolite agrees with the corresponding information of the 
chromatographic peak in the biological samples, i.e., difference of the first dimension 
retention time ≤ 10 s, difference of the second dimension retention time ≤ 0.05 s, and the 
mass spectral similarity ≥ 700.  
5.3. Results 
Four biological sample groups were formed in this study, pair-fed control mice without 
LGGs supplementation (PF-0, n = 5); pair-fed control mice with exposure to LGGs (PF-l, 
n = 7); alcohol fed mice without LGGs supplementation (AF-0, n = 4); and alcohol fed 
mice with LGGs supplementation (AF-l, n = 6). Metabolite identification was done in 
three sequential steps as described in our previous work, including mass spectral 
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matching, retention index matching, and comparison with authentic standards[16]. We 
compared the metabolic profile differences between PF-0 and AF-0, PF-1 and PF-0, and 
AF-1 and AF-0 in mouse liver and fecal samples, respectively. 
GC×GC–TOF MS instrument data provide four pieces of information for each metabolite, 
the first dimension retention time 
1
tR, the second dimension retention 
2
tR, fragment ion 
m/z, and peak height of each fragment ion. The information of fragment ion m/z and peak 
height forms the mass spectrum of the metabolite. Figure 20 is a contour plot of the 
GC×GC–TOF MS data acquired from a fecal sample randomly selected from sample 
group PF-0. Each chromatographic peak in Figure 20 is composed of many data points, 
where the number of data points in each chromatographic peak depends on the size of the 
chromatographic peak. The color of each data point is the signal intensity, i.e., the total 
ion current of all fragment ions in the corresponding mass spectrum. The inset in Figure 
20 demonstrates the increased separation power of GC×GC–TOF MS system. The two 
chromatographic peaks have identical retention time in the first dimension GC, but are 
completely separated from each other on the second dimension GC. Therefore, these two 
chromatographic peaks will co-elute on a GC-MS system and generate a mixed mass 




Figure 20.  Sample GC×GC–TOF MS chromatogram of metabolite extract from mouse 
fecal samples. The x-axis is the first dimension retention time 1tR in seconds. The y-axis is the 
second dimension retention time 2tR in seconds. The color bar shows the signal intensity of 
each peak plotted on the chromatogram in total ion current. 
 
By setting spectral similarity threshold to ≥ 600 in ChromaTOF, 440-1100 and 490-840 
and metabolites were respectively identified from the liver and fecal samples. The 
numbers of metabolites detected in liver samples and fecal samples were further reduced 
to 390-880 and 435-727 after retention index matching. After cross sample alignment and 
removing chromatographic peaks detected in blank samples, 236 metabolites presented in 
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more than 75% of liver samples in at least one sample group, while 212 in the fecal 
samples. 
Two-way ANOVA tests were employed to recognize metabolite with significant 
abundance changes between sample groups contributed by alcohol, LGGs, or their 
interaction. A term fold-change was defined as the ratio of the large abundance value 
(peak area) of a metabolite in one group divided by the small abundance value of the 
same metabolite in the other group. The positive sign and negative sign indicate the 
abundance increase and decrease in the testing sample group compared to the reference 
sample group, respectively.  
Figure 21A is an example of the metabolite abundance level changes detected in the liver 
samples. Abundance distribution of the metabolite, hexanoic acid, in liver samples was 
detected in the four sample groups, PF-0, PF-1, AF-0 and AF-1. Hexanoic acid (caproic 
acid), a natural fatty acid existing in all mammals, has been shown to be beneficial in 
high density lipoprotein synthesis in the liver. Compared with the abundance level of this 
metabolite in control group PF-0, the level of this metabolite was increased with a fold 
change of 1.56 in group AF-0, and 1.09 fold decrease in group PF-1. Comparing its 
abundance levels between groups AF-1 and AF-0, this metabolite is decreased with a fold 
change of 1.23 in the AF-1 group. The p-values for the factors of alcohol, LGGs, and 
their interaction are 0.002, 0.24, and 0.80, respectively. The alcohol factor has the 
smallest p-value of 0.002, indicating that this metabolite (hexanoic acid) has a significant 
alteration in abundance level in mouse livers because of the alcohol factor, while LGGs 
alone (p = 0.24) and the interaction of LGGs and alcohol (p = 0.80) did not significantly 
change the abundance level of this metabolite in liver. 
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Figure 21B depicts the abundance distribution of the same metabolite (hexanoic acid) in 
feces among the four sample groups. The trend of abundance distribution of this 
metabolite in fecal samples is completely different from that in the liver samples. 
Compared with the abundance of this metabolite in control group PF-0, the abundance 
level of this metabolite is decreased 1.54 fold in group PF-1 and by a1.25 fold decrease in 
sample group AF-0. Hexanoic acid is increased with a fold change of 1.58 in group AF-1 
compared to AF-0. The p-values of alcohol, LGGs, and their interaction are 0.05, 0.92, 
and 0.003, respectively. The large p-value of 0.92 indicates that LGGs alone did not 
significantly alter the abundance level of this metabolite in the mouse fecal metabolome, 
while alcohol alone affected the abundance level of this metabolite (p = 0.05). 
Importantly, the smallest magnitude of p-value (p = 0.003) for the interaction between 
alcohol and LGGs indicates that the abundance level of this metabolite was significantly 




























    
 
 
Figure 21.  Abundance distribution of metabolite hexanoic acid in four sample groups. (A) 
is in liver samples, and (B) is in fecal samples. 
 
Table 11 lists all metabolites that were detected with significant abundance changes from 
liver samples between the four sample groups with a threshold of p ≤ 0.05. These 
compounds include eight free fatty acids, six amino acids, three other acids and three 
other small compounds. Among the eight fatty acids, one is short chain fatty acid (SCFA, 
acetic acid), two are medium chain fatty acids (MCFA, hexanoic acid and dodecanoic 
acid), one long chain fatty acid (LCFA, tetradecanoic acid), two monounsaturated fatty 
acids (trans-9-octadecenoic acid and cis-9-hexadecenoic acid) and two polyunsaturated 
fatty acids (mead acid and arachidonic acid). The abundance levels of all four saturated 
fatty acids and cis-9-hexadecenoic acid were increased when the mice were fed with 
alcohol (column FC-2 in Table 11).  However, the abundance levels of these acids were 






















Table 11). Figure 22 depicts the results of total free fatty acid analysis, showing that the 
total non-esterified fatty acids were increased by alcohol exposure and decreased by 
LGGs supplementation. Histological examination confirmed our metabolomics finding 
that hepatic fat accumulation by alcohol was markedly increased, and LGGs 
supplementation prevented it (Figure 23).    
Among six amino acids, the abundances of five amino acids including L-isolucine, 
L-proline, L-threonine, L-phenylalanine and L-valine were decreased when mice were 
exposed to alcohol alone (column FC-2 in Table 11), while they all increased when the 
alcohol fed mice were exposed to LGGs (column FC-1 in Table 11).  
 
Table 11.  Metabolites with significant changes of abundance level among the four liver 
sample groups. 








 p-1d p-2e p-3f 
Fatty acids 
    
      
Acetic acid g 67226-76-0 1443 1.01 -1.05 2.05 1.22 1.3E-03 9.0E-01 2.9E-01 
Dodecanoic acid  143-07-7   1961  1.04  -1.41  1.59  -1.09  8.9E-03 7.6E-02 4.7E-01 
Hexanoic acid   142-62-1  1113  1.00  -1.23  1.56  -1.09  2.1E-03 2.4E-01 8.1E-01 
Tetradecanoic acid  4544-63-8 2196  1.06  -1.62  1.42 1.20  9.0E-01 4.4E-01 4.4E-02 
cis-9-Hexadecenoic 
acid g 
373-49-9 2385 1.11 -1.40 2.25 1.26 8.2E-03 9.9E-01 1.0E-01 
trans-9-Octadecenoi
c acid g 
112-79-8 2594 1.17 -2.44 -1.28 -2.28 3.6E-01 3.1E-02 8.5E-01 
Mead acid g 20590-32-3 2793  1.51  1.01  1.82  1.59  3.5E-02 2.7E-01 1.7E-01 
Arachidonic acid g 506-32-1 2762  1.51  1.35  -1.55  1.10  1.7E-02 7.9E-02 4.0E-01 
Amino acids 
    
      
L -Isoleucine 73-32-5 1748  0.99  1.43  -1.09  1.20  1.0E+00 3.9E-03 2.8E-01 
L -Proline   147-85-3 1803  1.08  1.33  -1.46  1.13  1.7E-03 2.2E-02 2.5E-01 
L -Threonine 72-19-5 1769 1.05 1.20 -1.08 -1.18 7.1E-05 1.4E-01 1.3E-02 
L-Phenylalanine 63-91-2 2189 1.16 1.28 -1.10 1.31 3.2E-01 2.8E-02 9.9E-01 
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L-Tyrosine 60-18-4 2768 1.38 1.22 1.02 1.20 6.6E-01 1.6E-02 8.8E-01 
L-Valine 72-18-4 1652 0.99 1.34 -1.06 1.16 9.7E-01 3.0E-02 4.8E-01 
Other acids 
    
      
2-aminobutanoic  
acid  
2835-81-6 1585  0.99  -2.16  3.57  -1.14  2.5E-04 1.3E-01 8.0E-02 
Glycolic acidg 79-14-1 1443  1.01  -1.05  2.05  1.22  1.4E-03 9.0E-01 2.9E-01 
α-thylphenylacetic 
acidg  
90-27-7  2499  1.29  1.30  -2.39  1.04  9.6E-04 3.7E-01 7.2E-01 
Others 
    
      
3Pyridinolg 109-00-2 1245  1.20  -1.18  1.43  1.46  3.3E-01 2.8E-01 1.2E-02 
Hypoxanthineg  68-94-0  2345  1.43  -1.09  1.55  1.26  3.2E-03 5.1E-01 9.4E-02 
2-(2-(2-ethoxyethox
y)ethoxy)acetic acidg 
16024-58-1 2456  1.05  4.20  -4.04  1.14  4.3E-03 3.9E-03 1.5E-02 
 
afold change for AF-1 to AF-0. bfold change for AF-0 to PF-0. cfold change for PF-1 to 
PF-0.dp-value of factor alcohol. ep-value of factor LGGs. fp-value of the interaction of 




Figure 22.  Effect of LGGs on hepatic free fatty acid levels. Stars * refer to the amount of 
total free fatty acids between two sample groups is significantly different with p < 0.05. 
 
Table 12 lists metabolites with significant abundance changes between sample groups 
detected from fecal samples with a threshold of p ≤ 0.05. A total of nine free fatty acids, 
nine amino acids, two alcohols, six other acids and nine other small compounds have 
significant changes in abundance level due to alcohol, LGGs or their synergetic 
interaction. Among these nine fatty acids, two are short chain fatty acids (SCFA, 
isovaleric acid and pentanoic acid), one MCFA (hexanoic acid), four LCFA 
(heptadecanoic acid, hexadecanoic acid, nonadecanoic acid, tetradecanoic acid), one 
polyunsaturated omega-6 fatty acid (9,12-octadecadienoic acid) and one omega-7 
monounsaturated fatty acid (cis-9-hexadecenoic acid). Compared with abundance levels 
in sample group AF-0, the abundance levels of these SCFAs, MCFAs and LCFAs in 
sample group AF-l were significantly increased while the omega-7 monounsaturated fatty 
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acid and polyunsaturated omega-6 fatty acid was decreased (column FC-1 in Table 12). 
Even though the fold-changes of most of the fatty acids are moderate, the abundance 
level of hexadecanoic acid was increased 20.6 fold in group AF-1. Among the 9 amino 
acids, the abundance levels of seven were decreased in group AF-0 compared to the 
group PF-0 (column FC-2 in Table 12), Among these seven amino acids, six amino acids 
were increased in the alcohol and LGGs treated group AF-1 compared to in the group 
AF-0 (column FC-1 in Table 12). It is interesting that the abundance level of L-Proline 
was decreased in group AF-1 compared to the group AF-0, decreased in group AF-0 
compared to group PF-0, and decreased in group PF-1 compared to that in group PF-0, 
respectively.  
 







a FC-2b FC-3c p-1d p-2e p-3f 
Fatty acids 
     
    
Isovaleric acid g 503-74-2   882  0.98  1.43  -2.22  1.02  1.7E-02 4.1E-01 5.5E-01 
Pentanoic acid   109-52-4 957  1.00  1.67  1.26  1.96  5.7E-01 1.7E-02 5.9E-01 
Hexanoic acid    142-62-1  1114  1.02  1.58  -1.25  -1.54  5.5E-02 9.2E-01 3.2E-03 
Heptadecanoic acid  506-12-7  2511  1.12  1.25  -2.41  1.44  1.5E-02 1.5E-01 5.5E-01 
Hexadecanoic acid   57-10-3  2396  1.10  20.6  2.04  8.74  1.3E-02 1.5E-02 6.5E-02 
Nonadecanoic acid   646-30-0 2728  1.31  1.06  1.69  -1.06  1.2E-03 9.6E-01 6.2E-01 
Tetradecanoic acid   544-63-8 2197  1.09  1.81  -1.41  -1.01  4.5E-01 1.6E-04 1.4E-04 
cis-9-Hexadecenoic 
acid g    
373-49-9   2385  1.14  -2.84  1.88  1.67  4.7E-01 5.1E-01 4.8E-02 
9,12-Octadecadienoi
c acid g 
60-33-3 2687 1.37 -1.82 1.02 -1.88 8.8E-01 4.1E-03 6.5E-01 
Amino acids 
     
    
L-Methionine   63-68-3 2047  1.15  1.61  -2.82  1.13  1.4E-04 4.0E-02 3.1E-01 
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L -Phenylalanine   63-91-2 2189  1.20  1.99  -2.57  -1.13  3.6E-03 1.4E-01 4.4E-02 
L -Ornithine g 70-26-8 2389  1.05  8.34  -1.68  1.13  3.4E-01 1.1E-02 4.5E-02 
L -Alanine   56-41-7 789  0.97  1.66  -1.18  1.47  3.9E-01 2.0E-02 9.1E-01 
L -Threonine     72-19-5 2101  1.01  1.04  -7.26  1.15  6.6E-06 7.9E-01 6.2E-01 
L-Aspartic acid 56-84-8 2255 1.08 1.58 -1.51 -1.68 6.1E-01 9.4E-01 4.8E-02 
L-Valine 72-18-4 1667 0.99 1.17 27.6 2.33 2.6E-06 4.4E-03 2.9E-02 
L -Proline   147-85-3 1803  1.11  -1.10  -1.33  -1.11  3.7E-03 2.7E-01 9.6E-01 
L -Glutamic acid   56-86-0 2381  1.10  -1.10  1.76  -1.22  3.2E-02 7.1E-01 6.6E-01 
Other acids 
     
    
4-hydroxybenzoic 
acid g   
99-96-7 2231  1.19  3.12  -2.83  -1.10  1.5E-01 4.9E-02 6.0E-02 
trans-Crotonic acid g    107-93-7  888  1.05  1.59  -1.31  -1.01  6.1E-01 8.9E-03 5.9E-03 
p-Coumaric acid g   501-98-4   2579  1.32  1.46  2.34  -1.43  7.0E-03 7.5E-01 2.6E-01 
2-ketobutyric acid g  600-18-0   1735  1.07  -1.11  3.37  1.72  2.6E-03 3.3E-01 2.4E-01 
Nicotinic acid g   59-67-6 1509  1.28  -1.07  6.29  1.12  1.6E-05 6.7E-01 8.6E-01 
Nonanedioic acid g   123-99-9 2391  1.17  1.89  1.42  1.14  3.0E-03 5.2E-02 1.6E-01 
Alcohols 
     
    
Propylene glycol g 57-55-6   1311  0.93  1.94  -3.15  -1.10  7.9E-05 4.2E-02 1.1E-02 
2-Hydroxybenzyl 
alcohol g 
90-01-7   1961  1.13  1.46  2.36  -1.36  6.6E-06 6.5E-01 1.3E-02 
Others 
     
    
Phenol 108-95-2 1100  1.13  1.51  -2.88  -1.04  2.4E-05 1.0E-01 3.9E-02 




1076  0.94  1.58  -2.12  -1.23  1.4E-03 2.2E-01 7.1E-03 
Ethanolamine, 
N-acetyl- g    
142-26-7 965  1.04  1.58  -1.68  -1.02  2.9E-02 7.1E-02 5.0E-02 
2-(2-(2-ethoxyethoxy
)ethoxy)acetic acid g 
16024-58
-1 
2455  1.07  -2.49  -1.13  -1.07  2.9E-02 4.3E-01 6.1E-01 
1,2-Pyrrolidinedicarb
oxylic acid, (2R)-g    
1067236-
75-2   
2139  1.29  1.70  -1.08  1.22  5.3E-01 2.1E-02 4.0E-01 
Urea  57-13-6 1657  1.17  1.86  2.00  1.77  8.7E-03 4.9E-02 9.0E-01 
3-Pyridinol g 109-00-2 1061  1.14  1.94  1.83  1.32  1.1E-04 2.5E-03 8.6E-02 
D,L-Homoserineg 
1927-25-
9   
2187  1.02  -1.67  2.31  -1.94  2.2E-02 1.5E-01 4.3E-01 
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afold change for AF-1 to AF-0. bfold change for AF-0 to PF-0. cfold change for PF-1 to 
PF-0.dp-value of factor alcohol. ep-value of factor LGGs. fp-value of the interaction of 
alcohol and LGGs. gTentative identification without verification using authentic standards. 
  
Figure 23.  Effect of LGGs on liver fat accumulation. Hepatic cryosections were Oil red O 
stained and images were acquired by light microscopy. 
 
5.4. Discussion 
Four sample groups were formed in this study to investigate the effect of alcohol, LGGs 
and their interaction on the mouse liver and fecal metabolome, respectively. Figure 24 
depicts clustering results of the metabolite profiles of the four liver sample groups 
(Figure 24A) and four fecal sample groups (Figure 24B), using partial least squares 
discriminant analysis (PLSDA). The clear separation between sample groups indicates 








Figure 24. Clustering of metabolite profiles using partial least squares discriminant analysis 
(PLSDA). (A) is the clustering result of metabolite profiles of all liver samples and (B) is the 























































Analysis of liver samples 
Excess alcohol consumption is one of the major factors in the development of fatty liver, 
which is characterized by hepatic accumulation of triglyceride, cholesterol and other 
types of lipids. A total of eight fatty acids were detected with significant alteration of 
abundance levels among the four sample groups. The four saturated fatty acids and 
cis-9-hexadecenoic acid have the same trend in alteration of abundance levels, while the 
polyunsaturated fatty acid arachidonic acid has opposite direction of abundance changes. 
The abundance levels of all four saturated fatty acids and cis-9-hexadecenoic acid are all 
increased in liver in the mice fed with alcohol. While SCFAs are metabolized in the 
mitochondria for energy production, MCFAs and LCFAs are mainly oxidized in the 
peroxisome[180].The higher levels of MCFAs and the LCFAs in the livers of mice fed 
alcohol strongly suggest that alcohol feeding interferes with lipid perexisomal oxidation, 
which is critical for hepatic fat elimination. However, hepatic levels of these fatty acids 
were significantly decreased in liver when LGGs was supplemented to alcohol-fed mice. 
This agrees with our total non-esterified fatty acids analysis and the results of histological 
examination of the liver sections (Figures 22 and 23). Taken together, the beneficial 
effects of LGGs on liver fat accumulation are mediated, at least in part, by increasing 
fatty acid peroxisomal oxidation.  
Another finding in current study is the decrease of five amino acids, L-isoleucine, 
L-proline, L-threonine, L-phenylalanine, L-valine, by alcohol feeding, and the 
normalization of their abundance levels by LGGs supplementation. L-threonine is an 
essential amino acid which is not synthesized in mice. L-Threonine deficiency causes fat 
build up in the liver, while supplementation with L-threonine lowers hepatic fat 
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concentration. [181]. L-Proline is a nonessential amino acid which can be synthesized 
from glutamate. Importantly, L-isoleucine is a branched-chain amino acid (BCAA), 
which is an essential amino acid and plays an important role in many aspects of hepatic 
physiology[182]. Clinical studies showed that BCAA enriched nutritional 
supplementation is beneficial for the treatment of ALD[183].Our results agree with these 
studies and demonstrate that LGGs supplementation increases L-isoleucine concentration 
to reduce the fat buildup induced by alcohol, likely through improved intestinal 
absorption. Altogether, our studies demonstrate that LGGs helps remedy the liver damage 
of amino acid depletion caused by alcohol consumption.  
Analysis of fecal samples 
We have previously demonstrated that saturated fat supplementation protects liver from 
alcohol-induced injury through stabilizing intestinal tight junctions leading to reduced 
circulating lipopolysaccharide (LPS)[150]. Although the underlying mechanisms are still 
unclear, recent studies showed that saturated fatty acids were metabolized by commensal 
Lactobacilli to promote their expansion[184]. Fatty acids can be synthesized by bacteria 
in the host in addition to being derived from the fat in the diet. In the current studies, we 
fed mice with the same amount of fat in the isocaloric diet in all animal groups. Therefore, 
the changes of fatty acids we observed are likely from bacterial production. The 
concentrations of five of nine detected fatty acids (i.e., isovaleric acid, hexanoic acid, 
heptadecanoic acid, tetradecanoic acid  and cis-9-hexadecenoic acid) were significantly 
reduced in the feces of mice fed alcohol. Of particular interest, hepatadecanoic acid 
(C17:0), which is a LCFA produced only by bacteria[185] was reduced 2.41 folds by 
118 
 
alcohol. Importantly, LGGs supplementation to both alcohol-fed and pair-fed mice 
significantly increased luminal levels of hepatadecanoic acid.  
Chronic alcohol exposure significantly changes the gut bacterial population[186]. 
Administration of probiotics to alcohol-exposed mice normalized gut microflora, restored 
intestinal barrier tight junctions, reduced endotoxin translocation and attenuated liver 
steatosis and inflammation[169]. The increased abundance levels of fatty acids (i.e., 
isovaleric acid, pentanoic acid, hexanoic acid, heptadecanoic acid, hexadecanoic acid, 
nonadecanoic acid and tetradecanoic acid), therefore, contributes to the beneficial effects 
of LGGs in the reduced fatty liver and liver injury in response to alcohol exposure.  
Similar to our findings in the liver, fecal concentrations of six amino acids (L-methionine, 
L-phenylalanine, L-omithine, L-alanine, L-threonine and L-aspartic acid)  were reduced 
by alcohol feeding and increased by LGGs supplementation. Proteins in the diet are 
degraded in the intestine to amino acids which serve as nutrients for intestinal cells and 
extraenteric tissues. Previous work demonstrated that gut microflora potentially play a 
major role in the proteolysis in the large intestine. Amino acid metabolism in the host 
cells depends on the types of bacteria and the amino acids. Currently, it is still unclear 
how a specific amino acid is metabolized in the gut in response to alcohol exposure. The 
fact that the decreased amino acid concentrations of six amino acids were increased by 
LGGs supplementation suggests that the effects of LGGs on amino acid anabolism could 
potentially contribute to the beneficial effects in ALD.  
While metabolite regulation differences between sample groups observed in this study 
are consistent with our histological study, our current work still has some limitations. 
Metabolites in mouse liver and mouse feces can have very diverse chemical 
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characteristics. In this work, metabolites were extracted by water and methanol. Most of 
the nonpolar metabolites were lost during this analytical step. The extracted metabolites 
were then analyzed on GC×GC–TOF MS. Even though GC×GC–TOF MS has better 
separation power compared to the conventional one dimensional GC–MS, it may not be 
enough to resolve all metabolites and may result in overlapping chromatographic peaks 
which would introduce significant challenges for metabolite identification and 
quantification. In this work, metabolite identification was first achieved by matching the 
experimental mass spectra to the mass spectra recorded in the NIST11 MS library. The 
incompleteness of the existing mass spectral library not only introduces a certain degree 
of false-positive identifications, but also leaves a number of chromatographic peaks 
without any compound identification. Besides the MS library, metabolite identification 
GC×GC–TOF MS can also be affected by the spectral similarity measure and the optimal 
weight factor used during mass spectral matching[139]. It is impossible to estimate the 
rate of false-positive identifications induced by the incompleteness of the NIST11 MS 
library, However, analysis of NIST MS library demonstrates that the accuracy mass 
spectral matching based metabolite identification can be improved from about 80% to 96% 
if the top five ranked metabolite candidates are considered as the identification 
results[139]. To increase the metabolite identification accuracy of using existing NIST11 
MS library, the top five ranked metabolite candidates for each chromatographic peak 
were used as the results of mass spectral matching and further subjected to retention 
index matching in this study. The metabolite candidate with the best retention index 
matching was kept for further analysis. All of these technical limitations in the current 
study prevent us from seeing the entire picture of the metabolite profile in mouse liver 
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and feces. Further studies, such as using different extraction methods and combining both 
GC×GC–TOF MS with two-dimensional liquid chromatography high resolution mass 
spectrometry (2D LC-MS) may provide more comprehensive results.   
5.5. Conclusions 
GC×GC–TOF MS was used to identify metabolites that have significant alteration in their 
abundance levels in mouse liver and fecal samples collected from mice fed with and 
without alcohol, with and without co-exposure to LGGs. Our results show that the 
abundance levels of saturated fatty acids increase in liver samples but the abundance levels 
of a fraction of these fatty acids decreased in fecal samples when the mice were fed with 
alcohol. However, the abundance levels of all saturated fatty acids were decreased in 
mouse livers but increased in mouse feces when the mice were co-exposed to LGGs. Also 
we found that alcohol consumption depletes some amino acids in mouse livers, and such 
liver damage can be remedied by supplementing the mice with LGGs. These results 
demonstrate that LGGs alleviates alcohol-induced fatty liver by the mechanisms involving 
increasing intestinal and decreasing hepatic fatty acids and increasing amino acid 



























SUMMARY AND CONCLUSIONS 
 
In this dissertation we first developed a bioanalytical platform LTQ-FTICR MS coupled 
with DI-nESI and the associated bioinformatic platform MetSign for metabolite biomarker 
discovery. We further applied the developed platforms for metabolite biomarker discovery 
and mechanistic studies including the analysis of Triacylglycerols Using High-Resolution 
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Mass Spectrometry in Combination with in vivo Metabolite Deuterium Labeling; 
Metabolomic Analysis of the Effects of Polychlorinated Biphenyls in Non-Alcoholic Liver 
Disease. 
The obvious disadvantage of direct infusion MS is easily getting ion suppression since 
there is no separation before detection. However, LTQ-FTICR MS has the advantages of 
high sensitivity and accuracy, wide dynamic range, and the ability to identify metabolites 
from complex samples. Also, chip-based nano-spray ESI ionization can get rid of carry 
over. In chapter 2, we profile all measurable metabolites. Metabolites were extracted based 
on Bligh & Dyer’s method to cover both polar and non-polar metabolites. In chapter 3, we 
focus on triglycerides. Thus chloroform: methanol (2:1) was used for lipid extraction. 
After extraction, we optimized the instrument parameter settings and applied it to analyze 
biological sample.  
MetSign software code was written by bioinformatics specialist from our group. The 
software has assignment and quantitative analysis function.  During assignment analysis, 
one m/z value gives more than one candidate. To narrow down the identification candidate, 
we used mass frontier software to get the theoretical MS/MS spectrum. At the same time, 
we did experiment to get the MS/MS spectrum of this particular m/z. By matching the 
similarities between the experimental spectrum and the theoretical MS/MS spectrum, we 
get the best matching ID. Then authentic standard was purchase and analyzed to get 
MS/MS spectrum to confirm our identification. By following this procedure, identification 
accuracy was greatly improved.  
Also I conducted spike-in experiments to test the identification and quantitative accuracy. 
The standard provided the identification information required to test our identification 
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accuracy. Spiking with different concentrations of standards provided quantitative results 
to test our accuracy of quantitative analysis. Overall, we improved the identification 
accuracy and quantitative accuracy of the direct infusion MS platform allowing it to be 
applied to biomarker discovery. However, biomarker clinical studies were not performed 
and the biomarker has not been validated in this work. 
In Chapter 2, we applied the developed platform to metabolomic analysis of the effects of 
polychlorinated biphenyls in non-alcoholic liver disease. We found several significant 
changes in molecules for different group comparisons. Notably, erythronic acid had the 
largest abundance change with a 28.8-fold increase in the HFD+PCB 153 group when 
compared to the HFD group. GSH had a 5.91-fold decrease in the HFD+PCB 153 group 
and its conjugate, S-(hydroxymethyl)glutathione had a 2.97-fold decrease. Based on these 
results, antioxidant depletion is likely to be an important consequence of this interaction. 
Our metabolomics study can give more detailed information and even demonstrate some 
mechanisms by comparing histological studies. 
In Chapter 3, we applied the developed platform combing with in vivo Metabolite 
Deuterium Labeling to study deuterium labeled triglycerides. Deuterium labeling water 
was used to feed mice, which make sure triglycerides in liver will be deuterium labeled. 
After 5 weeks feeding, normal water will be used to feed mice. Liver tissue and white 
adipose tissue were both collected to study. Time course study were also conducted, the 
mice were sacrificed after 2 weeks feeding or after 4 weeks feeding.  We found that 
deuterated  triacylglycerols (TGs) were significantly increased in alcohol induced fatty 
liver at two and four weeks of alcohol feeding periods, Also found that deuterated TGs 
were significantly decreased in both eWAT and sWAT at the two and four weeks. The 
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increase of deuterium incorporated TGs in alcohol-induced fatty liver and their decrease in 
both eWAT and sWAT indicate that alcohol exposure induces hepatic influx of fatty acids 
which are released from WATs. The time course results further indicate a mechanistic link 
between adipose fat loss and hepatic fat gain in alcoholic fatty liver. This mechanism 
cannot be found only by histological study. Deuterium labeling combining with our 
analytical platform were combined together to demonstrate the mechanism. 
We also successfully developed a GC×GC-TOF MS bioanalytical platform and MetPP 
bioinformatics platform for metabolomic profiling, and applied them to metabolite 
biomarker discovery including the effects of Chronic Arsenic Exposure in a Mouse Model 
of Diet-induced Fatty Liver Disease; Hepatic and Fecal Metabolomic Analysis of the 
Effects of Lactobacillus Rhamnosus GG on Alcoholic Fatty Liver Disease in Mice.  
GC×GC was originally described in 1991. However, the system is still not that widely used 
mainly due to two reasons. One is the system is much complicated, another reason is the 
bottleneck of processing high throughput of GC×GC MS data. GC×GC–TOF MS 
comparing with GC –TOF MS, it increased peak capacity, peak resolution, peak sensitivity, 
dynamic range, signal to noise ration when the system is optimized. However, the system is 
more complicated comparing with GC-TOF MS. A lot of parameters including column 
configuration including column stationary phase, column length, column width, 
temperature gradient, temperature offset of two column, flow rate, hot and cold pulse time 
ratio, modulation period will affect the separation power of the system. It is very critical to 
optimize all the parameters to get good metabolites coverage before sample analysis. We 
optimized each parameter based on peak resolution, detection limit, whether wrap around 
exist or not.  
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For data processing, currently commercially software like ChromaTOF can do peak 
picking and tentative metabolite identification based on similarity between EI spectrum 
with NIST database. However, there is relative high rate of false identification. Retention 
index matching was performed using iMatch software with p-value threshold set as p ≤ 
0.001, which use the information of retention time based on chemical property. Parts of the 
identified metabolites were confirmed by the first dimension retention index matching and 
parts were also preserved due to the lack of retention index information in the NIST11 
retention index database. However, amount of the mass spectral matched metabolites were 
removed due to the large first dimension retention index deviation from the database values. 
This will decrease ratio of false identification. After this step, commercially available 
authentic standards were also purchased and analyzed to get spectrum to confirm our 
identification. Some metabolites were tentatively assigned if there are no commercially 
available standards. Tentatively-identified metabolites were considered as false 
identifications and removed from the identification list, if they were recognized as drugs or 
from non-mammalian animals during metabolic network analysis by the Ingenuity 
Pathway Analysis (IPA) software (Ingenuity Systems, Inc., Redwood City, CA). 
Spike-in experiments were also carried out to test the identification and quantitative 
accuracy. The standard can give the identification information to test our identification 
accuracy. Spiking with different concentration of standards can provide quantitative results 
to test our accuracy of quantitative analysis. 
In Chapter 4, we applied the developed platform to metabolomic analysis of the effects of 
chronic arsenic exposure of diet induced fatty liver disease. We optimized our system 
before our sample analysis and we did spike-in experiment to test the accuracy of 
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identification and quantitation before sample analysis. A high value of AUC indicates a 
high accuracy of recognizing the concentration difference of the spiked-in compounds 
between sample groups.  
We found that the high fat diet significantly altered nine metabolites and the addition of 
arsenic resulted in further alterations in three of these metabolites. The HFD-induced 
increase in cysteine was amplified, whereas the increase in glutamate was blocked, by 
co-exposure to arsenic. Also, the HFD-induced decrease in lysine was reversed by arsenic. 
Glycine was decreased by the combination of arsenic and a high fat diet. Therefore, all 
three of the amino acids that constitute the antioxidant glutathione (glutamate, cysteine and 
glycine) were altered, with glutamate and glycine levels lower and cysteine levels higher. 
The results showed that there are distinct hepatic metabolomic profiles associated with 
eating a high fat diet, drinking arsenic contaminated water, and the combination of the two. 
Among the metabolites that were decreased when arsenic exposure was combined with a 
high fat diet were hepatoprotective shortchain and medium-chain fatty acid metabolites 
and the anti-inflammatory amino acid glycine. These results are consistent with the 
observed increase in inflammation and cell death in the livers of these mice and point to 
potentially novel mechanisms by which these metabolic pathways could be altered by 
arsenic in the context of diet-induced fatty liver disease. 
In Chapter 5, the platforms were applied to hepatic and fecal metabolomic analysis of the 
effects of LGG on alcoholic fatty liver disease in mice. Analysis of NIST MS library 
demonstrates that the accuracy mass spectral matching based metabolite identification can 
be improved from about 80% to 96% if the top five ranked metabolite candidates are 
considered as the identification results. To increase the metabolite identification accuracy 
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of using existing NIST11 MS library, the top five ranked metabolite candidates for each 
chromatographic peak were used as the results of mass spectral matching and further 
subjected to retention index matching. 
Fecal sample and liver sample were both collected. After analysis, we found that saturated 
fatty acids increase in liver samples, but decreased in fecal samples when the mice were fed 
with alcohol. However, all saturated fatty acids were decreased in mouse livers but 
increased in mouse feces when the mice were co-exposed to LGGs. Alcohol consumption 
depletes some amino acids in mouse livers, and such liver damage can be remedied by 
supplementing the mice with LGGs. It demonstrates that LGGs alleviates alcohol-induced 
fatty liver by the mechanisms involving increasing intestinal and decreasing hepatic fatty 










1. Zhao, Y. Y., Cheng, X. L., Vaziri, N. D., Liu, S., and Lin, R. C. (2014) UPLC-based 
metabonomic applications for discovering biomarkers of diseases in clinical chemistry, 
Clin Biochem. 
2. Wishart, D. S., Knox, C., Guo, A. C., Eisner, R., Young, N., Gautam, B., Hau, D. D., 
Psychogios, N., Dong, E., Bouatra, S., Mandal, R., Sinelnikov, I., Xia, J. G., Jia, L., Cruz, 
J. A., Lim, E., Sobsey, C. A., Shrivastava, S., Huang, P., Liu, P., Fang, L., Peng, J., 
Fradette, R., Cheng, D., Tzur, D., Clements, M., Lewis, A., De Souza, A., Zuniga, A., 
Dawe, M., Xiong, Y. P., Clive, D., Greiner, R., Nazyrova, A., Shaykhutdinov, R., Li, L., 
Vogel, H. J., and Forsythe, I. (2009) HMDB: a knowledgebase for the human 
metabolome, Nucleic Acids Research 37, D603-D610. 
3. Schmidt, R. H., Jokinen, J. D., Massey, V. L., Falkner, K. C., Shi, X., Yin, X. M., 
Zhang, X., Beier, J. I., and Arteel, G. E. (2013) Olanzapine Activates Hepatic 
Mammalian Target of Rapamycin: New Mechanistic Insight into Metabolic 
Dysregulation with Atypical Antipsychotic Drugs, Journal of Pharmacology and 
Experimental Therapeutics 347, 126-135. 
4. Shi, X., Wahlang, B., Wei, X. L., Yin, X. M., Falkner, K. C., Prough, R. A., Kim, S. H., 
Mueller, E. G., McClain, C. J., Cave, M., and Zhang, X. (2012) Metabolomic Analysis of 
129 
 
the Effects of Polychlorinated Biphenyls in Nonalcoholic Fatty Liver Disease, J Proteome 
Res 11, 3805-3815. 
5. Shi, X., Wei, X., Koo, I., Schmidt, R. H., Yin, X., Vaughn, A., Kim, S. H., McClain, C. 
J., Arteel, G. E., Zhang, X., and Watson, W. H. (2014) Metabolomic analysis of the 
effects of chronic arsenic exposure in a mouse model of diet-induced fatty liver disease, J. 
Proteome Res. 13, 547−554. 
6. Jin, S., Song, C., Li, S., Zhang, Y., Chen, C., Zhou, X., Xu, Y., Feng, Y., Zhang, Z., 
and Jiang, H. (2014) Preventive effects of turmeric on the high-fat diet-induced 
hyperlipidaemia in mice associated with a targeted metabolomic approach for the 
analysis of serum lysophosphatidylcholine using LC-MS/MS, J. Funct. Foods 11, 
130-141. 
7. Calder, A. G., and Smith, A. (1988) Stable isotope ratio analysis of leucine and 
ketoisocaproic acid in blood plasma by gas chromatography/mass spectrometry. Use of 
tertiary butyldimethylsilyl derivatives, Rapid Commun. Mass Spectrom. 2, 14-16. 
8. Baran, R., Bowen, B. P., Bouskill, N. J., Brodie, E. L., Yannone, S. M., and Northen, T. 
R. (2010) Metabolite Identification in Synechococcus sp. PCC 7002 Using Untargeted 
Stable Isotope Assisted Metabolite Profiling, Analytical Chemistry 82, 9034-9042. 
9. Creek, D. J., Chokkathukalam, A., Jankevics, A., Burgess, K. E. V., Breitling, R., and 
Barrett, M. P. (2012) Stable Isotope-Assisted Metabolomics for Network-Wide Metabolic 
Pathway Elucidation, Analytical Chemistry 84, 8442-8447. 
130 
 
10. Fan, T. W. M., Lane, A. N., Higashi, R. M., Farag, M. A., Gao, H., Bousamra, M., 
and Miller, D. M. (2009) Altered regulation of metabolic pathways in human lung cancer 
discerned by C-13 stable isotope-resolved metabolomics (SIRM), Molecular Cancer 8. 
11. Bathen, T. F., Sitter, B., Sjobakk, T. E., Tessem, M. B., and Gribbestad, I. S. (2010) 
Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer 
diagnostics and treatment evaluation, Cancer Res 70, 6692-6696. 
12. Powers, R. (2009) NMR metabolomics and drug discovery, Magn Reson Chem 47 
Suppl 1, S2-11. 
13. Schripsema, J. (2010) Application of NMR in plant metabolomics: techniques, 
problems and prospects, Phytochem Anal 21, 14-21. 
14. Viant, M. R., Rosenblum, E. S., and Tieerdema, R. S. (2003) NMR-based 
metabolomics: a powerful approach for characterizing the effects of environmental 
stressors on organism health, Environ Sci Technol 37, 4982-4989. 
15. Ward, J. L., Baker, J. M., and Beale, M. H. (2007) Recent applications of NMR 
spectroscopy in plant metabolomics, FEBS J 274, 1126-1131. 
16. Zhang, S., Nagana Gowda, G. A., Ye, T., and Raftery, D. (2010) Advances in 
NMR-based biofluid analysis and metabolite profiling, Analyst 135, 1490-1498. 
17. Dieterle, F., Riefke, B., Schlotterbeck, G., Ross, A., Senn, H., and Amberg, A. (2011) 
NMR and MS methods for metabonomics, Methods Mol Biol 691, 385-415. 
18. Bando, K., Kunimatsu, T., Sakai, J., Kimura, J., Funabashi, H., Seki, T., Bamba, T., 
and Fukusaki, E. (2010) GC-MS-based metabolomics reveals mechanism of action for 
hydrazine induced hepatotoxicity in rats, J Appl Toxicol. 
131 
 
19. Cevallos-Cevallos, J. M., Garcia-Torres, R., Etxeberria, E., and Reyes-De-Corcuera, J. 
I. (2010) GC-MS Analysis of Headspace and Liquid Extracts for Metabolomic 
Differentiation of Citrus Huanglongbing and Zinc Deficiency in Leaves of 'Valencia' 
Sweet Orange from Commercial Groves, Phytochem Anal. 
20. Lin, S., Liu, N., Yang, Z., Song, W., Wang, P., Chen, H., Lucio, M., Schmitt-Kopplin, 
P., Chen, G., and Cai, Z. (2010) GC/MS-based metabolomics reveals fatty acid 
biosynthesis and cholesterol metabolism in cell lines infected with influenza A virus, 
Talanta 83, 262-268. 
21. Stein, S. (1999) An Integrated Method for Spectrum Extraction and Compound 
Identification from GC/MS Data, J. Am. Soc. Mass Spectrom. 10, 12. 
22. Thysell, E., Surowiec, I., Hornberg, E., Crnalic, S., Widmark, A., Johansson, A. I., 
Stattin, P., Bergh, A., Moritz, T., Antti, H., and Wikstrom, P. (2010) Metabolomic 
characterization of human prostate cancer bone metastases reveals increased levels of 
cholesterol, PLoS One 5, e14175. 
23. Tikunov, Y., Lommen, A., de Vos, C. H., Verhoeven, H. A., Bino, R. J., Hall, R. D., 
and Bovy, A. G. (2005) A novel approach for nontargeted data analysis for metabolomics. 
Large-scale profiling of tomato fruit volatiles, Plant Physiol 139, 1125-1137. 
24. Lee do, Y., Bowen, B. P., and Northen, T. R. (2010) Mass spectrometry-based 
metabolomics, analysis of metabolite-protein interactions, and imaging, Biotechniques 49, 
557-565. 
25. Garcia, A., and Barbas, C. (2011) Gas chromatography-mass spectrometry 
(GC-MS)-based metabolomics, Methods Mol Biol 708, 191-204. 
132 
 
26. Kieken, F., Pinel, G., Antignac, J. P., Monteau, F., Christelle Paris, A., Popot, M. A., 
Bonnaire, Y., and Le Bizec, B. (2009) Development of a metabonomic approach based 
on LC-ESI-HRMS measurements for profiling of metabolic changes induced by 
recombinant equine growth hormone in horse urine, Anal Bioanal Chem 394, 2119-2128. 
27. Moco, S., Bino, R. J., Vorst, O., Verhoeven, H. A., de Groot, J., van Beek, T. A., 
Vervoort, J., and de Vos, C. H. (2006) A liquid chromatography-mass 
spectrometry-based metabolome database for tomato, Plant Physiol 141, 1205-1218. 
28. Mohamed, R., Varesio, E., Ivosev, G., Burton, L., Bonner, R., and Hopfgartner, G. 
(2009) Comprehensive analytical strategy for biomarker identification based on liquid 
chromatography coupled to mass spectrometry and new candidate confirmation tools, 
Anal Chem 81, 7677-7694. 
29. Sana, T. R., Roark, J. C., Li, X., Waddell, K., and Fischer, S. M. (2008) Molecular 
formula and METLIN Personal Metabolite Database matching applied to the 
identification of compounds generated by LC/TOF-MS, J Biomol Tech 19, 258-266. 
30. Zhang, A., Sun, H., Wang, P., Han, Y., and Wang, X. (2012) Modern analytical 
techniques in metabolomics analysis, Analyst 137, 293-300. 
31. Price, P. (2000) Mass spectrometry desk reference, edited by O. David Sparkman, J. 
Am. Soc. Mass Spectrom. 11, 1144. 
32. Mishur, R. J., and Rea, S. L. (2012) Applications of mass spectrometry to 
metabolomics and metabonomics: Detection of biomarkers of aging and of age-related 
diseases, Mass Spectrom Rev 31, 70-95. 
133 
 
33.González-Domínguez, R., Castilla-Quintero, R., García-Barrera, T., and Gómez-Ariza, 
J. L. (2014) Development of a metabolomic approach based on urine samples and direct 
infusion mass spectrometry, Anal Biochem 465, 20-27. 
34. Lokhov, P. G., Kharybin, O. N., and Archakov, A. I. (2012) Diagnosis of lung cancer 
based on direct-infusion electrospray mass spectrometry of blood plasma metabolites, Int 
J Mass Spectrom 309, 200-205. 
35. Lerma-García, M. J., Herrero-Martínez, J. M., Ramis-Ramos, G., and Simó-Alfonso, 
E. F. (2008) Prediction of the genetic variety of Spanish extra virgin olive oils using fatty 
acid and phenolic compound profiles established by direct infusion mass spectrometry, 
Food Chem 108, 1142-1148. 
36. Zhang, S., Van Pelt, C. K., and Henion, J. D. (2003) Automated chip-based 
nanoelectrospray-mass spectrometry for rapid identification of proteins separated by 
two-dimensional gel electrophoresis, Electrophoresis 24, 3620-3632. 
37. Wilm, M., and Mann, M. (1996) Analytical properties of the nanoelectrospray ion 
source, Anal Chem 68, 1-8. 
38. Weber, R. J. M., Southam, A. D., Sommer, U., and Viant, M. R. (2011) 
Characterization of Isotopic Abundance Measurements in High Resolution FT-ICR and 
Orbitrap Mass Spectra for Improved Confidence of Metabolite Identification, Anal Chem 
83, 3737-3743. 
39. Tan, A. M., Benetton, S., and Henion, J. D. (2003) Chip-based solid-phase extraction 
pretreatment for direct electrospray mass spectrometry analysis using an array of 
monolithic columns in a polymeric substrate, Anal Chem 75, 5504-5511. 
134 
 
40. Pereira-Medrano, A. G., Sterling, A., SnijderS, A. P. L., Reardon, K. F., and Wright, 
P. C. (2007) A systematic evaluation of chip-based nanoelectrospray parameters for rapid 
identification of proteins from a complex mixture, J Am Soc Mass Spectr 18, 1714-1725. 
41. Gabelica, V., Vreuls, C., Filee, P., Duval, V., Joris, B., and De Pauw, E. (2002) 
Advantages and drawbacks of nanospray for studying noncovalent protein-DNA 
complexes by mass spectrometry, Rapid Commun Mass Sp 16, 1723-1728. 
42. Chen, J., Canales, L., and Neal, R. E. (2011) Multi-Segment Direct Inject 
nano-ESI-LTQ-FT-ICR-MS/MS For Protein Identification, Proteome Sci 9. 
43. Theodoridis, G., Gika, H., Franceschi, P., Caputi, L., Arapitsas, P., Scholz, M., 
Masuero, D., Wehrens, R., Vrhovsek, U., and Mattivi, F. (2012) LC-MS based global 
metabolite profiling of grapes: solvent extraction protocol optimisation, Metabolomics 8, 
175-185. 
44. Ressom, H. W., Xiao, J. F., Tuli, L., Varghese, R. S., Zhou, B., Tsai, T.-H., Nezami 
Ranjbar, M. R., Zhao, Y., Wang, J., Di Poto, C., Cheema, A. K., Tadesse, M. G., 
Goldman, R., and Shetty, K. (2012) Utilization of metabolomics to identify serum 
biomarkers for hepatocellular carcinoma in patients with liver cirrhosis, Anal Chim Acta 
743, 90-100. 
45. Chen, F., Xue, J., Zhou, L., Wu, S., and Chen, Z. (2011) Identification of serum 
biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based 
metabonomic method, Anal Bioanal Chem 401, 1899-1904. 
135 
 
46. Liu, S.-Y., Zhang, R.-L., Kang, H., Fan, Z.-J., and Du, Z. (2013) Human liver tissue 
metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma, World 
J. Gastroenterol. 19, 3423-3432. 
47. Harn, H.-J., Chen, Y.-L., Lin, P.-C., Cheng, Y.-L., Lee, S.-C., Chiou, T.-W., and 
Yang, H.-H. (2010) Exploration of potential tumor markers for lung adenocarcinomas by 
two-dimensional gel electrophoresis coupled with nano-LC/MS/MS, J. Chin. Chem. Soc. 
(Taipei, Taiwan) 57, 180-188. 
48. Yang, Q., Shi, X., Wang, Y., Wang, W., He, H., Lu, X., and Xu, G. (2010) Urinary 
metabonomic study of lung cancer by a fully automatic hyphenated hydrophilic 
interaction/RPLC-MS system, J. Sep. Sci. 33, 1495-1503. 
49. Müller, D. C., Degen, C., Scherer, G., Jahreis, G., Niessner, R., and Scherer, M. 
(2014) Metabolomics using GC–TOF–MS followed by subsequent GC–FID and 
HILIC–MS/MS analysis revealed significantly altered fatty acid and phospholipid species 
profiles in plasma of smokers, Journal of Chromatography B 966, 117-126. 
50. Lisa, M., Cifkova, E., and Holcapek, M. (2011) Lipidomic profiling of biological 
tissues using off-line two-dimensional high-performance liquid chromatography mass 
spectrometry, Journal of Chromatography A 1218, 5146-5156. 
51. Fairchild, J. N., Horvath, K., Gooding, J. R., Campagna, S. R., and Guiochon, G. 
(2010) Two-dimensional liquid chromatography/mass spectrometry/mass spectrometry 
separation of water-soluble metabolites, Journal of Chromatography A 1217, 8161-8166. 
52. Xiao, J. F., Zhou, B., and Ressom, H. W. (2012) Metabolite identification and 
quantitation in LC-MS/MS-based metabolomics, Trends Analyt Chem 32, 1-14. 
136 
 
53. Zhang, T., and Watson, D. G. (2013) High performance liquid chromatographic 
approaches to mass spectrometry based metabolomics, Curr. Metabolomics 1, 58-83. 
54. Zhang, G.-F., Li, Q., Li, L., and Kasumov, T. (2012) Metabolomics research with 
tandem mass spectrometry, pp 309-330, InTech. 
55. Warth, B., Parich, A., Bueschl, C., Schoefbeck, D., Neumann, N. K. N., Kluger, B., 
Schuster, K., Krska, R., Adam, G., Lemmens, M., and Schuhmacher, R. (2014) GC-MS 
based targeted metabolic profiling identifies changes in the wheat metabolome following 
deoxynivalenol treatment, Metabolomics, Ahead of Print. 
56. Kobayashi, T., Nishiumi, S., Kawana, S., Azuma, T., and Yoshida, M. (2013) 
Biomarker discovery for the pancreatic cancer by the serum metabolomics based on gas 
chromatography mass spectrometry, Shimadzu Hyoron 70, 117-121. 
57. Schaffert, C. S., Duryee, M. J., Hunter, C. D., Hamilton, B. C., 3rd, DeVeney, A. L., 
Huerter, M. M., Klassen, L. W., and Thiele, G. M. (2009) Alcohol metabolites and 
lipopolysaccharide: roles in the development and/or progression of alcoholic liver disease, 
World J Gastroenterol 15, 1209-1218. 
58. Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.-C., and Roudot-Thoraval, 
F. (2013) The burden of liver disease in Europe: A review of available epidemiological 
data, J Hepatol 58, 593-608. 
59. Ludwig, J., Viggiano, T. R., McGill, D. B., and Oh, B. J. (1980) Nonalcoholic 
steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease, Mayo Clin 
Proc 55, 434-438. 
137 
 
60. Hashimoto, E., Taniai, M., and Tokushige, K. (2013) Characteristics and diagnosis of 
NAFLD/NASH, J Gastroenterol Hepatol 28 Suppl 4, 64-70. 
61. Lin, X., Zhang, Y., Ye, G., Li, X., Yin, P., Ruan, Q., and Xu, G. (2011) Classification 
and differential metabolite discovery of liver diseases based on plasma metabolic 
profiling and support vector machines, J Sep Sci 34, 3029-3036. 
62. Ji, P., Wei, Y., Sun, H., Xue, W., Hua, Y., Li, P., Zhang, W., Zhang, L., Zhao, H., and 
Li, J. (2014) Metabolomics research on the hepatoprotective effect of Angelica sinensis 
polysaccharides through gas chromatography–mass spectrometry, Journal of 
Chromatography B 973, 45-54. 
63. Shi, X., Wei, X., Koo, I., Schmidt, R. H., Yin, X., Vaughn, A., Kim, S. H., McClain, 
C. J., Arteel, G. E., Zhang, X., and Watson, W. H. (2014) Metabolomic analysis of the 
effects of chronic arsenic exposure in a mouse model of diet-induced fatty liver disease, J. 
Proteome Res. 13, 547−554. 
64. Morikawa, T., Ninomiya, K., Miyake, S., Miki, Y., Okamoto, M., Yoshikawa, M., 
and Muraoka, O. Flavonol glycosides with lipid accumulation inhibitory activity and 
simultaneous quantitative analysis of 15 polyphenols and caffeine in the flower buds of 
Camellia sinensis from different regions by LCMS, Food Chem 140, 353-360. 
65. Trammell, S. A. J., and Brenner, C. (2013) TARGETED, LCMS-BASED 
METABOLOMICS FOR QUANTITATIVE MEASUREMENT OF NAD+ 
METABOLITES, Computational and Structural Biotechnology Journal 4, 1-9. 
138 
 
66. MacIntyre, L., Zheng, L. A., Scullion, P., Keating, P., and Watson, D. G. (2011) 
Metabolomic profiling of biomarkers of liver X receptor-induced toxicity in mouse liver 
tissue, Metabolomics 7, 54-70. 
67. Loftus, N., Barnes, A., Ashton, S., Michopoulos, F., Theodoridis, G., Wilson, I., Ji, C., 
and Kaplowitz, N. (2011) Metabonomic Investigation of Liver Profiles of Nonpolar 
Metabolites Obtained from Alcohol-Dosed Rats and Mice Using High Mass Accuracy 
MS(n) Analysis, J Proteome Res 10, 705-713. 
68. Cave, M., Appana, S., Patel, M., Falkner, K. C., McClain, C. J., and Brock, G. (2010) 
Polychlorinated Biphenyls, Lead, and Mercury Are Associated with Liver Disease in 
American Adults: NHANES 2003-2004, Environ Health Persp 118, 1735-1742. 
69. Lyche, J. L., Skaare, J. U., Larsen, H. J. S., and Ropstad, E. (2004) Levels of PCB 
126 and PCB 153 in plasma and tissues in goats exposed during gestation and lactation, 
Chemosphere 55, 621-629. 
70. Wahlang, B., Falkner, K., Conklin, D., McClain, C., and Cave, M. (2012) 
Polychlorinated biphenyl 153 worsens non-alcoholic fatty liver disease in C57BL/6 mice, 
The Toxicologist CD Supplement to Toxicological Sciences — An Official Journal of the 
Society of Toxicology. 126, 84. 
71. Zhong, W., Zhao, Y. T., Tang, Y. N., Wei, X. L., Shi, X., Sun, W. L., Sun, X. H., Yin, 
X. M., Sun, X. G., Kim, S., McClain, C. J., Zhang, X., and Zhou, Z. X. (2011) Chronic 
Alcohol Exposure Causes Adipose Fat Overflux to the Liver in Mice: A Mechanistic 
Link between Lipodystrophy and Steatosis, Hepatology 54, 978a-978a. 
139 
 
72. Weber, R. J., Southam, A. D., Sommer, U., and Viant, M. R. (2011) Characterization 
of isotopic abundance measurements in high resolution FT-ICR and Orbitrap mass 
spectra for improved confidence of metabolite identification, Anal Chem 83, 3737-3743. 
73. Higgs, R. E., Zahn, J. A., Gygi, J. D., and Hilton, M. D. (2001) Rapid method to 
estimate the presence of secondary metabolites in microbial extracts, Appl Environ 
Microbiol 67, 371-376. 
74. Bradford, B. U., O'Connell, T. M., Han, J., Kosyk, O., Shymonyak, S., Ross, P. K., 
Winnike, J., Kono, H., and Rusyn, I. (2008) Metabolomic profiling of a modified alcohol 
liquid diet model for liver injury in the mouse uncovers new markers of disease, Toxicol 
Appl Pharm 232, 236-243. 
75. Bligh, E. G., and Dyer, W. J. (1959) A rapid method of total lipid extraction and 
purification, Can J Biochem Physiol 37, 911-917. 
76. Wei, X., Sun, W., Shi, X., Koo, I., Wang, B., Zhang, J., Yin, X., Tang, Y., Bogdanov, 
B., Kim, S., Zhou, Z., McClain, C., and Zhang, X. (2011) MetSign: a computational 
platform for high-resolution mass spectrometry-based metabolomics, Anal Chem 83, 
7668-7675. 
77. Bolstad, B. M., Irizarry, R. A., Astrand, M., and Speed, T. P. (2003) A comparison of 
normalization methods for high density oligonucleotide array data based on variance and 
bias, Bioinformatics 19, 185-193. 
78. Jahn, M., Baynes, J. W., and Spiteller, G. (1999) The reaction of hyaluronic acid and 
its monomers, glucuronic acid and N-acetylglucosamine, with reactive oxygen species, 
Carbohydr Res 321, 228-234. 
140 
 
79. Harding, J. J., Hassett, P. C., Rixon, K. C., Bron, A. J., and Harvey, D. J. (1999) 
Sugars including erythronic and threonic acids in human aqueous humour, Curr Eye Res 
19, 131-136. 
80. Kim, H. J., Kim, J. H., Noh, S., Hur, H. J., Sung, M. J., Hwang, J. T., Park, J. H., 
Yang, H. J., Kim, M. S., Kwon, D. Y., and Yoon, S. H. (2011) Metabolomic Analysis of 
Livers and Serum from High-Fat Diet Induced Obese Mice, J Proteome Res 10, 722-731. 
81. Goncharov, A., Pavuk, M., Foushee, H. R., and Carpenter, D. O. (2011) Blood 
pressure in relation to concentrations of PCB congeners and chlorinated pesticides, 
Environ Health Perspect 119, 319-325. 
82. Nehme, A., Lobenhofer, E. K., Stamer, W. D., and Edelman, J. L. (2009) 
Glucocorticoids with different chemical structures but similar glucocorticoid receptor 
potency regulate subsets of common and unique genes in human trabecular meshwork 
cells, Bmc Med Genomics 2. 
83. Pompella, A., Visvikis, A., Paolicchi, A., De Tata, V., and Casini, A. F. (2003) The 
changing faces of glutathione, a cellular protagonist, Biochem Pharmacol 66, 1499-1503. 
84. Kelly, A., and Stanley, C. A. (2001) Disorders of glutamate metabolism, Mental 
retardation and developmental disabilities research reviews 7, 287-295. 
85. Hirano, T., Kaplowitz, N., Tsukamoto, H., Kamimura, S., and Fernandez-Checa, J. C. 
(1992) Hepatic mitochondrial glutathione depletion and progression of experimental 
alcoholic liver disease in rats, Hepatology 16, 1423-1427. 
141 
 
86. Pastore, A., Ciampalini, P., Tozzi, G., Pecorelli, L., Passarelli, C., Bertini, E., and 
Piemonte, F. (2012) All glutathione forms are depleted in blood of obese and type 1 
diabetic children, Pediatric Diabetes 13, 272-277. 
87. Altomare, E., Vendemiale, G., and Albano, O. (1988) HEPATIC GLUTATHIONE 
CONTENT IN PATIENTS WITH ALCOHOLIC AND NONALCOHOLIC 
LIVER-DISEASES, Life Sci 43, 991-998. 
88. Jeong, Y. C., Walker, N. J., Burgin, D. E., Kissling, G., Gupta, M., Kupper, L., 
Birnbaum, L. S., and Swenberg, J. A. (2008) Accumulation of M(1)dG DNA adducts 
after chronic exposure to PCBs, but not from acute exposure to polychlorinated aromatic 
hydrocarbons, Free Radical Bio Med 45, 585-591. 
89. Lutz, R. J., Dedrick, R. L., Tuey, D., Sipes, I. G., Anderson, M. W., and Matthews, H. 
B. (1984) Comparison of the Pharmacokinetics of Several Polychlorinated-Biphenyls in 
Mouse, Rat, Dog, and Monkey by Means of a Physiological Pharmacokinetic Model, 
Drug Metab Dispos 12, 527-535. 
90. Safe, S., Bandiera, S., Sawyer, T., Robertson, L., Safe, L., Parkinson, A., Thomas, P. 
E., Ryan, D. E., Reik, L. M., Levin, W., Denomme, M. A., and Fujita, T. (1985) PCBS - 
STRUCTURE-FUNCTION-RELATIONSHIPS AND MECHANISM OF ACTION, 
Environ Health Persp 60, 47-56. 
91. Twaroski, T. P., O'Brien, M. L., and Robertson, L. W. (2001) Effects of selected 
polychlorinated biphenyl (PCB) congeners on hepatic glutathione, glutathione-related 
enzymes, and selenium status: implications for oxidative stress, Biochemical 
Pharmacology 62, 273-281. 
142 
 
92. Kalhan, S. C., Guo, L., Edmison, J., Dasarathy, S., McCullough, A. J., Hanson, R. W., 
and Milburn, M. (2011) Plasma metabolomic profile in nonalcoholic fatty liver disease, 
Metabolism 60, 404-413. 
93. Barr, J., Vazquez-Chantada, M., Alonso, C., Perez-Cormenzana, M., Mayo, R., Galan, 
A., Caballeria, J., Martin-Duce, A., Tran, A., Wagner, C., Luka, Z., Lu, S. C., Castro, A., 
Le Marchand-Brustel, Y., Martinez-Chantar, M. L., Veyrie, N., Clement, K., Tordjman, 
J., Gual, P., and Mato, J. M. (2010) Liquid chromatography-mass spectrometry-based 
parallel metabolic profiling of human and mouse model serum reveals putative 
biomarkers associated with the progression of nonalcoholic fatty liver disease, J 
Proteome Res 9, 4501-4512. 
94. Xiao, C., Hsieh, J., Adeli, K., and Lewis, G. F. (2011) Gut-liver interaction in 
triglyceride-rich lipoprotein metabolism, Am. J. Physiol. 301, E429-E446. 
95. Sethi, J. K., and Vidal-Puig, A. J. (2007) Adipose tissue function and plasticity 
orchestrate nutritional adaptation, J. Lipid Res. 48, 1253-1262. 
96. Cusi, K. (2010) The role of adipose tissue and lipotoxicity in the pathogenesis of type 
2 diabetes, Curr. Diabetes Rep. 10, 306-315. 
97. Bradbury MW, B. P. (2004) Lipid metabolism in hepatic steatosis, Clinics in liver 
disease 8, 639-671. 
98. Sozio, M. S., Liangpunsakul, S., and Crabb, D. (2010) The role of lipid metabolism in 




99. Berk PD, Z. S., Bradbury MW. (2005) Increased hepatocellular uptake of long chain 
fatty acids occurs by different mechanisms in fatty livers due to obesity or excess ethanol 
use, contributing to development of steatohepatitis in both settings, Trans Am Clin 
Climatol Assoc 116, 335-344. 
100. Addolorato, G., Capristo, E., Greco, A. V., Stefanini, G. F., and Gasbarrini, G. 
(1997) Energy expenditure, substrate oxidation, and body composition in subjects with 
chronic alcoholism: new findings from metabolic assessment, Alcohol Clin Exp Res 21, 
962-967. 
101. Addolorato, G., Capristo, E., Greco, A. V., Stefanini, G. F., and Gasbarrini, G. 
(1998) Influence of chronic alcohol abuse on body weight and energy metabolism: is 
excess ethanol consumption a risk factor for obesity or malnutrition?, J Intern Med 244, 
387-395. 
102. Kang, L., Chen, X., Sebastian, B. M., Pratt, B. T., Bederman, I. R., Alexander, J. C., 
Previs, S. F., and Nagy, L. E. (2007) Chronic Ethanol and Triglyceride Turnover in 
White Adipose Tissue in Rats: Inhibition of the anti-lipolytic action of insulin after 
chronic ethanol contributes to increased triglyceride degradation, J. Biol. Chem. 282, 
28465-28473. 
103. Zhou, S. L., Gordon, R. E., Bradbury, M., Stump, D., Kiang, C. L., and Berk, P. D. 
(1998) Ethanol up-regulates fatty acid uptake and plasma membrane expression and 




104. Kang, X., Zhong, W., Liu, J., Song, Z., McClain, C. J., Kang, Y. J., and Zhou, Z. 
(2009) Zinc supplementation reverses alcohol-induced steatosis in mice through 
reactivating hepatocyte nuclear factor-4α and peroxisome proliferator-activated 
receptor-α, Hepatology (Hoboken, NJ, U. S.) 50, 1241-1250. 
105. Zhong, W., Zhao, Y., Tang, Y., Wei, X., Shi, X., Sun, W., Sun, X., Yin, X., Sun, X., 
Kim, S., McClain, C. J., Zhang, X., and Zhou, Z. (2012) Chronic alcohol exposure 
stimulates adipose tissue lipolysis in mice: role of reverse triglyceride transport in the 
pathogenesis of alcoholic steatosis, Am. J. Pathol. 180, 998-1007. 
106. Sun, X., Tang, Y., Tan, X., Li, Q., Zhong, W., Sun, X., Jia, W., McClain, C. J., and 
Zhou, Z. (2012) Activation of peroxisome proliferator-activated receptor-γ by 
rosiglitazone improves lipid homeostasis at the adipose tissue-liver axis in ethanol-fed 
mice, Am. J. Physiol. 302, G548-G557. 
107. Pouteau, E., Beysen, C., Saad, N., and Turner, S. (2009) Dynamics of adipose tissue 
development by 2H2O labeling, Methods Mol. Biol. (Totowa, NJ, U. S.) 579, 337-358. 
108. Wei, X., Sun, W., Shi, X., Koo, I., Wang, B., Zhang, J., Yin, X., Tang, Y., 
Bogdanov, B., Kim, S., Zhou, Z., McClain, C., and Zhang, X. (2011) MetSign: a 
computational platform for high-resolution mass spectrometry-based metabolomics, Anal 
Chem 83, 7668-7675. 
109. Newton MA, N. A., Sarkar D, Ahlquist P. (2004) Detecting differential gene 
expression with a semiparametric hierarchical mixture method, Biostatistics 5, 155-176. 
110. Fisher, R. (1948) Questions and answers #14, The American Statistician 2, 30-31. 
145 
 
111. Fisher, R. (1932) Statistical Methods for Research Workers, 4th ed,  Edinburgh, 
Oliver and Boyd. 
112. Sumner, L. W., Amberg, A., Barrett, D., Beale, M. H., Beger, R., Daykin, C. A., Fan, 
T. W. M., Fiehn, O., Goodacre, R., Griffin, J. L., Hankemeier, T., Hardy, N., Harnly, J., 
Higashi, R., Kopka, J., Lane, A. N., Lindon, J. C., Marriott, P., Nicholls, A. W., Reily, M. 
D., Thaden, J. J., and Viant, M. R. (2007) Proposed minimum reporting standards for 
chemical analysis. Chemical Analysis Working Group (CAWG) Metabolomics Standards 
Initiative (MSI), Metabolomics 3, 211-221. 
113. Wang, M.-Y., Grayburn, P., Chen, S., Ravazzola, M., Orci, L., and Unger, R. H. 
(2008) Adipogenic capacity and the susceptibility to type 2 diabetes and metabolic 
syndrome, Proc. Natl. Acad. Sci. U. S. A. 105, 6139-6144. 
114. Large, V., Peroni, O., Letexier, D., Ray, H., and Beylot, M. (2004) Metabolism of 
lipids in human white adipocyte, Diabetes Metab. 30, 294-309. 
115. Kang, L., and Nagy, L. E. (2006) Chronic ethanol feeding suppresses β-adrenergic 
receptor-stimulated lipolysis in adipocytes isolated from epididymal fat, Endocrinology 
147, 4330-4338. 
116. You, M., and Rogers, C. Q. (2009) Adiponectin: a key adipokine in alcoholic fatty 
liver, Exp. Biol. Med. (Maywood, NJ, U. S.) 234, 850-859. 
117. Greco, A. V., Mingrone, G., Favuzzi, A., Capristo, E., Gniuli, D., Addolorato, G., 
Brunani, A., Cavagnin, F., and Gasbarrini, G. (2000) Serum leptin levels in post-hepatitis 
liver cirrhosis, J. Hepatol. 33, 38-42. 
146 
 
118. Santolaria, F., Perez-Cejas, A., Aleman, M.-R., Gonzalez-Reimers, E., Milena, A., 
De La Vega, M.-J., Martinez-Riera, A., and Gomez-Rodriguez, M.-A. (2003) Low serum 
leptin levels and malnutrition in chronic alcohol misusers hospitalized by somatic 
complications, Alcohol Alcohol. (Oxford, U. K.) 38, 60-66. 
119. You, M., Considine, R. V., Leone, T. C., Kelly, D. P., and Crabb, D. W. (2005) Role 
of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver 
in mice, Hepatology (Hoboken, NJ, U. S.) 42, 568-577. 
120. Shen, Z., Liang, X., Rogers, C. Q., Rideout, D., and You, M. (2010) Involvement of 
adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against 
alcoholic fatty liver in mice, Am. J. Physiol. 298, G364-G374. 
121. Tan, X., Sun, X., Li, Q., Zhao, Y., Zhong, W., Sun, X., Jia, W., McClain, C. J., and 
Zhou, Z. (2012) Leptin deficiency contributes to the pathogenesis of alcoholic fatty liver 
disease in mice, Am. J. Pathol. 181, 1279-1286. 
122. Gao, B., and Bataller, R. (2011) Alcoholic Liver Disease: Pathogenesis and New 
Therapeutic Targets, Gastroenterology 141, 1572-1585. 
123. Janero, D. R., Siuta-Mangano, P., Miller, K. W., and Lane, M. D. (1984) Synthesis, 
processing, and secretion of hepatic very low density lipoprotein, J. Cell. Biochem. 24, 
131-152. 
124. Yao Z, Z. H., Figeys D, Wang Y, Sundaram M. (2012) Microsome-associated 
lumenal lipid droplets in the regulation of lipoprotein secretion, Curr Opin Lipidol. 
147 
 
125. Kharbanda, K. K., Todero, S. L., Ward, B. W., Cannella, J. J., III, and Tuma, D. J. 
(2009) Betaine administration corrects ethanol-induced defective VLDL secretion, Mol. 
Cell. Biochem. 327, 75-78. 
126. Tomita K, A. T., Kitamura N, Nishida J, Tamiya G, et al. (1999) Hepatocyte growth 
factor leads to recovery from alcohol-induced fatty liver in rats, J Clin Invest 103, 
313-320. 
127. Day, C. P., and James, O. F. (1998) Steatohepatitis: a tale of two "hits"?, 
Gastroenterology 114, 842-845. 
128. Tilg, H., and Moschen, A. R. (2010) Evolution of inflammation in nonalcoholic fatty 
liver disease: the multiple parallel hits hypothesis, Hepatology 52, 1836-1846. 
129. Cave, M., Deaciuc, I., Mendez, C., Song, Z., Joshi-Barve, S., Barve, S., and 
McClain, C. (2007) Nonalcoholic fatty liver disease: predisposing factors and the role of 
nutrition, J Nutr Biochem 18, 184-195. 
130. Wahlang, B., Beier, J. I., Clair, H. B., Bellis-Jones, H. J., Falkner, K. C., McClain, C. 
J., and Cave, M. C. (2013) Toxicant-associated Steatohepatitis, Toxicol. Pathol. 41, 
343-360. 
131. Tan, M., Schmidt, R. H., Beier, J. I., Watson, W. H., Zhong, H., States, J. C., and 
Arteel, G. E. (2011) Chronic subhepatotoxic exposure to arsenic enhances hepatic injury 
caused by high fat diet in mice, Toxicol Appl Pharmacol 257, 356-364. 
132. Argos, M., Kalra, T., Rathouz, P. J., Chen, Y., Pierce, B., Parvez, F., Islam, T., 
Ahmed, A., Rakibuz-Zaman, M., Hasan, R., Sarwar, G., Slavkovich, V., van Geen, A., 
Graziano, J., and Ahsan, H. (2010) Arsenic exposure from drinking water, and all-cause 
148 
 
and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study, 
Lancet 376, 252-258. 
133. Waalkes, M. P., Liu, J., Chen, H., Xie, Y., Achanzar, W. E., Zhou, Y. S., Cheng, M. 
L., and Diwan, B. A. (2004) Estrogen signaling in livers of male mice with hepatocellular 
carcinoma induced by exposure to arsenic in utero, J. Natl. Cancer Inst. 96, 466-474. 
134. Mazumder, D. N. (2005) Effect of chronic intake of arsenic-contaminated water on 
liver, Toxicol. Appl. Pharmacol. 206, 169-175. 
135. States, J. C., Singh, A. V., Knudsen, T. B., Rouchka, E. C., Ngalame, N. O., Arteel, 
G. E., Piao, Y., and Ko, M. S. (2012) Prenatal arsenic exposure alters gene expression in 
the adult liver to a proinflammatory state contributing to accelerated atherosclerosis, 
PLoS One 7, e38713. 
136. Ralston-Hooper, K., Hopf, A., Oh, C., Zhang, X., Adamec, J., and Sepulveda, M. S. 
(2008) Development of GCxGC/TOF-MS metabolomics for use in ecotoxicological 
studies with invertebrates, Aquat Toxicol 88, 48-52. 
137. Mohler, R. E., Dombek, K. M., Hoggard, J. C., Pierce, K. M., Young, E. T., and 
Synovec, R. E. (2007) Comprehensive analysis of yeast metabolite GC x GC-TOFMS 
data: combining discovery-mode and deconvolution chemometric software, Analyst 132, 
756-767. 
138. Huang, X., and Regnier, F. E. (2008) Differential metabolomics using stable isotope 
labeling and two-dimensional gas chromatography with time-of-flight mass spectrometry, 
Anal. Chem. 80, 107-114. 
149 
 
139. Kim, S., Koo, I., Jeong, J., Wu, S., Shi, X., and Zhang, X. (2012) Compound 
identification using partial and semipartial correlations for gas chromatography-mass 
spectrometry data, Anal. Chem. 84, 6477-6487. 
140. Koo, I., Zhang, X., and Kim, S. (2011) Wavelet- and Fourier-transform-based 
spectrum similarity approaches to compound identification in gas chromatography/mass 
spectrometry, Anal. Chem. 83, 5631-5638. 
141. Wei, X., Shi, X., Koo, I., Kim, S., Schmidt, R. H., Arteel, G. E., Watson, W. H., 
McClain, C., and Zhang, X. (2013) MetPP: a computational platform for comprehensive 
two-dimensional gas chromatography time-of-flight mass spectrometry-based 
metabolomics, Bioinformatics 29, 1786-1792. 
142. Castillo, S., Mattila, I., Miettinen, J., Oresic, M., and Hyotylainen, T. (2011) Data 
analysis tool for comprehensive two-dimensional gas chromatography/time-of-flight 
mass spectrometry, Anal Chem 83, 3058-3067. 
143. Hoggard, J. C., and Synovec, R. E. (2008) Automated resolution of nontarget 
analyte signals in GC x GC-TOFMS data using parallel factor analysis, Analytical 
Chemistry 80, 6677-6688. 
144. Kozul, C. D., Nomikos, A. P., Hampton, T. H., Warnke, L. A., Gosse, J. A., Davey, 
J. C., Thorpe, J. E., Jackson, B. P., Ihnat, M. A., and Hamilton, J. W. (2008) Laboratory 
diet profoundly alters gene expression and confounds genomic analysis in mouse liver 
and lung, Chem. Biol. Interact. 173, 129-140. 
150 
 
145. Tong, T., and Zhao, H. (2008) Practical guidelines for assessing power and false 
discovery rate for a fixed sample size in microarray experiments, Stat Med 27, 
1960-1972. 
146. Sydor, S., Gu, Y., Schlattjan, M., Bechmann, L. P., Rauen, U., Best, J., Paul, A., 
Baba, H. A., Sowa, J. P., Gerken, G., and Canbay, A. (2013) Steatosis does not impair 
liver regeneration after partial hepatectomy, Lab. Invest. 93, 20-30. 
147. Shi, X., Wahlang, B., Wei, X., Yin, X., Falkner, K. C., Prough, R. A., Kim, S. H., 
Mueller, E. G., McClain, C. J., Cave, M., and Zhang, X. (2012) Metabolomic analysis of 
the effects of polychlorinated biphenyls in nonalcoholic fatty liver disease, J Proteome 
Res 11, 3805-3815. 
148. Lu, S. C. (2013) Glutathione synthesis, Biochim Biophys Acta 1830, 3143-3153. 
149. Santra, A., Maiti, A., Chowdhury, A., and Mazumder, D. N. (2000) Oxidative stress 
in liver of mice exposed to arsenic-contaminated water, Indian J Gastroenterol 19, 
112-115. 
150. Ohlsson, L. (2010) Dairy products and plasma cholesterol levels, Food Nutr. Res. 
54. 
151. Kirpich, I. A., Feng, W., Wang, Y., Liu, Y., Barker, D. F., Barve, S. S., and McClain, 
C. J. (2012) The type of dietary fat modulates intestinal tight junction integrity, gut 
permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic 
liver disease, Alcohol. Clin. Exp. Res. 36, 835-846. 
151 
 
152. Kono, H., Fujii, H., Asakawa, M., Yamamoto, M., Matsuda, M., Maki, A., and 
Matsumoto, Y. (2003) Protective effects of medium-chain triglycerides on the liver and 
gut in rats administered endotoxin, Ann Surg 237, 246-255. 
153. Ronis, M. J., Baumgardner, J. N., Sharma, N., Vantrease, J., Ferguson, M., Tong, Y., 
Wu, X., Cleves, M. A., and Badger, T. M. (2013) Medium chain triglycerides 
dose-dependently prevent liver pathology in a rat model of non-alcoholic fatty liver 
disease, Exp Biol Med (Maywood) 238, 151-162. 
154. Gupta, S., Knight, A. G., Keller, J. N., and Bruce-Keller, A. J. (2012) Saturated 
long-chain fatty acids activate inflammatory signaling in astrocytes, Journal of 
neurochemistry 120, 1060-1071. 
155. Huang, S., Rutkowsky, J. M., Snodgrass, R. G., Ono-Moore, K. D., Schneider, D. A., 
Newman, J. W., Adams, S. H., and Hwang, D. H. (2012) Saturated fatty acids activate 
TLR-mediated proinflammatory signaling pathways, Journal of lipid research 53, 
2002-2013. 
156. Murumalla, R. K., Gunasekaran, M. K., Padhan, J. K., Bencharif, K., Gence, L., 
Festy, F., Cesari, M., Roche, R., and Hoareau, L. (2012) Fatty acids do not pay the toll: 
effect of SFA and PUFA on human adipose tissue and mature adipocytes inflammation, 
Lipids in health and disease 11, 175. 
157. Harvey, K. A., Walker, C. L., Pavlina, T. M., Xu, Z., Zaloga, G. P., and Siddiqui, R. 
A. (2010) Long-chain saturated fatty acids induce pro-inflammatory responses and 
impact endothelial cell growth, Clin Nutr 29, 492-500. 
152 
 
158. Begriche, K., Massart, J., Robin, M. A., Bonnet, F., and Fromenty, B. (2013) 
Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease, 
Hepatology. 
159. Joseloff, E., Sha, W., Bell, S. C., Wetmore, D. R., Lawton, K. A., Milburn, M. V., 
Ryals, J. A., Guo, L., and Muhlebach, M. S. (2013) Serum metabolomics indicate altered 
cellular energy metabolism in children with cystic fibrosis, Pediatric pulmonology. 
160. Ikejima, K., Iimuro, Y., Forman, D. T., and Thurman, R. G. (1996) A diet 
containing glycine improves survival in endotoxin shock in the rat, Am. J. Physiol. 271, 
G97-103. 
161. Rose, M. L., Germolec, D., Arteel, G. E., Schoonhoven, R., and Thurman, R. G. 
(1997) Dietary glycine prevents increases in hepatocyte proliferation caused by the 
peroxisome proliferator WY-14,643, Chem. Res. Toxicol. 10, 1198-1204. 
162. Ikejima, K., Qu, W., Stachlewitz, R. F., and Thurman, R. G. (1997) Kupffer cells 
contain a glycine-gated chloride channel, Am. J. Physiol. 272, G1581-1586. 
163. Wheeler, M. D., Ikejema, K., Enomoto, N., Stacklewitz, R. F., Seabra, V., Zhong, Z., 
Yin, M., Schemmer, P., Rose, M. L., Rusyn, I., Bradford, B., and Thurman, R. G. (1999) 
Glycine: a new anti-inflammatory immunonutrient, Cell. Mol. Life Sci. 56, 843-856. 
164. Leoncini, R., Pagani, R., Marinello, E., and Keleti, T. (1989) Double inhibition of 
L-threonine dehydratase by aminothiols, Biochim. Biophys. Acta 994, 52-58. 
165. Manohar, R., and Appaji Rao, N. (1984) Identification of active-site residues of 
sheep liver serine hydroxymethyltransferase, Biochem. J. 224, 703-707. 
153 
 
166. Gavilanes, F., Peterson, D., Bullis, B., and Schirch, L. (1983) Structure and 
reactivity of cysteine residues in mitochondrial serine hydroxymethyltransferase, J. Biol. 
Chem. 258, 13155-13159. 
167. Huang, C., Yin, Q., Zhu, W., Yang, Y., Wang, X., Qian, X., and Xu, Y. (2011) 
Highly selective fluorescent probe for vicinal-dithiol-containing proteins and in situ 
imaging in living cells, Angew. Chem. Int. Ed. Engl. 50, 7551-7556. 
168. Kirpich, I. A., and McClain, C. J. (2012) Probiotics in the treatment of the liver 
diseases, Journal of the American College of Nutrition 31, 14-23. 
169. Wang, Y., Kirpich, I., Liu, Y., Ma, Z., Barve, S., McClain, C. J., and Feng, W. 
(2011) Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible 
factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury, Am. J. 
Pathol. 179, 2866-2875. 
170. Forsyth, C. B., Farhadi, A., Jakate, S. M., Tang, Y., Shaikh, M., and Keshavarzian, 
A. (2009) Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative 
stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis, Alcohol 
(N. Y., NY, U. S.) 43, 163-172. 
171. Kelishadi, R., Farajian, S., and Mirlohi, M. (2013) Probiotics as a Novel Treatment 
for Non-Alcoholic Fatty Liver Disease; A Systematic Review on the Current Evidences, 
Hepatitis Monthly 13. 
172. Wang, Y., Liu, Y., Kirpich, I., Ma, Z., Wang, C., Zhang, M., Suttles, J., McClain, C., 
and Feng, W. (2013) Lactobacillus rhamnosus GG reduces hepatic TNFα production and 
inflammation in chronic alcohol-induced liver injury, J. Nutr. Biochem. 24, 1609-1615. 
154 
 
173. Wang, Y., Liu, Y., Sidhu, A., Ma, Z., McClain, C., and Feng, W. (2012) 
Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced 
intestinal permeability and liver injury, Am. J. Physiol. 303, G32-G41. 
174. Zhang, M., Wang, C., Wang, C., Zhao, H., Zhao, C., Wang, Y., McClain, C., and 
Feng, W. (2014) Enhanced AMPK phosphorylation contributes to the beneficial effects 
of  Lactobacillus rhamnosus GG supernatant on chronic alcohol-induced fatty liver 
disease, J Nutr Biochem In press. 
175. Ralston-Hooper, K., Hopf, A., Oh, C., Zhang, X., Adamec, J., and Sepulveda, M. S. 
(2008) Development of GCxGC/TOF-MS metabolomics for use in ecotoxicological 
studies with invertebrates, Aquat Toxicol 88, 48-52. 
176. Liu, S. M., Miller, D. M., and Roberts, R. F. (2011) Cloning of genes encoding 
colicin E2 in Lactococcus lactis subspecies lactis and evaluation of the colicin-producing 
transformants as inhibitors of Escherichia coli O157:H7 during milk fermentation, 
Journal of Dairy Science 94, 1146-1154. 
177. Godsey, H. S., Oviatt, C. G., Miller, D. M., and Chan, M. A. (2011) Stratigraphy 
and chronology of offshore to nearshore deposits associated with the Provo shoreline, 
Pleistocene Lake Bonneville, Utah, Palaeogeogr Palaeocl 310, 442-450. 
178. Koo, I., Zhang, X., and Kim, S. (2011) Wavelet- and Fourier-Transform-Based 
Spectrum Similarity Approaches to Compound Identification in Gas 
Chromatography/Mass Spectrometry, Analytical Chemistry 83, 5631-5638. 
179. Zhang, J., Fang, A. Q., Wang, B., Kim, S. H., Bogdanov, B., Zhou, Z. X., McClain, 
C., and Zhang, X. (2011) iMatch: A retention index tool for analysis of gas 
155 
 
chromatography-mass spectrometry data, Journal of Chromatography A 1218, 
6522-6530. 
180.Rao, M. S., and Reddy, J. K. (2001) Peroxisomal β-oxidation and steatohepatitis, 
Semin. Liver Dis. 21, 43-55. 
181. Vila, L., Roglans, N., Alegret, M., Sanchez, R. M., Vazquez-Carrera, M., and 
Laguna, J. C. (2008) Suppressor of cytokine signaling-3 (SOCS-3) and a deficit of 
serine/threonine (Ser/Thr) phosphoproteins involved in leptin transduction mediate the 
effect of fructose on rat liver lipid metabolism, Hepatology (Hoboken, NJ, U. S.) 48, 
1506-1516. 
182. Charlton, M. (2006) Branched-chain amino acid enriched supplements as therapy for 
liver disease, J. Nutr. 136, 295S-298S. 
183. Calvey, H., Davis, M., and Williams, R. (1985) Controlled trial of nutritional 
supplementation, with and without branched chain amino acid enrichment, in treatment 
of acute alcoholic hepatitis, J Hepatol 1, 141-151. 
184. Chen, P., Loomba, R., Torralba, M., DePew, J., Nelson, K. E., Tan, J., Embree, M., 
Zengler, K., Starkel, P., Pijkeren, J.-P. v., Ho, S. B., Bajaj, J. S., Mutlu, E. A., 
Keshavarzian, A., Tsukamoto, H., Fouts, D. E., and Schnabl, B. (2014) Supplementation 
of Saturated Long-chain Fatty Acids Maintains Intestinal Eubiosis and Reduces 
Ethanol-induced Liver Injury in Mice, Gastroenterology. 
185. Aggarwal, S., Suzuki, T., Taylor, W. L., Bhargava, A., and Rao, R. K. (2011) 
Contrasting effects of ERK on tight junction integrity in differentiated and 
under-differentiated Caco-2 cell monolayers, Biochem. J. 433, 51-63. 
156 
 
186. Bull-Otterson, L., Feng, W., Kirpich, I., Wang, Y., Qin, X., Liu, Y., Gobejishvili, L., 
Joshi-Barve, S., Ayvaz, T., Petrosino, J., Kong, M., Barker, D., McClain, C., and Barve, 
S. (2013) Metagenomic analyses of alcohol induced pathogenic alterations in the 
intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment, PLoS 





















LIST OF ABBREVIATIONS 
 
AF: Alcohol-containing Diet  
AFLD: Alcoholic Fatty Liver Disease 
ALT: Plasma Alanine Aminotransferase  
AMPKα: Adenosine Monophosphate-activated Protein Kinase-α  
AUC: Area Under Curve  
BCAA: Branched-chain Amino Acid  
BHT: Butylatedhydroxytoluene  
CD: Control Diet 
CID: Collision-induced Dissociation 
DI-MS: Direct Infusion Mass Spectrometry 
DI-nESI: Direct Infusion Chip-based Nano-electrospray Ionization 
eWAT: epididymal White Adipose Tissue 
FDR: False Discovery Rate 
FFA: Free Fatty Acids 
FLD: Fatty Liver Disease 
FN: False-negative 
FP: False-positive  
FTICR-MS: Fourier Transform Ion Cyclotron Resonance Mass Spectrometry 
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GMM: Gaussian Mixture Model 
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HMDB: Human Metabolome Database 
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IPA: Ingenuity Pathway Analysis 
KEGG: Kyoto Encyclopedia of Genes and Genomes 
LCFA: Long Chain Fatty Acid 
LC-MS: Liquid Chromatography Mass Spectrometry 
LGG: Lactobacillus Rhamnosus GG 
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MS: Mass Spectrometry 
NAFLD: Non-alcoholic Fatty Liver Disease 
NASH: Non-alcoholic Steatohepatitis 
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nESI: Nano-electrospray Ionization 
NMR: Nuclear Magnetic Resonance 
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SCE: Strong Cation Exchange 
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SIAM: Stable Isotope Assisted Metabolomics  
SIR: Selected Ion Recording  
SPF: Second-order Polynomial Fitting  
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TGs: Triacylglycerols  
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TPR: True-positive Rate  
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GC-MS, GC-HRT MS, GC×GC-TOF MS, Nanomate-LTQ-FTICR MS, LC/UV/Vis, LC-MS, UPLC-MS, 
CE-ED, AAS 
Software Packages:  
Instrument control: ChromaTOF, ChemStation, Xcalibur, Chromeleon 
Data mining: 
ChromaTOF, Mass Frontier, Ingenuity Pathway Analysis (IPA), ChemBioDraw, MetPP, MetSign, 
MetaCore, MetaDrug, MZmine, NIST MS 
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Ph.D. Thesis Research                              University of Louisville 
Metabolomic analysis of the effects of chronic arsenic exposure in a mouse model of diet-induced fatty 
liver disease by using GC×GC-TOF MS 
 Pegasus 4D GC×GC-TOF MS instrument trouble shooting and maintenance 
 Optimized extraction, derivatization method and GC×GC-TOF MS method development for 
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